Change Healthcare (CHNG) 10-K 26 May 22 2022 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Mar. 31, 2022	May 16, 2022	Sep. 30, 2021
Document Type	10-K
Document Annual Report	true
Current Fiscal Year End Date	--03-31
Document Period End Date	Mar. 31, 2022
Document Fiscal Year Focus	2022
Document Transition Report	false
Entity File Number	001-38961
Entity Registrant Name	Change Healthcare Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-2152098
Entity Address, Address Line One	424 Church Street
Entity Address, Address Line Two	Suite 1400
Entity Address, City or Town	Nashville
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37219
City Area Code	615
Local Phone Number	932-3000
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		318,546,445
Entity Public Float			$ 5,262,545,459
Amendment Flag	false
Entity Central Index Key	0001756497
Document Fiscal Period Focus	FY
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s definitive proxy statement for the registrant’s next Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K.
Auditor Name	Deloitte & Touche LLP
Auditor Location	Atlanta, GA
Auditor Firm ID	34
Common Stock [Member]
Title of 12(b) Security	Common Stock, par value $.001 per share
Trading Symbol	CHNG
Security Exchange Name	NASDAQ
Tangible Equity Units [Member]
Title of 12(b) Security	6.00% Tangible Equity Units
Trading Symbol	CHNGU
Security Exchange Name	NASDAQ

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Total revenue	$ 3,480,815	$ 3,090,421	$ 196,792
Operating expenses
Cost of operations (exclusive of depreciation and amortization below)	1,415,267	1,335,075	71,435
Research and development	277,930	227,036	11,559
Sales, marketing, general and administrative	734,554	686,645	39,893
Customer postage	219,612	196,532	12,631
Depreciation and amortization	681,808	591,048	30,838
Accretion and changes in estimate with related parties, net	14,833	13,158	15,823
Gain on sale of businesses		(59,143)
Tax Receivable Agreement charges			164,633
Goodwill impairment charge			561,164
Total operating expenses	3,344,004	2,990,351	907,976
Operating income (loss)	136,811	100,070	(711,184)
Non-operating (income) expense
Interest expense, net	234,244	245,241	16,652
Loss on extinguishment of debt	3,885	8,924
Loss from Equity Method Investment in the Joint Venture			380,713
(Gain) loss on forward purchase contract			(15,881)
Other, net	4,683	(6,698)	(1,817)
Total non-operating (income) expense	242,812	247,467	379,667
Income (loss) before income tax provision (benefit)	(106,001)	(147,397)	(1,090,851)
Income tax provision (benefit)	(48,611)	(35,187)	(143,254)
Net income (loss)	$ (57,390)	$ (112,210)	$ (947,597)
Net income (loss) per share:
Basic and diluted	$ (0.18)	$ (0.35)	$ (6.92)
Weighted average common shares outstanding:
Basic and diluted	323,996,600	320,771,789	136,996,624
Solutions [Member]
Total revenue	$ 3,261,203	$ 2,893,889	$ 184,161
Postage [Member]
Total revenue	$ 219,612	$ 196,532	$ 12,631

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Consolidated Statements of Comprehensive Income (Loss) [Abstract]
Net income (loss)	$ (57,390)	$ (112,210)	$ (947,597)
Other comprehensive income (loss):
Foreign currency translation adjustment	3,741	21,214	(5,519)
Changes in fair value of interest rate caps, net of taxes	20,154	(2,621)	981
Unrealized gain (loss) on available for sale debt securities of the Joint Venture, net of taxes			1,045
Realized gain (loss) on available for sale debt securities of the Joint Venture			(1,045)
Other comprehensive income (loss)	23,895	18,593	(4,538)
Total comprehensive income (loss)	$ (33,495)	$ (93,617)	$ (952,135)

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Current assets:
Cash & cash equivalents	$ 252,298	$ 113,101
Accounts receivable, net	720,122	732,614
Contract assets, net	162,828	132,856
Prepaid expenses and other current assets	177,659	140,258
Total current assets	1,312,907	1,118,829
Property and equipment, net	141,340	174,370
Operating lease right-of-use assets, net	65,680	93,412
Goodwill	4,112,904	4,108,792
Intangible assets, net	3,699,603	4,187,072
Other noncurrent assets, net	600,061	430,141
Total assets	9,932,495	10,112,616
Current liabilities:
Accounts payable	104,273	57,449
Accrued expenses	461,506	484,293
Deferred revenue	469,098	436,666
Due to related parties, net	13,057	10,766
Current portion of long-term debt	10,006	27,339
Current portion of operating lease liabilities	21,726	30,608
Total current liabilities	1,079,666	1,047,121
Long-term debt, excluding current portion	4,580,087	4,734,775
Long-term operating lease liabilities	52,286	75,396
Deferred income tax liabilities	563,606	605,291
Tax receivable agreement obligations due to related parties	104,863	103,151
Tax receivable agreement obligations	202,762	229,082
Other long-term liabilities	73,118	65,572
Total liabilities	6,656,388	6,860,388
Commitments and contingencies
Stockholders' Equity
Common Stock (par value, $0.001), 9,000,000,000 and 9,000,000,000 shares authorized and 313,131,714 and 306,796,076 shares issued and outstanding at March 31, 2022 and March 31, 2021, respectively	313	307
Preferred stock (par value, $0.001), 900,000,000 shares authorized and no shares issued and outstanding at both March 31, 2022 and March 31, 2021
Additional paid-in capital	4,340,759	4,283,391
Accumulated other comprehensive income (loss)	35,116	11,221
Accumulated deficit	(1,100,081)	(1,042,691)
Total stockholders' equity	3,276,107	3,252,228
Total liabilities and stockholders' equity	$ 9,932,495	$ 10,112,616

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2022	Mar. 31, 2021
Consolidated Balance Sheets [Abstract]
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	9,000,000,000	9,000,000,000
Common Stock, shares issued	313,131,714	306,796,076
Common Stock, shares outstanding	313,131,714	306,796,076
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	900,000,000	900,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]Cumulative Effect, Period of Adoption, Adjustment [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]Cumulative Effect, Period of Adoption, Adjustment [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]	Total
Balance (ASC 606 [Member]) at Mar. 31, 2019			$ 35,796				$ 35,796
Balance (ASU 2018-02 [Member]) at Mar. 31, 2019			(422)		$ 422
Balance at Mar. 31, 2019	$ 75	$ 1,153,509		$ (17,841)		$ (3,256)		$ 1,132,487
Balance, shares at Mar. 31, 2019	75,474,654
Equity compensation expense		30,372						30,372
Issuance of the Company's common stock upon initial public offering	$ 49	608,630						608,679
Issuance of the Company's common stock upon initial public offering, shares	49,285,713
Effect of initial public offering issuance costs on Joint Venture equity		(4,160)						(4,160)
Issuance of tangible equity units		232,929						232,929
Unrealized gain (loss) on available for sale debt securities of the Joint Venture						1,045		1,045
Realized gain (loss) on available for sale debt securities of the Joint Venture						(1,045)		(1,045)
Issuance of the Company's common stock upon exercise of equity awards	$ 1	6,023						6,024
Issuance of the Company's common stock upon exercise of equity awards, shares	708,962
Net income (loss)				(947,597)				(947,597)
Foreign currency translation adjustment						(5,519)		(5,519)
Change in fair value of interest rate caps, net of taxes						981		981
Issuance of the Company's common stock upon Merger	$ 176	2,194,484						2,194,660
Issuance of the Company's common stock upon Merger, shares	175,995,192
Conversion of tangible equity units	$ 2	(2)
Conversion of tangible equity units, shares	1,963,621
Other		795						795
Balance (ASU 2016-13 [Member]) at Mar. 31, 2020			$ (417)				$ (417)
Balance at Mar. 31, 2020	$ 303	4,222,580		(930,064)		(7,372)		3,285,447
Balance, shares at Mar. 31, 2020	303,428,142
Equity compensation expense		44,200						44,200
Issuance of common stock under equity compensation plans	$ 3	21,290						21,293
Issuance of common stock under equity compensation plans, shares	2,698,032
Employee tax withholding on vesting of equity compensation awards		(4,108)						(4,108)
Employee tax withholding on vesting of equity compensation awards, shares	(303,486)
Net income (loss)				(112,210)				(112,210)
Foreign currency translation adjustment						21,214		21,214
Change in fair value of interest rate caps, net of taxes						(2,621)		(2,621)
Conversion of tangible equity units	$ 1	(1)
Conversion of tangible equity units, shares	973,388
Other		(570)						(570)
Balance at Mar. 31, 2021	$ 307	4,283,391		(1,042,691)		11,221		3,252,228
Balance, shares at Mar. 31, 2021	306,796,076
Equity compensation expense		90,320						90,320
Issuance of common stock under equity compensation plans	$ 5	5,152						5,157
Issuance of common stock under equity compensation plans, shares	5,552,759
Employee tax withholding on vesting of equity compensation awards	$ (2)	(37,751)						(37,753)
Employee tax withholding on vesting of equity compensation awards, shares	(1,714,934)
Net income (loss)				(57,390)				(57,390)
Foreign currency translation adjustment						3,741		3,741
Change in fair value of interest rate caps, net of taxes						20,154		20,154
Conversion of tangible equity units	$ 3	(3)
Conversion of tangible equity units, shares	2,497,813
Other		(350)						(350)
Balance at Mar. 31, 2022	$ 313	$ 4,340,759		$ (1,100,081)		$ 35,116		$ 3,276,107
Balance, shares at Mar. 31, 2022	313,131,714

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands		12 Months Ended
		Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net income (loss)		$ (57,390)	$ (112,210)	$ (947,597)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization		681,808	591,048	30,838
Amortization of capitalized software developed for sale		3,509	1,326
Accretion and changes in estimate, net		25,276	11,644	15,823
Equity compensation		95,730	59,016	1,701
Deferred income tax expense (benefit)		(49,060)	(50,114)	(143,822)
Amortization of debt discount and issuance costs		31,284	32,532	2,235
Loss on extinguishment of debt		3,885	8,924
(Gain) loss on other investments				(15,881)
Non-cash lease expense		26,648	29,114
Gain on sale of businesses			(59,143)
Goodwill impairment charge				561,164
Loss from Equity Method Investment in the Joint Venture				380,713
Tax receivable agreement charges				164,633
Other, net		17,658	8,257	(1,110)
Changes in operating assets and liabilities:
Accounts receivable, net		12,295	(6,064)	(21,211)
Contract assets, net		(26,114)	158
Prepaid expenses and other assets		(82,507)	(87,540)	(6,219)
Accounts payable		34,825	(21,407)	7,532
Accrued expenses and other liabilities		(61,032)	14,178	(195,207)
Deferred revenue		40,063	166,477	11,304
Due to the Joint Venture, net				1,176
Net cash provided by (used in) operating activities		696,878	586,196	(153,928)
Cash flows from investing activities:
Capitalized expenditures		(276,276)	(246,381)	(13,002)
Acquisitions, net of cash acquired			(439,483)	330,667
Proceeds from sale of businesses			115,733
Investment in the Joint Venture				(610,784)
Investment in debt and equity securities of the Joint Venture				(278,875)
Other, net		(663)	2,099	7,332
Net cash provided by (used in) investing activities		(276,939)	(568,032)	(564,662)
Cash flows from financing activities:
Payments on Term Loan Facility		(180,000)	(315,000)
Payments under tax receivable agreements		(21,537)	(20,691)
Receipts (payments) on derivative instruments		(22,709)	(29,538)	(890)
Employee tax withholding on vesting of equity compensation awards		(37,751)	(4,108)
Payments on deferred financing obligations		(10,991)	(19,519)
Payment of senior amortizing notes		(16,384)	(15,636)	(11,094)
Proceeds from exercise of equity awards		8,933	17,514
Payments on Revolving Facility			(250,000)
Proceeds from Revolving Facility				250,000
Proceeds from issuance of Senior Notes			325,000
Proceeds from initial public offering, net of issuance costs				608,679
Proceeds from issuance of equity component of tangible equity units, net of issuance costs				232,929
Proceeds from issuance of debt component of tangible equity units				47,367
Other, net		(468)	(6,800)	(1,421)
Net cash provided by (used in) financing activities		(280,907)	(318,778)	1,125,570
Effect of exchange rate changes on cash and cash equivalents		165	3,310	16
Net increase (decrease) in cash and cash equivalents		139,197	(297,304)	406,996
Cash and cash equivalents at beginning of period		113,101	410,405	3,409
Cash and cash equivalents at end of period		252,298	113,101	410,405
Supplemental disclosures of cash flow information
Cash paid for interest		223,658	240,232	265,633
Cash paid for income taxes		7,983	11,169	(714)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows		36,729	41,262
Financing cash flows		468	642
Issuance of common stock upon exercise of equity awards:
Investment in the Joint Venture				5,077
Dividend receivable				(5,077)
Change Healthcare Inc. portion of the Joint Venture equity transactions:
Investment in the Joint Venture				13,902
Additional paid in capital				(11,133)
Accumulated other comprehensive income				(2,769)
Capitalized Expenditures:
Property and equipment, net		9,130	2,662	5,295
Other noncurrent assets, net		30,756	25,338	14,169
Intangible assets, net		2,725	1,491	2,855
Accounts payable		(24,533)	(11,040)	(9,843)
Accrued expenses		(18,078)	(18,452)	$ (12,476)
Right-of-use assets obtained in exchange for lease liabilities
Operating Leases	[1]	$ 3,325	16,185
Finance Leases	[1]		$ 363
[1]	Amounts exclude the impact of adopting ASC 842. See Note 2, Significant Accounting Policies .

Nature of Business and Organiza

Nature of Business and Organization	12 Months Ended
	Mar. 31, 2022
Nature of Business and Organization [Abstract]
Nature of Business and Organization	1. Nature of Business and Organization Change Healthcare Inc. (the “Company”, “our” or “we”) is a healthcare technology company, focused on accelerating the transformation of the healthcare system through the power of our healthcare platform. We provide data and analytics-driven solutions to improve clinical, financial and patient engagement outcomes in the U.S. healthcare system. Our platform and comprehensive suite of software, analytics, technology-enabled services and network solutions drive improved results in the complex workflows of healthcare system payers and providers by enhancing clinical decision making, simplifying billing, collection and payment processes, and enabling a better patient experience. We are a Delaware corporation originally formed on June 22, 2016, to initially hold an equity investment in Change Healthcare LLC (the “Joint Venture”), a joint venture between the Company and McKesson Corporation (“McKesson”). Effective July 1, 2019, we completed our initial public offering. The proceeds from the common stock offering were subsequently contributed to the Joint Venture in exchange for additional units of the Joint Venture, which together with the Company’s existing holdings represented an approximate 41 % interest in the Joint Venture. On March 10, 2020, McKesson completed a split-off of its interest in the Joint Venture through an exchange offer of its common stock for shares of PF2 SpinCo, Inc, a Delaware corporation and wholly owned subsidiary of McKesson (“SpinCo”). Immediately following consummation of the exchange offer, SpinCo was merged with and into Change Healthcare Inc. (the “Merger”). Subsequent to the Merger, we own 100 % of Change Healthcare LLC, and as a result, consolidate the financial statements of Change Healthcare LLC. UnitedHealth Group Incorporated On January 5, 2021, we entered into an Agreement and Plan of Merger (the “UHG Agreement”) with UnitedHealth Group Incorporated (“UnitedHealth Group”), and UnitedHealth Group’s wholly owned subsidiary Cambridge Merger Sub Inc. Pursuant to the UHG Agreement, UnitedHealth Group has agreed to acquire all of the outstanding shares of the Company’s common stock for $ 25.75 per share in cash (the “UHG Transaction”). On April 13, 2021, our stockholders approved a proposal to adopt the UHG Agreement, thereby satisfying one of the closing conditions contained in the UHG Agreement. The consummation of the transaction remains subject to the satisfaction or, to the extent permitted by law, waiver of other customary closing conditions. The UHG Agreement contains representations, warranties, covenants, closing conditions and termination rights customary for transactions of this type. Until the earlier of the termination of the UHG Agreement and the consummation of the UHG Transaction, we have agreed to operate our business in the ordinary course and have agreed to certain other operating covenants, as set forth in the UHG Agreement. If UnitedHealth Group terminates the UHG Agreement after we materially breach the agreement, and we fail to cure such breach, and then within 12 months of such termination we enter into an alternative transaction to sell the Company, or if the Board recommends to stockholders that they approve an alternative transaction to sell the Company, and such alternative transaction is subsequently consummated, then we may be required to pay UnitedHealth Group a termination fee of $ 300 million at the time such alternative transaction is consummated. On February 24, 2022, the DOJ and certain other parties commenced litigation to block the UHG Transaction, and the Company continues to support UnitedHealth Group in working toward closing the merger. On April 4, 2022, the parties to the UHG Agreement entered into a waiver (the “Waiver”) pursuant to which, among other things, the Company and UnitedHealth Group each waived its right to terminate the UHG Agreement due to a failure of the UHG Transaction to have been consummated by the Outside Date until the earlier of (i) 5:00 p.m. (New York time) on the tenth business day following a final order (whether or not appealable) issued by the U.S. District Court for the District of Columbia (the “Trial Court”) with respect to the complaint filed by the U.S. Department of Justice and certain other parties regarding the UHG Transaction that permanently prohibits the consummation of the UHG Transaction and (ii) 11:59 p.m. (New York time) on December 31, 2022 (the “Waiver Period”); provided, that if (A) the Trial Court issues a final order that permits the consummation of the UHG Transaction (whether or not subject to conditions), (B) any plaintiff appeals such order and (C) the ability to consummate the UHG Transaction is enjoined or otherwise prohibited by a governmental entity pending such appeal, then the Waiver Period may be extended by either UnitedHealth Group or the Company (in each case, acting in its sole discretion) to 5:00 p.m. (New York time) on March 31, 2023, by providing written notice to the other party prior to 11:59 p.m. (New York time) on December 31, 2022. The Waiver provides that, if the Company or UnitedHealth Group terminates the UHG Agreement pursuant to Section 9.2(a) or Section 9.2(c) of the UHG Agreement at a time when any of the conditions to the closing set forth in Sections 8.1(b), 8.1(c) (in connection with a legal restraint of a governmental antitrust entity) or 8.2(c) of the UHG Agreement has not been satisfied or, to the extent permitted by applicable law, waived, UnitedHealth Group will pay to the Company an amount equal to $ 650 million. The Waiver also provides that the Company may declare and pay a one-time special dividend of up to $ 2.00 in cash per each issued and outstanding share of common stock of the Company, with a record date and payment date to be determined in the sole discretion of the Board of Directors of the Company (or a committee thereof). We expect to pay the dividend at or about the time of closing of the UHG Transaction. On April 22, 2022, UnitedHealth Group, as seller, entered into an equity purchase agreement and related agreements relating to the sale of the Company’s claims editing business (“ClaimsXten”) to an affiliate of investment funds of TPG Capital for a base purchase price in cash equal to $ 2.2 billion (subject to customary adjustments). Consummation of the transaction is contingent on a number of conditions, including the consummation of the UHG Transaction. COVID-19 Considerations On March 11, 2020, the World Health Organization declared the coronavirus (“COVID-19”) outbreak to be a global pandemic. In response to this declaration and the rapid spread of COVID-19 within the U.S., federal, state and local governments imposed varying degrees of restrictions on social and commercial activity to promote social distancing in an effort to slow the spread of the illness. These measures led to weakened conditions in many sectors of the economy, including a decline in healthcare transaction volumes that are integral to our business. In calendar 2021 and the first quarter of 2022 , the global economy has with certain setbacks, beg u n reopening and wider distribution of vaccines will likely continue to encourage greater economic activity. Nevertheless, we are unable to predict how widely the vaccines will be utilized, whether they will be effective in preventing the spread of COVID-19 (including its variant strains), and the extent to which our business, results of operations, financial condition or liquidity will ultimately be impacted by COVID-19. Accordingly, the full extent of the impact of COVID-19 on the global economy generally, and on the Company’s business, in particular, remains uncertain. However, we are not presently aware of events or circumstances arising from COVID-19 that would require us to revise the carrying value of our assets or liabilities, nor do we expect the impact of COVID-19 to cause us to be unable to comply with our debt covenants or meet our contractual obligations .

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Mar. 31, 2022
Significant Accounting Policies [Abstract]
Significant Accounting Policies	2. Significant Accounting Policies Basis of Presentation Our consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and include the accounts of our wholly owned subsidiaries. The results of operations for companies acquired are included in our consolidated financial statements from the effective date of acquisition. All intercompany accounts and transactions have been eliminated upon consolidation. Accounting Estimates The preparation of financial statements in conformity with GAAP requires us to make a number of estimates and assumptions that affect the amounts reported in our financial statements and accompanying notes. We base our estimates on historical experience, current business factors and various other assumptions that we believe are necessary in order to form a basis for making judgments about the carrying values of assets and liabilities, the reported amounts of revenues and expenses and disclosure of contingent assets and liabilities. We are subject to uncertainties such as the impact of future events, economic, environmental and political factors and changes in our business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of our financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as our operating environment changes. Changes in estimates are made when circumstances warrant. Estimates and assumptions affect: the allowance for credit losses; the fair value assigned to assets acquired and liabilities assumed in business combinations; the carrying value of long-lived assets (including goodwill and intangible assets); the amortization period of long-lived assets (excluding goodwill); the carrying value, capitalization and amortization of software development costs; operating lease right-of-use assets; the carrying value of our investments; tax receivable agreement obligations; the fair value of interest rate cap agreement obligations; components of our tangible equity units; the values attributed to equity awards; operating lease liabilities; contingent consideration; loss accruals; certain accrued expenses; revenue recognition; and the income tax provision or benefit and related deferred tax accounts. Business Combinations We recognize the consideration transferred (i.e., purchase price) in a business combination, as well as the acquired business’ identifiable assets, liabilities and noncontrolling interests at their acquisition date fair value. The excess of the consideration transferred over the fair value of the identifiable assets, liabilities and noncontrolling interest, if any, is recorded as goodwill. The fair values of the consideration transferred, assets, liabilities and noncontrolling interests are estimated based on one or a combination of income, cost or market approaches as determined based on the nature of the asset or liability and the level of inputs available (i.e., quoted prices in an active market, other observable inputs or unobservable inputs). To the extent our initial accounting for a business combination is incomplete at the end of a reporting period, provisional amounts are reported for those items which are incomplete. Cash and Cash Equivalents For the purposes of reporting, cash and cash equivalents include unrestricted cash on hand and investments with an original maturity from the date of purchase of three months or less. Our cash and cash equivalents are deposited with several financial institutions. Deposits may exceed the amounts insured by the Federal Deposit Insurance Corporation in the U.S. and similar deposit insurance programs in other jurisdictions. We mitigate the risk of our short-term investment portfolio by depositing funds with reputable financial institutions and monitoring risk profiles. From time to time, our cash balances include funds we manage for customers, the most significant of which relates to funds remitted to retail pharmacies. Such funds are not restricted; however, funds are generally paid out in satisfaction of the processing obligations pursuant to the management contracts. At the time of receipt, we record a corresponding liability within Accrued expenses on the consolidated balance sheets. Such liabilities are summarized as “Pass-through payments” within Note 12, Accrued Expenses . Allowance for Credit Losses The allowance for credit losses of $ 22,224 and $ 24,126 at March 31, 2022 and 2021, respectively, was primarily based on historical credit loss experience, current conditions, future expected credit losses, and adjustments for certain asset-specific risk characteristics. The following table summarizes activity related to the allowance for credit losses: Year Ended March 31, 2022 2021 Balance at beginning of period $ 24,126 $ 22,360 Cumulative effect of accounting change-ASU 2016-13 — 417 Acquisitions and Dispositions (1) — ( 4,952 ) Provisions 8,733 14,645 Write-offs ( 10,635 ) ( 8,344 ) Balance at end of period $ 22,224 $ 24,126 (1) For the year ended March 31, 2021, this amount relates primarily to the sales of Connected Analytics and Capacity Management. Capitalized Software Developed for Sale Development costs for software developed for sale to external customers are capitalized once a project has reached the point of technological feasibility. Completed projects are amortized after reaching the point of general availability using the straight-line method based on an estimated useful life of three years . At each balance sheet date, or earlier if an indicator of an impairment exists, we evaluate the recoverability of unamortized capitalized software costs based on estimated future undiscounted revenues net of estimated related costs over the remaining amortization period. Capitalized Software Developed for Internal Use We provide services to many of our customers using software developed for internal use. The costs that are incurred to develop such software are expensed as incurred during the preliminary project stage and classified within Research and development in the consolidated statements of operations. Training and maintenance costs are also expensed as incurred. Once certain criteria have been met, direct costs incurred in developing or obtaining computer software are capitalized. Capitalized software costs are included in Other noncurrent assets, net on the consolidated balance sheets and are generally amortized over the estimated useful life of three years . Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the related assets. Expenditures for maintenance, repair and renewals of minor items are expensed as incurred. Expenditures for repair and renewals that extend the useful life of an asset are capitalized. Long-Lived Assets Long-lived assets used in operations , which include capitalized software developed for internal use and property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that carrying amounts may not be recoverable. For long-lived assets to be held and used, we recognize an impairment loss only if the carrying amount is not recoverable when compared to our undiscounted cash flows and the impairment loss is measured based on the difference between the carrying amount and fair value. Long-lived assets held for sale are reported at the lower of cost or fair value less costs to sell. Goodwill and Intangible Assets Goodwill and intangible assets resulting from acquisitions are accounted for using the acquisition method of accounting. In business combinations, we generally recognize goodwill attributable to the assembled workforce and expected synergies among the operations of the acquired entities and our existing operations. Goodwill is generally deductible for federal income tax purposes when a business combination is treated as an asset purchase and is generally not deductible for federal income tax purposes when a business combination is treated as a stock purchase. We assess goodwill for impairment annually (as of January 1 of each year) or whenever significant indicators of impairment are present. Using a qualitative analysis, we first assess whether it is more likely than not that goodwill is impaired. To the extent we cannot reach a conclusion using only a qualitative analysis, we compare the fair value of each reporting unit to its associated carrying value. We will recognize an impairment charge for the amount, if any, by which the carrying amount of the reporting unit exceeds its fair value. Intangible assets with definite lives are amortized over their useful lives either on a straight-line basis or using an accelerated method, depending on the pattern we expect the economic benefits of the assets to be consumed. Useful lives are generally as follows: Customer relationships 12 - 18 years Tradenames 18 years Technology-based intangible assets 6 - 12 years Derivatives Derivative financial instruments are used to manage our interest rate exposure and we do not enter into financial instruments for speculative purposes. Derivative financial instruments are accounted for and measured at fair value. For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same line item associated with the forecasted transaction in the same period or periods during which the hedged transaction affects earnings (e.g., in “Interest expense, net” when the hedged transactions are interest cash flows associated with floating-rate debt). Tangible Equity Units In connection with our initial public offering, we completed an offering of TEUs. Each TEU includes an amortizing note and a purchase contract, both of which are freestanding instruments and separate units of account. The amortizing notes were issued at par and are classified as debt on the consolidated balance sheets. The purchase contracts are accounted for as prepaid forward contracts and are classified as equity. The TEU proceeds and issuance costs were allocated to the amortizing notes and purchase contracts on a relative fair value basis. Equity Compensation We measure stock-based compensation cost based on the estimated fair value of the award on the grant date and recognize the expense over the requisite service period, typically on a straight-line basis. We recognize stock-based compensation cost for awards with performance conditions if and when we conclude that it is probable that the performance conditions will be achieved. The fair value of equity awards is recognized as expense in the same period and in the same manner as if we had paid cash for the goods or services. Forfeitures are recognized as they occur. We issue new shares of common stock upon vesting of equity awards and upon exercise of vested options. We do not intend to repurchase any issued shares of common stock. Prior to the Merger, these equity awards, as well as awards granted under our previous equity incentive plan, were granted to employees of the Joint Venture, and therefore were subject to the accounting framework for awards granted to non-employees. Under this framework, we measured compensation expense for equity awards based on the estimated fair value of such awards at the grant date, in a manner consistent with the recognition of expense for awards to employees. The recognized pre-Merger equity-based compensation is classified within Loss from Equity Method Investment in the Joint Venture on the consolidated statement of operations. Leases We determine whether an arrangement contains a lease based on the conveyed rights and obligations at the inception date. If an agreement contains an operating or finance lease, at the commencement date, we record a right-of-use asset and a corresponding lease liability based on the present value of the minimum lease payments. As most of our leases do not provide an implicit borrowing rate, to determine the present value of lease payments, we use the portfolio approach and determine our hypothetical secured borrowing rate based on information available at lease commencement. Further, we make certain estimates and judgements regarding the lease term and lease payments, noted below. Leases with an initial term of 12 months or less are not recorded on the balance sheet and we recognize lease expense for these leases on a straight-line basis over the lease term. Most leases include one or more options to renew, with renewal terms that can extend the lease term from one month to one year or more. Additionally, some of our leases include an option for early termination. We include renewal periods and exclude termination periods from our lease term if, at commencement, we are reasonably certain to exercise the option. For our real estate lease arrangements, we do not consider a lease to be abandoned and do not adjust the corresponding right-of-use asset in instances where we have the intent and ability to sublease the space. Certain of our lease agreements include rental payments that are adjusted periodically for inflation or passage of time. These step payments are included within our present value calculation as they are known adjustments at commencement. Some of our lease agreements include variable payments that are excluded from our present value calculation. For example, some of our equipment leases include a component which varies based on the asset’s use. Additionally, we have lease agreements that include lease and non-lease components, such as equipment leases, which are generally accounted for as a single lease component. For these leases, lease payments include all fixed payments stated within the contract. For other leases, such as office space, lease and non-lease components are accounted for separately. Our lease agreements do not contain any material residual value guarantees that would impact our lease payments. Tax Receivable Agreements Upon the consummation of the Merger, we assumed obligations related to certain tax receivable agreements entered into by the Joint Venture with its current and former owners. The tax receivable agreements were measured at their fair value as part of the Merger and are recognized at their initial fair value plus recognized accretion to date on the consolidated balance sheets. Accretion expense recorded during the period pertaining to related party payments is recorded within Accretion and changes in estimate with related parties, net, whereas non-related party accretion is recorded within Sales, marketing, general and administrative in the consolidated statement of operations. In connection with the closing of the Merger, we, along with the Joint Venture, the subsidiaries of McKesson that served as members of the Joint Venture and McKesson entered into a tax receivable agreement (the “McKesson Tax Receivable Agreement”). Following the Merger and based on anticipated amortization allocations, we recorded an obligation for the McKesson Tax Receivable Agreement estimated payments, which represents a loss contingency under ASC 450. Future changes in this value will be reflected within Sales, marketing, general and administrative in the consolidated statement of operations. The current and non-current portions of the non-related party obligations for our tax receivable agreements, including the McKesson Tax Receivable agreement, are recorded within Accrued expenses and Tax receivable agreement obligations, respectively, within the consolidated balance sheets. The current and non-current portions of the related party obligations for our tax receivable agreements are recorded within Due to related parties, net and Tax receivable agreement obligations due to related parties, respectively, within the consolidated balance sheets. Revenue We recognize revenue at an amount that reflects the consideration we expect to be entitled to in exchange for transferring goods or services to a customer, in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”), which we adopted on April 1, 2019. We had no revenue-generating operations prior to the Merger, therefore the impact of the adoption of ASC 606 was limited to recognition of an adjustment to Accumulated Deficit as a result of our equity method investment at the time of the Joint Venture’s adoption. See Note 3, Revenue Recognition, for additional information. Foreign Currency Translation Our reporting currency is the U.S. dollar and our foreign subsidiaries generally consider their local currency to be their functional currency. Foreign currency-denominated assets and liabilities of foreign subsidiaries are translated into U.S. dollars at year-end exchange rates, equity accounts are primarily translated at historical exchange rates and revenues and expenses are translated at average exchange rates during the corresponding period. Foreign currency translation adjustments are included in the consolidated statements of comprehensive income (loss) and the cumulative effect is included within Accumulated deficit on the consolidated balance sheets. Realized gains and losses from currency exchange transactions are included in Sales, marketing, general and administrative expenses in the consolidated statements of operations. We release the cumulative translation adjustment from equity into net income as a gain or loss only upon complete or substantially complete liquidation of a controlling interest in a subsidiary or a group of assets within a foreign entity. Income Taxes We record deferred income taxes for the tax effect of differences between book and tax bases of our assets and liabilities, as well as differences relating to the timing of recognition of income and expenses. Deferred income taxes reflect the available net operating losses and the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of the future tax benefits related to deferred tax assets is dependent on many factors, including our past earnings history, expected future earnings, the character and jurisdiction of such earnings, reversing taxable temporary differences, unsettled circumstances that, if unfavorably resolved, would adversely affect utilization of its deferred tax assets, carryback and carryforward periods and tax strategies that could potentially enhance the likelihood of realization of a deferred tax asset. We recognize tax benefits for uncertain tax positions when we conclude that the tax position, based solely on its technical merits, is more likely than not to be sustained upon examination. The benefit, if any, is measured as the largest amount of benefit, determined on a cumulative probability basis that is more likely than not to be realized upon ultimate settlement. Tax positions failing to qualify for initial recognition are subsequently recognized when they meet the more likely than not standard, upon resolution through negotiation or litigation with the taxing authority or on expiration of the statute of limitations. Equity Method Investment in the Joint Venture Prior to the Merger, we accounted for our investment in the Joint Venture using the equity method of accounting. During that period, we evaluated our equity method investment for impairment whenever an event or change in circumstances occurred that had a potentially significant adverse impact on the carrying value of our investment. During the period from the inception of the Joint Venture through the date of the Merger, we did not identify any loss in the value of our investment that was deemed other than temporary, and therefore, did no t recognize any impairment loss. Recently Adopted Accounting Pronouncements London Interbank Offered Rate (LIBOR) Reform In March 2020, the FASB issued ASU No. 2020-04, as amended by ASU No. 2021-01, which created Topic 848 – Reference Rate Reform. ASU No. 2020-04 contains optional practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts which may be elected over time as activities occur. Among other things, the ASU intends to ease the transition from LIBOR to an alternative reference rate. During the first quarter of fiscal year 2021, we elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. We continue to evaluate the impacts of ASU No. 2020-04 and may apply other elections as reference rate reform activities progress. Accounting Pronouncements Not Yet Adopted Derivatives and Convertible Instruments In August 2020, the FASB issued ASU No. 2020-06 which simplifies the accounting for convertible instruments and amends the guidance addressing the derivatives scope exception for contracts in an entity’s own equity. The standard is scheduled to be effective for us beginning April 1, 2022. Given the forward purchase contracts of our Tangible Equity Units qualify for the derivatives scope exception and are currently accounted for under that guidance, we do not expect a material impact upon adoption. Contract Assets and Liabilities from Contracts with Customers In October 2021, the FASB issued ASU No. 2021-08 which improves the accounting for revenue contracts with customers acquired in a business combination by addressing diversity in practice and requiring the acquirer to measure contract assets and liabilities acquired in accordance with ASC 606. The standard is scheduled to be effective for us beginning April 1, 2023, with early adoption permitted. Once adopted, the updated guidance could potentially have a material impact on the amount of assets, liabilities, and revenue recognized from acquired businesses, depending on the size and nature of those transactions.

Revenue Recognition

Revenue Recognition	12 Months Ended
	Mar. 31, 2022
Revenue Recognition [Abstract]
Revenue Recognition	3. Revenue Recognition We generate most of our solutions revenue using technology solutions (generally Software as a Service (“SaaS”)) to provide services to our customers that automate and simplify business and administrative functions for payers, providers, pharmacies, and channel partners and through the licensing of software, software systems (consisting of software, hardware and maintenance support) and content. We recognize revenue when the customer obtains control of the good or service through satisfying a performance obligation by transferring the promised good or service to the customer. Principal Revenue Generating Products and Services Hosted solutions and SaaS – We enter into arrangements whereby we provide the customer access to a Company-owned software solution, which are generally marketed under annual and multi-year arrangements. The customer is only provided “access” (not a license) to the software application. In these arrangements, the customer does not purchase equipment nor does the customer take physical possession of the software. The related revenue is recognized ratably over the contracted term. For fixed fee arrangements, revenue recognition begins after set-up and implementation are complete. For per-transaction fee arrangements, revenue is recognized as transactions are processed beginning on the service start date. Revenue for hosted solutions and SaaS, which is included in Solutions revenue, is generated by the Software and Analytics, Network Solutions, and Technology-Enabled Services segments. Transaction processing services – We provide transaction processing (such as claims processing) services to hospitals, pharmacies and health systems via a cloud-based (“SaaS”) platform. The promised service is to stand ready to process transactions for our customers over the contractual period on an as needed basis. Revenue related to these services is recognized over time as the transactions are processed, and the revenue is recognized over the individual days in which the services are performed. Revenue is recognized as Solutions revenue in the Software and Analytics, Network Solutions, and Technology-Enabled Services segments, with the exception of revenue related to postage that is generated through the delivery of certain of these services. Postage revenue is discussed below and is separately presented on the consolidated statement of operations. Any fixed annual fees and implementation fees are recognized ratably over the contract period. Contingent fee services – We provide services to customers in which the transaction price is contingent on future occurrences, such as savings generated or amounts collected on behalf of our customers through the delivery of our services. In some cases, we perform services in advance of invoicing the customer, thereby creating a contract asset. Revenue in these arrangements is estimated and constrained until we determine that it is probable a significant revenue reversal will not occur, and variable consideration is allocated to the performance obligation for which we earn a contingent fee. We use the expected value method when estimating variable consideration, as we have a large number of contracts with similar characteristics and consider a portfolio of data from other similar contracts to form our estimate of expected value. Revenue for contingent fee services, which is included in Solutions revenue, is generated by the Software and Analytics and Technology-Enabled Services segments. Content license subscriptions and time-based software – Our content license subscriptions and time-based software arrangements provide a license to use a software for a specified period of time. At the end of the contractual period, the customer either renews the license for an additional term or ceases to use the software. Software licenses are typically delivered to the customer with functionality that the customer can benefit from the software on its own or together with readily available resources. As contracts for these solutions generally do not price individual components separately, we allocate the transaction price to the license and ongoing support performance obligations based on standalone selling price, primarily determined by historical value relationships between licenses and ongoing support and updates. Revenue allocated to content license subscriptions and time-based software license agreements is generally recognized at the point-in-time of delivery of the license or the content update upon transfer of control of the underlying license to the customer. Generally, software implementation fees are recognized over the implementation period through an input measure of progress method. Revenue allocated to maintenance and support is recognized ratably over the period covered by the agreements, as passage of time represents a faithful depiction of the transfer of these services. In some cases, software arrangements provide licenses to several software applications that are highly integrated with the implementation services and software updates and cannot function separately. The bundle is a single performance obligation since the individually promised goods and services are not distinct in the context of the contract because the related implementation services significantly modify and customize the software and the updates provided to the integrated software solution are critical to the software’s utility. The related revenue is recognized on a straight-line basis, ratably over the contractual term due to the frequency and criticality of the updates throughout the license period. Revenue for content license subscriptions and time-based software, which is included in Solutions revenue, is generated by the Software and Analytics segment. Perpetual software licenses – Our perpetual software arrangements provide a license for a customer to use software in perpetuity. Software licenses are typically delivered to the customer with functionality from which the customer can benefit from the license on its own or together with readily available resources. Perpetual software arrangements are recognized at the time of delivery or through an input measure of progress method over the installation period if the arrangements require significant production or modification or customization of the software. Contracts accounted for through an input measure of progress method are generally measured based on the ratio of labor hours incurred to date to total estimated labor hours to be incurred. Software implementation fees are recognized as the work is performed or under the input method for perpetual software. Hardware revenue is generally recognized upon delivery. Maintenance is recognized ratably over the term of the agreement as passage of time represents a faithful depiction of the transfer of these services. License, implementation, hardware and maintenance revenue for these arrangements, which is included in Solutions revenue, is generated by the Software and Analytics and Network Solutions segments. Professional services – We provide training and consulting services to our customers, and the services may be fixed fee or time and materials based. Consulting services that fall outside of the standard implementation services vary depending on the scope and complexity of the service requested by the customer. Consulting services are deemed to be capable of being distinct from other products and services, and the services are satisfied either at a point of time or over time based on delivery and are recognized as Solutions revenue in the Software and Analytics and Technology-Enabled Services segments. Training services are usually provided as an optional service to enhance the customer’s experience with a software product or provides additional education surrounding the general topic of the solution. Training services are capable of being distinct from other products and services. We treat training services as a distinct performance obligation, and they are satisfied at a point of time and recognized as Solutions revenue in the Software and Analytics and Technology-Enabled Services segments. Postage Revenue Postage revenue is the result of providing delivery services to customers in our payment and communication solutions. Postage revenue is generally billed as a pass-through cost to our customers. The service is part of a combined performance obligation with the printing and handling services provided to the customer because the postage services are not distinct within the context of the contract. We present Postage revenue separately from Solutions revenue on the consolidated statements of operations as doing so makes the financial statements more informative for the users. The revenue related to the combined performance obligation of the postage, printing, and handling service is recognized as the transactions are processed, and the revenue is recognized over the individual days in which the services are performed. Contract Balances We generally recognize a contract asset when revenue is recognized in advance of invoicing on a customer contract, unless the right to payment for that revenue is unconditional (i.e., requiring no further performance and only the passage of time). If a right to payment is determined to meet the criteria to be considered 'unconditional', then we will recognize a receivable. We did no t recognize any impairment losses on accounts receivable or contract assets during the years ended March 31, 2022 and 2021. We record deferred revenue when billings or payments are received from customers in advance of our performance. Deferred revenue is generally recognized when control transfers to the customer. Deferred revenue is driven by multiple factors, including the frequency of renewals, invoice timing, invoice duration, and fair value adjustments as a result of the Merger. As of March 31, 2022, we expect 94 % of the deferred revenue balance to be recognized in one year or less. Approximately $ 409,808 of the balance at the beginning of the period was recognized during the year ended March 31, 2022. Costs to Obtain or Fulfill a Contract Sales commissions and certain other incentive payments (e.g., bonuses that are contingent solely on obtaining a contract or a pool of contracts) are capitalized as incremental costs to obtain a contract. We typically do not offer commissions on contract renewals. Decremented commissions upon renewal (i.e., non-commensurate with initial commissions) are offered to the sales associates for certain customers and are immaterial. All commissions and other qualifying incentive payments capitalized are amortized over an expected period of benefit defined as the initial contract term plus anticipated renewals, if any. In determining the appropriate period of benefit, we evaluate both qualitative and quantitative factors such as the expected customer relationship period and technology obsolescence. In addition, prior to solution go-live, we incur certain contract fulfillment costs primarily related to SaaS setup for our clients. These costs are capitalized to the extent they are directly related to a contract, are recoverable, and create a resource used to deliver our SaaS services. Capitalized costs to fulfill a contract are amortized over the expected period of benefit. At March 31, 2022 and 2021, we had capitalized costs to obtain a contract of $ 12,478 and $ 6,042 , respectively, in Prepaid expenses and other current assets and $ 79,351 and $ 38,833 , respectively, in Other noncurrent assets. At March 31, 2022 and 2021, we had capitalized costs to fulfill a contract of $ 7,096 and $ 3,526 in Prepaid and other current assets, respectively, and $ 40,460 and $ 24,240 in Other noncurrent assets, respectively. Amortization of such capitalized costs to obtain and fulfill was $ 10,878 and $ 2,182 , respectively, for the year ended March 31, 2022. Amortization of such capitalized costs to obtain and fulfill was immaterial for the years ended March 31, 2021 and 2020. Arrangements with Multiple Performance Obligations We engage in customer arrangements which may include multiple performance obligations, such as any combination of software, hardware, implementation, SaaS-based offerings, consulting services, or maintenance services. For such arrangements, we allocate revenue to each performance obligation on a relative standalone selling price basis. For substantially all such arrangements, a performance obligation’s standalone selling price is determined based on the directly observable prices charged to customers. When directly observable prices charged to customers are not available, other methods are used such as the adjusted market assessment approach, the expected cost plus a margin approach, or other approaches in cases where distinct performance obligations are not sold separately but instead sold at a bundled price. For performance obligations with historical pricing that is highly variable, the residual approach is used. Such instances primarily relate to our perpetual software arrangements in which we sell the same products to different customers for a broad range of amounts. Remaining Performance Obligations The aggregate amount of transaction price allocated to performance obligations that are unsatisfied (or partially unsatisfied) for executed contracts includes deferred revenue and other revenue yet to be recognized from non-cancellable contracts. As of March 31, 2022, remaining performance obligations totaled $ 1,444,943 , of which 53 % is expected to be recognized over the next 12 months , and the remaining 47 % thereafter . In this balance, we do not include the value of unsatisfied performance obligations related to those contracts for which we recognize revenue at the amount for which we have the right to invoice for services performed. Additionally, this balance does not include revenue related to performance obligations that are part of a contract with an original expected duration of one year or less. Lastly, this balance does not include variable consideration allocated to the individual goods or services in a series of distinct goods or services that are substantially the same and that have the same pattern of transfer to the customer. Examples includes variable fees associated with transaction processing and contingent fee services. Customer Incentives Certain customers, which include our channel partners, may receive cash-based incentives or rebates based on actual sales and achievement of a cumulative level of sales, which are accounted for as variable consideration. We consider these amounts to be consideration payable to the customer, and therefore, we estimate these amounts based on the expected amount to be provided to customers and reduce the transaction price accordingly. Disaggregated Revenue We disaggregate the revenue from contracts with customers by operating segment as we believe doing so best depicts how the nature, amount, time and uncertainty of revenues are affected by economic factors. See Note 26, Segment Reporting , for total revenue disaggregated by operating segment for the years ended March 31, 2022 and 2021. In addition to disaggregating revenue by operating segment, we disaggregate between revenue that is recognized over time and revenue that is recognized at a point in time. For the years ended March 31, 2022 and 2021, 96 % of revenue was recognized over time and 4 % of revenue was recognized at a point in time. Practical Expedients and Exemptions We have elected to utilize either the right to invoice practical expedient or the series-based variable consideration allocation framework for most transaction processing services not subject to contingencies. We have also elected to exclude sales taxes and other similar taxes from the measurement of the transaction price in contracts with customers. Therefore, revenue is recognized net of such taxes. In certain customer arrangements, we determined there are certain promised goods or services which are immaterial in the context of the contract from both a quantitative and qualitative perspective, and therefore, the goods and services are disregarded when assessing the performance obligations in the customer arrangement. We have elected to apply the significant financing practical expedient, and as a result, we will not adjust the promised amount of consideration in a customer contract for the effects of a significant financing component when the period of time between when we transfer a promised good or service to a customer and when the customer pays for the good or service will be one year or less.

Business Combinations

Business Combinations	12 Months Ended
	Mar. 31, 2022
Business Combinations [Abstract]
Business Combinations	4. Business Combinations Fiscal Year 2021 Transactions eRx Network Holdings, Inc. On May 1, 2020, we exercised our option to purchase and completed the acquisition of 100 % of the ownership interest in eRx Network Holdings, Inc. (“eRx”), a leading provider in comprehensive, innovative and secure data-driven solutions for pharmacies. At the time of the acquisition, all outstanding eRx equity awards were canceled and holders of eRx stock options and vested eRx stock appreciation rights were able to elect to receive consideration in the form of a cash payment or vested stock appreciation rights of the Company. See Note 18, Incentive Compensation Plans , for additional information. Prior to the acquisition, we held an option to purchase eRx which we accounted for as an equity investment. Therefore, our acquisition of eRx was accounted for as a business combination achieved in stages under the acquisition method in accordance with Accounting Standards Codification 805, Business Combinations (“ASC 805”). Accordingly, at the acquisition, we remeasured our business purchase option to fair value and recognized a loss of $ 6,000 which is recorded in Other, net on our consolidated statement of operations for the year ended March 31, 2021. Our consolidated statement of operations for the year ended March 31, 2021, also included $ 63,393 of total revenue from the acquired business. The following table summarizes information related to this acquisition as of the acquisition date. The fair values of the assets acquired and the liabilities assumed were determined based on information available to the Company using primarily an income-based approach. We consider our accounting for the assets acquired and liabilities assumed in the eRx acquisition to be complete. eRx Cash paid at closing $ 249,359 Fair value of eRx purchase option 140,500 Fair value of vested stock appreciation rights 5,097 Cash paid for canceled eRx equity awards 5,891 Total Consideration Fair Value at Acquisition Date $ 400,847 Allocation of the Consideration Transferred: Cash $ 54,108 Accounts receivable 12,747 Prepaid expenses and other current assets 609 Goodwill 225,156 Identifiable intangible assets: Customer relationships (life 17 years) 131,200 Technology-based intangible assets (life 9 - 12 years) 29,700 Other noncurrent assets 20 Accounts payable ( 2,543 ) Accrued expenses and other current liabilities ( 10,933 ) Deferred income tax liabilities ( 39,217 ) Total consideration transferred $ 400,847 The goodwill recognized, all of which is assigned to the Network Solutions segment, is primarily attributable to expected synergies of the combined businesses and the acquisition of an assembled workforce knowledgeable of the healthcare and information technology industries. The goodwill is not expected to be deductible for tax purposes. See Note 10, Goodwill and Intangible Assets . Acquisition costs related to the purchase of eRx were not material. PDX, Inc. On June 1, 2020, we completed the cash purchase of 100 % of the ownership interest in PDX, Inc. (“PDX”), a company focused on delivering patient-centric and innovative technologies for pharmacies and health systems. We accounted for this transaction as a business combination using the acquisition method. Our consolidated statement of operations for the year ended March 31, 2021, included $ 57,599 of total revenue from the acquired business. The fair values of the assets acquired and the liabilities assumed were determined based on information available to the Company using primarily an income-based approach. We consider our accounting for the other assets acquired and liabilities assumed in the PDX acquisition to be complete. After customary working capital adjustments, transaction fees and other adjustments, the total consideration fair value at the acquisition date was $ 198,291 . The following table summarizes the allocation of consideration transferred: PDX Cash $ 755 Accounts receivable 5,739 Prepaid expenses and other current assets 2,251 Property and equipment 840 Goodwill 98,830 Identifiable intangible assets: Customer relationships (life 18 years) 74,300 Technology-based intangible assets (life 10 - 11 years) 25,300 Other noncurrent assets 690 Accounts payable ( 3,882 ) Deferred revenue, current ( 2,946 ) Accrued expenses and other current liabilities ( 3,364 ) Other long-term liabilities ( 222 ) Total consideration transferred $ 198,291 The goodwill recognized, all of which is assigned to the Network Solutions segment, is primarily attributable to expected synergies of the combined businesses and the acquisition of an assembled workforce knowledgeable of the healthcare and information technology industries. The goodwill is expected to be deductible for tax purposes. See Note 10, Goodwill and Intangible Assets . Acquisition costs related to the purchase of PDX were not material. Nucleus.io In August 2020, we completed the acquisition of Nucleus.io, a leader in the development of advanced, fully enabled, cloud-native imaging and workflow technology. We acquired Nucleus.io for total consideration of $ 35,120 and accounted for the acquisition as a business combination. The consideration transferred was primarily allocated to technology-based intangible assets of $ 11,700 (life of 15 years) and goodwill of $ 22,341 . The goodwill recognized is assigned to the Software and Analytics segment and is not expected to be deductible for tax purposes. We consider our accounting for the Nucleus.io acquisition to be complete. Acquisition costs related to the purchase of Nucleus.io were not material. Fiscal Year 2020 Transactions The Merger On March 10, 2020, pursuant to the Agreement and Plan of Merger, dated December 20, 2016 (the “Merger Agreement”), the Company combined with SpinCo in a two-step all-stock “Reverse Morris Trust” transaction that involved (i) a separation of SpinCo from McKesson, followed by (ii) the merger of SpinCo with and into the Company, with the Company as the surviving company. As a result, the Joint Venture became a wholly owned subsidiary of the Company. McKesson accepted 15,426,537 shares of its own common stock, par value $ 0.01 (the “McKesson Common Stock”) in exchange for all 175,995,192 issued and outstanding shares of SpinCo common stock, par value $ 0.001 per share (the “SpinCo Common Stock”). All shares of SpinCo Common Stock were then converted into an equal number of shares of common stock of the Company, par value $ 0.001 (the “Change Common Stock”), which the Company issued to the former holders of SpinCo Common Stock, together with cash in lieu of any fractional shares. Immediately following the Merger, approximately 58 % of the outstanding Change Common Stock was held by pre-Merger holders of McKesson Common Stock and approximately 42 % of the outstanding Change Common Stock was held by pre-Merger holders of Change Common Stock. Prior to the Merger, we accounted for our investment in the Joint Venture under the equity method of accounting. Therefore, the acquisition of control of the Joint Venture was accounted for as a business combination achieved in stages under the acquisition method, in accordance with ASC 805. Accordingly, we remeasured our previously held equity interest in the Joint Venture to fair value by reference to the publicly traded price of the common shares issued to SpinCo shareholders in exchange for the remaining 58 % equity interest in the Joint Venture. Upon remeasurement, we recognized a loss of $ 230,229 which is included in Loss from Equity Method Investment in the Joint Venture in the consolidated statement of operations. The loss represents the amount by which the carrying value of our investment in the Joint Venture exceeded the fair value of our 42 % interest immediately prior to the Merger. The fair values of the assets acquired and the liabilities assumed were determined based on information available to the Company. During fiscal year 2021, we continued to make purchase price allocation adjustments to refine the fair values of assets acquired and liabilities assumed. These refinements primarily included net increases to our deferred tax liability and income taxes payable, which also impacted goodwill. There were no impacts to the consolidated statement of operations as a result of the adjustments. We consider our accounting for the assets acquired and liabilities assumed in the Merger to be complete. The following table summarizes our net assets acquired and purchase price allocation : Net assets acquired: Amount Cash $ 330,665 Accounts receivable, net of allowance of $ 22,059 718,895 Contract assets 132,704 Prepaid expenses and other current assets 115,436 Investment in business purchase option 146,500 Property and equipment, net 206,751 Goodwill 4,363,282 Other noncurrent assets 169,539 Identified intangible assets: Customer relationships (life 12 - 16 years) 3,056,000 Tradenames (life 18 years) 146,000 Technology-based intangible assets (life 6 - 12 years) 1,188,000 Accounts payable ( 60,637 ) Accrued expenses ( 563,791 ) Deferred revenue, current ( 292,528 ) Current portion of long-term debt ( 28,969 ) Other current liabilities ( 22,732 ) Long-term debt, excluding current portion ( 4,713,565 ) Deferred income tax liabilities ( 576,546 ) Tax receivable agreement obligations due to related parties ( 176,586 ) Other long-term liabilities ( 102,675 ) Net assets acquired $ 4,035,743 Summary of purchase consideration: Fair value of shares issued to SpinCo shareholders ( 175,995,192 shares at $ 12.47 per share): Common Stock, $ 0.001 par value $ 176 Additional paid-in capital 2,194,484 Fair value of Joint Venture equity interest previously held 1,589,040 Fair value of Joint Venture equity interest previously held through TEUs 216,764 Settlement of dividend receivable 42,778 Repayment of advances to member ( 7,499 ) Purchase consideration $ 4,035,743 The goodwill recognized in the Merger is primarily attributable to expected synergies of the combined businesses and the acquisition of an assembled workforce knowledgeable of the healthcare and information technology industries. The goodwill is not deductible for tax purposes. Acquisition costs related to the Merger were not material. Results of Operations Subsequent to the Merger, the results of operations attributable to the Joint Venture are included in our consolidated statements of operations. We generated revenues of $ 196,792 and a pre-tax loss of $ 4,288 from the Joint Venture from the acquisition date to March 31, 2020. Pro Forma Financial Information (unaudited) The following pro forma financial information was derived from the historical financial statements of the Company and the Joint Venture and gives effect to the acquisition as if it had occurred on April 1, 2018. The pro forma amounts were calculated by applying the Company’s accounting policies and adjusting the results of the Joint Venture to reflect (i) the additional depreciation and amortization that would have been charged resulting from the fair value adjustments to property and equipment and intangible assets, (ii) the additional interest expense associated with the consolidation of the Joint Venture’s long-term borrowings, and (iii) the decrease to revenue resulting from the fair value adjustment of assumed deferred revenue obligations. (Unaudited) Year Ended March 31, 2021 (1) 2020 2019 Total revenue n/a $ 3,290,734 $ 3,133,907 Net income (loss) n/a $ ( 228,234 ) $ ( 128,889 ) Net income (loss) per share, basic and diluted n/a $ ( 0.75 ) $ ( 0.43 ) (1) Pro forma information is not applicable as the Joint Venture’s results are fully consolidated for the year ended March 31, 2021 .

Dispositions

Dispositions	12 Months Ended
	Mar. 31, 2022
Dispositions [Abstract]
Dispositions	5. Dispositions Connected Analytics On May 1, 2020, we completed the sale of our Connected Analytics business, which was included in our Software and Analytics segment, for total consideration of $ 55,000 , subject to a customary working capital adjustment, including a $ 25,000 note receivable from the buyer which was recorded within Other noncurrent assets, net on the consolidated balance sheets. The net book value of the Connected Analytics business prior to the sale was $ 23,428 , which includes primarily net accounts receivable of $ 16,636 , goodwill of $ 21,705 and deferred revenue of $ 17,083 . In connection with this transaction, we recognized a pre-tax gain on disposal of $ 24,337 , which is included within Gain on sale of businesses on the consolidated statement of operations. In July 2020, we received $ 25,000 plus interest from the buyer in satisfaction of the outstanding note receivable. Capacity Management On December 2, 2020, we completed the sale of our Capacity Management business, which was included in our Software and Analytics segment, for total consideration of $ 67,500 , subject to a customary working capital adjustment. The net book value of the Capacity Management business prior to the sale was $ 31,690 , which includes primarily net accounts receivable of $ 14,991 , goodwill of $ 26,944 and deferred revenue of $ 15,230 . In connection with this transaction, we recognized a pre-tax gain on disposal of $ 31,690 , which is included within Gain on sale of businesses on the consolidated statement of operations.

Concentration of Credit Risk

Concentration of Credit Risk	12 Months Ended
	Mar. 31, 2022
Concentration of Credit Risk [Abstract]
Concentration of Credit Risk	6. Concentration of Credit Risk We maintain our cash and cash equivalent balances in either bank depository accounts or money market mutual funds. The money market mutual funds are limited to investments in low-risk securities such as U.S. or government agency obligations, or repurchase agreements secured by such securities.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Mar. 31, 2022
Prepaid Expenses and Other Current Assets [Abstract]
Prepaid Expenses and Other Current Assets	8. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets generally include items for which we have paid the related vendor or supplier in advance of receiving the related service. Prepaid expenses and other current assets consisted of the following: March 31, 2022 March 31, 2021 Prepaid expenses $ 103,023 $ 86,307 Other current assets 74,636 53,951 Prepaid expenses and other current assets $ 177,659 $ 140,258

Property and Equipment

Property and Equipment	12 Months Ended
	Mar. 31, 2022
Property and Equipment [Abstract]
Property and Equipment	9. Property and Equipment Property and equipment consisted of the following: March 31, 2022 March 31, 2021 Land $ 406 $ 406 Buildings and leasehold improvements 59,067 60,716 Computer equipment 125,847 105,450 Production equipment 17,215 17,046 Office equipment, furniture and fixtures 33,702 34,696 Construction in process 21,010 15,497 Property and equipment, gross 257,247 233,811 Accumulated depreciation ( 115,907 ) ( 59,441 ) Property and equipment, net $ 141,340 $ 174,370 Depreciation expense was $ 56,708 , $ 56,240 , and $ 2,960 , for the years ended March 31, 2022, 2021 and 2020, respectively.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets [Abstract]
Goodwill and Intangible Assets	10. Goodwill and Intangible Assets Goodwill We assess goodwill for impairment annually (as of January 1 of each year) or whenever significant indicators of impairment are present. We recognized no impairment in conjunction with our most recent annual impairment analysis. The following table presents the changes in the carrying amount of goodwill: Software and Analytics Network Solutions Technology-Enabled Services Total Balance at March 31, 2020 $ 1,770,118 $ 1,645,831 $ 379,376 $ 3,795,325 Acquisitions 22,341 323,986 — 346,327 Dispositions ( 51,136 ) — — ( 51,136 ) Effects of foreign currency 15,583 — — 15,583 Adjustments 1,396 922 376 2,693 Balance at March 31, 2021 $ 1,758,302 $ 1,970,739 $ 379,752 $ 4,108,792 Effects of foreign currency 4,254 — — 4,254 Adjustments ( 142 ) — — ( 142 ) Balance at March 31, 2022 $ 1,762,414 $ 1,970,739 $ 379,752 $ 4,112,904 Fiscal Year 2020 Impairment Charge In accordance with ASC 805, on March 10, 2020, goodwill was recognized as a result of the Merger and was allocated to the Company’s reporting units on a relative fair value basis. Subsequent to the Merger, we concluded a triggering event had occurred due to the expected impact on our financial results due to COVID-19. Therefore, we performed a goodwill impairment test as of March 31, 2020 to compare each reporting unit’s carrying value to the respective fair value. The fair value of each reporting unit was determined using a combination of an income approach based on a discounted cash flow model and a market approach based on appropriate valuation multiples observed for the reporting unit’s guideline public companies. Fair value estimates resulted from a complex series of judgments about future events and uncertainties and relied heavily on estimates and assumptions. The estimates considered most impactful to the goodwill impairment test included our expectation on the amount of time it will take to return to a normal level of healthcare activity, the discount rate used in the income approach, and the market multiples used in the market approach. Reporting unit fair values were considered a Level 3 measurement due to the significance of unobservable inputs developed using company specific information. Based on the results of the interim impairment test, we recorded a non-cash pre-tax goodwill impairment charge of $ 561,164 for the year ended March 31, 2020, which was not deductible for income tax purposes. Intangible Assets Intangible assets subject to amortization consist of the following: March 31, 2022 March 31, 2021 Gross Carrying Accumulated Gross Carrying Accumulated Amount Amortization Net Amount Amortization Net Customer relationships $ 3,263,631 $ ( 556,029 ) $ 2,707,602 $ 3,263,653 $ ( 276,682 ) $ 2,986,971 Technology-based intangible assets 1,262,020 ( 407,940 ) 854,080 1,261,285 ( 200,773 ) 1,060,512 Tradenames and other 158,010 ( 20,089 ) 137,921 150,538 ( 10,948 ) 139,590 Total $ 4,683,661 $ ( 984,058 ) $ 3,699,603 $ 4,675,476 $ ( 488,403 ) $ 4,187,073 Amortization expense was $ 498,843 , $ 463,334 , and $ 24,194 for the years ended March 31, 2022, 2021, and 2020, respectively. Aggregate amortization expense for intangible assets by fiscal year as of March 31, 2022 is estimated to be: 2023 $ 450,660 2024 403,831 2025 369,362 2026 335,823 2027 302,891 Thereafter 1,837,036 Total $ 3,699,603

Other Noncurrent Assets

Other Noncurrent Assets	12 Months Ended
	Mar. 31, 2022
Other Noncurrent Assets [Abstract]
Other Noncurrent Assets	11. Other Noncurrent Assets Other noncurrent assets consist of the following: March 31, 2022 March 31, 2021 Capitalized software developed for internal use, net $ 364,617 $ 260,858 Other noncurrent assets, net 235,444 169,283 Other noncurrent assets, net $ 600,061 $ 430,141 Capitalized software developed for internal use, net includes accumulated amortization of $ 168,532 and $ 71,356 as of March 31, 2022 and 2021, respectively. Amortization expense for capitalized software developed for internal use was $ 126,257 and $ 71,473 for the years ended March 31, 2022 and 2021, respectively, and was immaterial for the year ended March 31, 2020. Changes in the carrying amount of capitalized software developed for sale, net, were as follows: March 31, 2022 March 31, 2021 Balance at beginning of period $ 10,779 $ 574 Amounts capitalized 11,343 13,919 Amortization expense ( 3,509 ) ( 1,326 ) Disposal from sale of businesses — ( 837 ) Other ( 846 ) ( 1,551 ) Balance at end of period $ 17,767 $ 10,779 Activity related to capitalized software developed for sale, net, was immaterial for the year ended March 31, 2020.

Accrued Expenses

Accrued Expenses	12 Months Ended
	Mar. 31, 2022
Accrued Expenses [Abstract]
Accrued Expenses	12. Accrued Expenses Accrued expenses consist of the following: March 31, 2022 March 31, 2021 Customer deposits $ 46,129 $ 48,337 Accrued compensation 143,092 177,509 Accrued outside services 53,844 45,349 Accrued insurance 12,784 10,897 Accrued income, sales and other taxes 39,496 57,742 Accrued interest 6,715 6,783 Pass-through payments 29,762 16,799 Tax receivable agreement obligations 36,702 10,646 Interest rate cap agreements — 22,360 Other accrued liabilities 92,982 87,871 Accrued expenses $ 461,506 $ 484,293

Long-Term Debt

Long-Term Debt	12 Months Ended
	Mar. 31, 2022
Long-Term Debt [Abstract]
Long-Term Debt	13. Long-Term Debt Long-term debt consists of the following: March 31, 2022 March 31, 2021 Senior Credit Facilities $ 5,100,000 Term Loan Facility, due March 1, 2024 , net of unamortized discount of $ 55,763 and $ 87,698 at March 31, 2022 and March 31, 2021, respectively (effective interest rate of 4.42 % and 4.42 %, respectively) $ 3,257,487 $ 3,405,552 $ 785,000 Revolving Facility, expiring July 3, 2024 , and bearing interest at a variable interest rate — — Senior Notes $ 1,325,000 5.75 % Senior Notes due March 1, 2025 , net of unamortized discount of $ 5,303 and $ 6,921 at March 31, 2022 and March 31, 2021, respectively (effective interest rate of 5.90 % and 5.90 %, respectively) 1,319,697 1,318,079 Tangible Equity Unit Senior Amortizing Note $ 47,367 Senior Amortizing Notes due June 30, 2022 , net of unamortized discount of $ 20 and $ 293 at March 31, 2022 and March 31, 2021, respectively (effective interest rate of 7.44 % and 7.44 %, respectively) 4,234 20,345 Other 8,675 18,138 Less current portion ( 10,006 ) ( 27,339 ) Long-term debt, excluding current portion $ 4,580,087 $ 4,734,775 Senior Credit Facilities Our long-term indebtedness includes a senior secured term loan facility (the “Term Loan Facility”) and a revolving credit facility (the “Revolving Facility”; together with the Term Loan Facility, the “Senior Credit Facilities”). The Senior Credit Facilities provide us with the right at any time to request additional term loan tranches and/or term loan increases, increases in the revolving commitments and/or additional revolving credit facilities up to the sum of (i) (a) the greater of $ 1,080,000 or an amount equal to 100 % of EBITDA for the most recently ended four fiscal quarters, plus (b) certain voluntary prepayments, repurchases, redemptions and other retirements of indebtedness and commitments under our Senior Credit Facilities, incremental equivalent debt, and refinancings thereof, plus (ii) an additional aggregate amount such that, after giving pro forma effect to such incurrence, (x) if such additional amounts are secured on a pari passu basis with the first lien obligations under our Senior Credit Facilities, our consolidated first lien net leverage ratio does not exceed 4.90 to 1.00, (y) if such additional amounts are secured on a junior lien basis to the first lien obligations under our Senior Credit Facilities, our consolidated secured net leverage ratio does not exceed 5.75 to 1.00 and (z) if such additional amounts are unsecured, either our consolidated total net leverage ratio does not exceed 6.00 to 1.00 or we could incur at least $ 1.00 of additional indebtedness under a consolidated interest coverage ratio test under our Senior Credit Facilities of 2.00 to 1.00. The lenders under the Senior Credit Facilities are not obligated to provide any such incremental commitments or loans, which are uncommitted, and any such addition of or increase in commitments or loans are subject to obtaining commitments and certain customary conditions precedent in our Senior Credit Facilities. Borrowings under the Senior Credit Facilities bear interest at a rate equal to either (i) LIBOR for the relevant interest period, adjusted for statutory reserve requirements (the Term Loan Facility is subject to a floor of 1.0 % per year and the Revolving Facility is subject to a floor of 0.0 % per year), plus an applicable margin or (ii) a base rate equal to the highest of (a) the rate of interest in effect as publicly announced by the administrative agent as its prime rate, (b) the federal funds effective rate plus 0.5 % and (c) adjusted LIBOR for an interest period of one month plus 1.0 % (the Term Loan Facility may be subject to a floor of 2.0 % per year), in each case, plus an applicable margin. In addition to paying interest on outstanding principal, under the Revolving Facility, we are required to pay a commitment fee of 0.375 % per year based on the unutilized commitments thereunder. We must also pay customary letter of credit fees and an annual administrative agency fee. The Senior Credit Facilities requires us to prepay outstanding term loans, subject to certain exceptions, with:  50 % of the Company’s annual Excess Cash Flow (as defined in the Senior Credit Facilities) commencing with the first full fiscal year completed after the closing of the Senior Credit Facilities (percentage is reduced to 25 % and 0 % if we achieve and maintain specified first lien net leverage ratios), subject to certain credits and exceptions;  100 % of the net cash proceeds of non-ordinary course asset sales or other dispositions of property, including insurance condemnation proceeds (percentage is reduced to 50 %, 25 % and 0 % if we achieve and maintain specified first lien net leverage ratios), subject to certain exceptions, in excess of a minimum threshold and subject to our right to reinvest the proceeds; and  100 % of the net cash proceeds of any incurrence of debt by the Company, other than proceeds from debt permitted per the terms of the Senior Credit Facilities. The foregoing mandatory prepayments will be applied, subject to certain exceptions, to the term loans outstanding under the Senior Credit Facilities then outstanding as directed by us. We may voluntarily repay outstanding loans or reduce outstanding commitments under the Senior Credit Facilities at any time without premium or penalty, subject to reimbursements of the lenders’ redeployment costs actually incurred in the case of a prepayment of LIBOR borrowings prior to the last day of the relevant interest period. Voluntary prepayments may be applied to the scheduled installments of principal of the Term Loan Facility in any order and applied to any class of loans. The Term Loan Facility amortizes in equal quarterly installments in aggregate annual amounts equal to 1.0 % of the principal amount outstanding, with the balance being payable at maturity. Principal amounts outstanding under the Revolving Facility are due and payable in full at maturity. We do no t have any remaining quarterly amortization payments. All obligations of the borrowers under the Senior Credit Facilities and under any swap agreements and cash management arrangements that are entered into are unconditionally guaranteed by all material wholly owned direct and indirect domestic restricted subsidiaries of the borrowers and by the direct parent of the Parent Borrower, with customary exceptions including, among other things, where providing such guarantees is not permitted by law, regulation or contract or would result in adverse tax consequences. All obligations of the borrowers under the Senior Credit Facilities and under any swap agreements and cash management arrangements are secured, subject to permitted liens and other exceptions, by substantially all of the assets of the borrowers and each guarantor, including but not limited to: (i) a perfected pledge of all of the capital stock issued by the parent borrower and each direct wholly owned domestic restricted subsidiary of the borrowers or any subsidiary guarantor (subject to certain exceptions) and up to 65 % of the capital stock issued and outstanding by each direct wholly owned foreign restricted subsidiary of the borrowers or any subsidiary guarantor (subject to certain exceptions) and (ii) perfected security interests in and mortgages on substantially all tangible and intangible personal property and material owned real property of the borrowers and the subsidiary guarantors (subject to certain exceptions and exclusions). In June 2020, we repaid our outstanding Revolving Facility balance of $ 250,000 . The Revolving Facility has a total borrowing capacity of $ 785,000 less outstanding letters of credit which totaled $ 5,485 and $ 6,194 at March 31, 2022 and 2021, respectively. This leaves $ 779,515 and $ 778,806 available for borrowing as of March 31, 2022 and 2021, respectively. During fiscal years 2022 and 2021, we repaid $ 180,000 and $ 315,000 , respectively, on our Term Loan Facility and recognized a Loss on extinguishment of debt of $ 3,885 and $ 8,924 , respectively, in our consolidated statement of operations. As of March 31, 2022, we were in compliance with all of the applicable covenants under the Senior Credit Facilities. Senior Notes Our long-term indebtedness also includes 5.75 % senior notes due March 1, 2025 (the “Senior Notes”) with interest payable semi-annually on March 1 and September 1 of each year. In April 2020, we issued an additional $ 325,000 aggregate principal amount of 5.75 % Senior Notes due 2025 (the “Notes”) and incurred issuance costs of $ 6,161 . The notes were issued as part of the same series as the $ 1,000,000 Senior Notes in February 2017. We may redeem the Senior Notes, in whole or in part, at any time on or after March 1, 2020 at the applicable redemption price, plus accrued and unpaid interest. If we experience specific kinds of changes in control (including the closing of the UHG Transaction), we must offer to purchase the Senior Notes at a price equal to 101 % of the principal amount, plus accrued and unpaid interest. The Senior Notes are senior unsecured obligations and rank equally in right of payment with all of our existing and future indebtedness and senior in right of payment to all of our existing and future subordinated indebtedness. Our obligations under the Senior Notes are guaranteed on a senior basis by all of our existing and subsequently acquired or organized wholly owned U.S. restricted subsidiaries that guarantee the Senior Credit Facilities. The Senior Notes and the related guarantees are effectively subordinated to our existing and future secured obligations and that of our affiliate guarantors to the extent of the value of the collateral securing such obligations and are structurally subordinated to all existing and future indebtedness and other liabilities of any of our subsidiaries that do not guarantee the Senior Notes. As of March 31, 2022, we were in compliance with all of the applicable covenants under the Senior Notes. Tangible Equity Unit Senior Amortizing Note See Note 16, Tangible Equity Units, for information. Other From time to time, we enter into deferred financing arrangements with certain vendors. The obligations under such arrangements are recorded at the present value of the scheduled payments. Such future payments totaled approximately $ 7,498 and $ 16,346 at March 31, 2022 and 2021, respectively. In addition, we have certain finance lease obligations that are classified as debt as discussed in Note 7, Leases . Aggregate Future Maturities The aggregate amounts of future maturities by fiscal year under long-term debt arrangements are as follows: 2023 $ 10,006 2024 3,315,832 2025 1,325,340 2026 — 2027 — Thereafter — Total $ 4,651,178

Interest Rate Cap Agreements

Interest Rate Cap Agreements	12 Months Ended
	Mar. 31, 2022
Interest Rate Cap Agreements [Abstract]
Interest Rate Cap Agreements	14. Interest Rate Cap Agreements Risk Management Objective of Using Derivatives We are exposed to certain risks arising from both our business operations and economic conditions. We principally manage exposures to a wide variety of business and operational risks through management of core business activities. We manage economic risks, including interest rate, liquidity and credit risk, primarily by managing the amount, sources and duration of debt funding and the use of derivative financial instruments. Specifically, we enter into derivative financial instrument contracts to manage differences in the amount, timing and duration of known or expected cash receipts and known or expected cash payments principally related to existing borrowings. Cash Flow Hedges of Interest Rate Risk Our objectives in using interest rate derivatives are to add stability to interest expense and to manage exposure to interest rate movements. To accomplish these objectives, we primarily use interest rate cap agreements as part of our interest rate risk management strategy. Payments and receipts related to interest rate cap agreements are included in cash flows from financing activities in the consolidated statements of cash flows. In August 2018, the Joint Venture executed annuitized interest rate cap agreements with notional amounts of $ 500,000 , accreting to $ 1,500,000 to limit the exposure of the variable component of interest rates under the Term Loan Facility or future variable rate indebtedness to a maximum of 1.0 %. The interest rate cap agreements became effective August 31, 2018 , accreted to $ 1,500,000 and expired December 31, 2021 . Upon completion of the Merger, these agreements were redesignated as cash flow hedges of the Company. In March 2020, we executed additional annuitized interest rate cap agreements with notional amounts totaling $ 1,000,000 to limit the exposure of the variable component of the interest rates under the Term Loan Facility or future variable rate indebtedness to a maximum of 1.0 %. Each interest rate cap agreement became effective March 31, 2020 and expires March 31, 2024 . At March 31, 2022, each of our outstanding interest rate cap agreements were designated as cash flow hedges of interest rate risk and were determined to be highly effective. Amounts reported in accumulated other comprehensive income related to derivatives will be reclassified to interest expense as interest payments are made on our variable-rate debt. We estimate that $ 6,025 will be reclassified as an increase to interest expense within one year. The fair value of derivative instruments is as follows: Fair Values of Derivative Financial Instruments Asset (Liability) Derivative financial instruments designated as hedging instruments: Balance Sheet Location March 31, 2022 March 31, 2021 Interest rate cap agreements Prepaid and other current assets $ 7,214 $ — Interest rate cap agreements Other noncurrent assets, net 18,257 — Interest rate cap agreements Accrued expenses — ( 22,360 ) Interest rate cap agreements Other long-term liabilities — ( 365 ) Total $ 25,471 $ ( 22,725 ) Effect of Derivative Instruments on the Statement of Operations The effect of the derivative instruments on the consolidated statements of operations is as follows: Year Ended Year Ended Year Ended Derivative financial instruments in cash flow hedging relationships: March 31, 2022 March 31, 2021 March 31, 2020 Gain (loss) related to derivative financial instruments recognized in other comprehensive income (loss) $ 25,563 $ ( 4,855 ) $ ( 1,361 ) (Gain) loss related to portion of derivative financial instruments reclassified from accumulated other comprehensive (income) loss to interest expense $ 1,938 $ 1,202 $ ( 22 ) Credit Risk-Related Contingent Features We have agreements with each of our derivative counterparties providing that if we default on any of our indebtedness, including a default where repayment of the indebtedness has not been accelerated by the lender, then we also could be declared in default on our derivative obligations. As of March 31, 2022, each of our derivative financial instruments was in a net asset position. As of March 31, 2021, the termination value of derivative financial instruments in a net liability position, which includes accrued interest but excludes any adjustment for nonperformance risk, was $ 23,063 . If we had defaulted on any of our indebtedness at March 31, 2021, we could have been required to settle our obligations under the agreements at this termination value. We do not offset any derivative financial instruments and the derivative financial instruments are not subject to collateral posting requirements.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Mar. 31, 2022
Fair Value Measurements [Abstract]
Fair Value Measurements	15. Fair Value Measurements Assets and Liabilities Measured at Fair Value on a Recurring Basis The following table below summarizes our assets and liabilities measured at fair value on a recurring basis, aggregated by the level in the fair value hierarchy within which those measurements fall: Quoted in Significant Other Significant Identical Markets Observable Inputs Unobservable Inputs Total (Level 1) (Level 2) (Level 3) Balance at March 31, 2022: Interest rate cap agreements $ 25,471 $ — $ 25,471 $ — Total $ 25,471 $ — $ 25,471 $ — Balance at March 31, 2021: Interest rate cap agreements $ (22,725) $ — $ (22,725) $ — Total $ ( 22,725 ) $ — $ ( 22,725 ) $ — Derivative Financial Instruments The valuation of our derivative financial instruments is determined using widely accepted valuation techniques, including a discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivative, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair value of the interest rate cap agreements is determined using the market standard methodology of discounting the future expected cash receipts that would occur if variable interest rates rise above the strike rate of the caps. The variable interest rates used in the calculation of projected receipts on the cap are based on an expectation of future interest rates derived from observable market interest rate curves and volatilities. We incorporate credit valuation adjustments to appropriately reflect both our own nonperformance risk and the respective counterparty’s nonperformance risk in the fair value measurements. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we consider the impact of netting and any applicable credit enhancements. We measure the credit risk of our derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio. Although we have determined that the majority of the inputs used to value our derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments utilize Level 3 inputs to evaluate the likelihood of both our own default and counterparty default. As of March 31, 2022, we determined that the credit valuation adjustments are not significant to the overall valuation of our derivatives and therefore, the valuations are classified in Level 2 of the fair value hierarchy. Contingent Consideration Prior to December 31, 2020, the valuation of our contingent consideration obligations was determined using a discounted cash flow method that involved a Monte Carlo simulation. This analysis reflects the contractual terms of the purchase agreements (i.e., minimum and maximum payments, length of earn-out periods, manner of calculating amounts due, etc.) and utilizes assumptions with regard to future cash flows that were determined using a Monte Carlo simulation which were then discounted to present value using an appropriate discount rate. Significant increases in future revenue assumptions would have resulted in a higher fair value measurement while an increase in the discount rate would have resulted in a lower fair value measurement. The measurement period ended December 31, 2020 at which point no obligations remained and the contingent consideration was reduced to zero. The table below presents a reconciliation of the fair value of the liabilities that use significant unobservable inputs (Level 3): Year Ended Year Ended March 31, 2022 March 31, 2021 Balance at beginning of period $ — $ ( 3,000 ) Gain (loss) included in Other, net — 3,000 Balance at end of period $ — $ — The contingent consideration obligation was acquired as part of the Merger and there was no significant activity for the year ended March 31, 2020. Assets and Liabilities Measured at Fair Value upon Initial Recognition The carrying amount and the fair value of financial instruments held as of March 31, 2022 and 2021 were as follows: March 31, 2022 March 31, 2021 Carrying Amount Fair Value Carrying Amount Fair Value Cash and cash equivalents $ 252,298 $ 252,298 $ 113,101 $ 113,101 Senior Credit Facilities (Level 2) $ 3,257,487 $ 3,288,401 $ 3,405,552 $ 3,488,883 Senior Notes (Level 2) $ 1,319,697 $ 1,316,785 $ 1,318,079 $ 1,351,500 Debt component of tangible equity units (Level 2) $ 4,234 $ 4,284 $ 20,345 $ 21,435 As described in Note 10, Goodwill and Intangible Assets , our prior year goodwill impairment analysis utilized Level 3 inputs in determining reporting unit fair values. Additionally, the assets acquired and liabilities assumed as part of business acquisitions were recorded at fair value upon initial recognition. See Note 4, Business Combinations , for additional information.

Tangible Equity Units

Tangible Equity Units	12 Months Ended
	Mar. 31, 2022
Tangible Equity Units [Abstract]
Tangible Equity Units	16. Tangible Equity Units In July 2019, we completed our offering of 5,750,000 TEUs. Total proceeds, net of underwriting discounts, were $ 278,875 . Each TEU, which has a stated amount of $ 50 , is comprised of a stock purchase contract and a senior amortizing note due June 30, 2022 . We allocated the proceeds from the issuance of the TEUs to equity and debt based on the relative fair values of the respective components of each TEU. The value allocated to the stock purchase contracts is reflected net of issuance costs in additional paid in capital. The value allocated to the senior amortizing notes is reflected in debt on the consolidated balance sheets. Issuance costs, reflected as a reduction of the face amount of the amortizing notes, are being accreted to the face amount of the debt under the effective interest method. The aggregate values assigned upon issuance of the TEUs, based on the relative fair value of the respective components of each TEU, were as follows: Equity Component Debt Component Total Price per TEU $ 41.7622 $ 8.2378 $ 50.00 Gross proceeds 240,133 47,367 287,500 Issuance costs ( 7,204 ) ( 1,421 ) ( 8,625 ) Net proceeds $ 232,929 $ 45,946 $ 278,875 Each senior amortizing note has an initial principal amount of $ 8.2378 and bears interest at 5.5 % per year. On each March 30, June 30, September 30 and December 30, we pay equal quarterly cash installments of $ 0.7500 per amortizing note (except for the September 30, 2019 installment payment, which was $ 0.7417 per amortizing note). Each installment constitutes a payment of interest and partial payment of principal. Unless settled earlier, each purchase contract will automatically settle on June 30, 2022 . Holders of the purchase contracts may elect to early settle prior to June 30, 2022 at the minimum settlement rate, resulting in the holder receiving the minimum number of shares for that purchase contract. We will deliver between a minimum of 12,994,501 shares and a maximum of 15,593,320 shares of common stock, subject to adjustment, based on the Applicable Market Value (as defined below) of common stock as described below:  If the Applicable Market Value is greater than $ 15.60 per share, holders will receive 3.2051 shares of common stock per purchase contract.  If the Applicable Market Value is less than or equal to $ 15.60 per share but greater than or equal to $ 13.00 per share, the holder will receive a number of shares of common stock per purchase contract equal to $ 50 , divided by the Applicable Market Value; and  If the Applicable Market Value is less than $ 13.00 per share, the holder will receive 3.8461 shares of common stock per purchase contract. The Applicable Market Value is defined as the arithmetic average of the volume weighted average price per share of common stock over the twenty consecutive trading day period immediately preceding the balance sheet date, or June 30, 2022, for settlement of the stock purchase contracts. The minimum shares to be issued are included in the calculation of basic net income (loss) per share. The difference between the minimum shares and the maximum shares are potentially dilutive securities, and accordingly, are included in the diluted net income (loss) per share on a pro rata basis to the extent the Applicable Market Value is higher than $ 13.00 but is less than $ 15.60 at period end. After the initial issuance date, we may elect to have the purchase contracts settled prior to the mandatory settlement date, June 30, 2022 . Upon settlement, each purchase contract will be settled for common stock equal to 3.2051 shares of common stock per purchase contract. In the event of certain types of changes in control (including the consummation of the UHG Transaction) or other specified Reorganization Events (as defined in the TEU agreements), each outstanding purchase contract will convert to a contract entitling the holder to receive cash or other assets that holders of the Company’s common stock are entitled to receive in the Reorganization Event. The amount of cash or other assets each holder is entitled to following a Reorganization Event is based on the Applicable Market Value and the corresponding settlement rate in effect at the time. The following table summarizes TEU activity: Tangible Equity Units Outstanding at March 31, 2020 5,137,345 Conversions ( 303,700 ) Outstanding at March 31, 2021 4,833,645 Conversions ( 779,325 ) Outstanding at March 31, 2022 4,054,320

Equity Method Investment in Cha

Equity Method Investment in Change Healthcare LLC	12 Months Ended
	Mar. 31, 2022
Equity Method Investment in Change Healthcare LLC [Abstract]
Equity Method Investment in Change Healthcare LLC	1 7. Equity Method Investment in Change Healthcare LLC Equity Method Investment in Change Healthcare LLC In connection with the creation of the Joint Venture in March 2017, we exchanged our 45.615 % investment in Change Healthcare Performance, Inc. (“Legacy CHC “) for 30 % of the membership units of the Joint Venture. At this time, the Joint Venture issued debt and used the proceeds to acquire the remaining 54.385 % of Legacy CHC. In March 2017, the fair value of the Joint Venture was determined using a combination of the income and the market valuation approaches. Under the income approach, a discounted cash flow model was used in which cash flows anticipated over several periods, plus a terminal value at the end of that time horizon, were discounted to their present value using an expected rate of return. Under the market approach, valuation multiples of reasonably similar publicly traded companies or guideline companies were applied to the Joint Venture’s operating results. These valuation approaches were considered a Level 3 fair value measurement because they required complex assumptions and judgments by management in projecting future operating results, selecting guideline companies for comparisons, determining appropriate market value multiples, selecting the discount rate to measure the risks inherent in the future cash flows and assessing the business’s life cycle and the competitive trends impacting the business, including considering technical, legal, regulatory, or economic barriers to entry. Following our initial public offering in July 2019, the Company contributed the offering proceeds to the Joint Venture in exchange for 49,285,713 additional units of the Joint Venture, representing approximately 11 % of additional ownership interest. As a result of the additional ownership interest acquired, the Company measured additional basis differences based on the fair value of the Joint Venture’s assets and liabilities as of the date of the initial public offering using valuation approaches substantially similar to those used at creation of the Joint Venture. Prior to the Merger on March 10, 2020, we accounted for our investment in the Joint Venture using the equity method of accounting. During the period from April 1, 2019 to March 10, 2020, we recorded a proportionate share of the loss from this investment of $ 380,713 , which included transaction and integration expenses incurred by the Joint Venture and basis adjustments, including amortization expenses, associated with equity method intangible assets. The amounts are included in Loss from Equity Method Investment in the Joint Venture in the consolidated statements of operations. Following completion of the Merger, we consolidate the Joint Venture and no longer account for our ownership interest as an equity method investment. Summarized financial information of the Joint Venture is as follows: Period of April 1, 2019 to Statement of Operations Data: March 10, 2020 Total revenue $ 3,092,875 Cost of operations (exclusive of depreciation and amortization) $ 1,263,244 Customer postage $ 215,448 Net income (loss) $ 123,771 Other Investments At the time of our initial public offering, we invested in a unit purchase contract and a debt instrument of the Joint Venture on terms that substantially mirror the economics of the TEUs (see Note 16, Tangible Equity Units ). Prior to the Merger, we accounted for these mirror arrangements as investments in debt and equity securities. After the Merger, our investments in the TEUs of the Joint Venture are eliminated in consolidation. The following table presents a reconciliation of the activity related to the other investments: Year Ended March 31, 2020 Balance at beginning of period $ — Acquisition of forward purchase contracts 232,928 Acquisition of available-for-sale debt securities 45,946 Receipt of payments on debt securities ( 7,332 ) Change in fair value of forward purchase contracts 14,836 Change in fair value of debt securities 1,489 TEU conversions of forward purchase contracts ( 31,000 ) Settlement of investment in forward purchase contracts (1) ( 216,764 ) Elimination of investment in debt securities (2) ( 40,103 ) Balance at end of period $ — (1) Amount is included as part of the Merger purchase price. See Note 4, Business Combinations for additional information. (2) Amount is eliminated as part of consolidation.

Incentive Compensation Plans

Incentive Compensation Plans	12 Months Ended
	Mar. 31, 2022
Incentive Compensation Plans [Abstract]
Incentive Compensation Plans	18. I ncentive Compensation Plans Omnibus Incentive Plan Long-term Incentive Plan Awards Effective as of our initial public offering, we adopted the Change Healthcare Inc. 2019 Omnibus Incentive Plan (the “Omnibus Incentive Plan”) pursuant to which 25.0 million shares of common stock were reserved for issuance to employees, directors and consultants. In connection with the Omnibus Incentive Plan, during the years ended March 31, 2022, 2021 and 2020, we granted to our employees and directors one or a combination of time-vesting restricted stock units, performance stock units, cash settled restricted stock units and time-vesting deferred stock units, under vesting terms that generally vary from one to four years from the date of grant. The fair value of each of these awards was determined on a per share basis based on our closing stock price on the date of grant. Each of these instruments are described below. Restricted Stock Units (“RSUs”) – The RSUs are subject to either a graded vesting schedule over four years , or a one- or four- year cliff vesting schedule, depending on the terms of the specific award. Certain RSUs were granted with accelerated vesting terms, in which 50 % of the RSUs will vest on the first anniversary of the vesting commencement date and 25 % of the RSUs will vest on each of the second and third anniversaries of the vesting commencement date. Upon vesting, RSUs are exchanged for shares of common stock. Performance Stock Units (“PSUs”) – The PSUs consist of two tranches, one for which the quantity of awards expected to vest varies based on the Company’s compound annual revenue growth rate over a three year period in comparison to a target percentage and one for which the quantity of awards expected to vest varies based on the Company’s compound annual adjusted EBITDA growth rate over a three year period in comparison to a target percentage. The awards granted during the year ended March 31, 2020 that are earned upon satisfaction of the performance conditions vest on the fourth anniversary of the vesting commencement date of the award (i.e., continued service is required beyond the satisfaction of the performance condition prior to vesting). The awards granted during the year ended March 31, 2021 that are earned upon satisfaction of the performance conditions vest on the third anniversary of the vesting commencement date of the award. We recognize compensation expense for PSUs based on the number of awards that are considered probable to vest. Recognition of expense is based on the probability of achievement of performance targets and is periodically reevaluated. Cash Settled Restricted Stock Units (“CSRSUs”) – The CSRSUs are expected to vest ratably over one or three years , depending on the terms of the specific award. Upon vesting, we are required to pay cash in settlement of such CSRSUs based on their fair value at the vesting date. As such, these awards are classified as liabilities and are recorded as Accrued liabilities on our consolidated balance sheets. During the years ended March 31, 2022 and 2021, we made cash payments of $ 8,300 and $ 2,273 , respectively, to settle Cash Settled Restricted Stock Units upon vesting. Deferred Stock Units (“DSUs”) – The DSUs vest 100 % upon the one-year anniversary of the date of grant. Unlike the RSUs, the DSUs are exchanged for shares of the Company’s common stock following the participant’s separation from service. The following table summarizes the Long-term Incentive Plans activity for the years ended March 31, 2022: Restricted Deferred Cash Settled Performance Stock Units Stock Units Restricted Stock Units Stock Units Weighted Weighted Weighted Weighted Average Average Average Average Grant Date Grant Date Grant Date Grant Date Shares Fair Value Shares Fair Value Shares Fair Value Shares Fair Value Unvested at April 1, 2021 14,120,518 $ 16.98 86,916 $ 11.93 434,512 $ 13.49 2,058,530 $ 14.32 Granted 1,188,176 $ 22.20 49,952 $ 23.15 — — — — Canceled ( 1,600,533 ) $ 17.50 — — ( 6,126 ) $ 13.54 ( 107,134 ) $ 14.00 Vested (1) ( 4,465,437 ) $ 17.58 ( 86,916 ) $ 11.93 ( 373,153 ) $ 13.45 ( 8,817 ) $ 13.76 Unvested at March 31, 2022 9,242,724 $ 17.26 49,952 $ 23.15 55,233 $ 13.78 1,942,579 $ 14.34 (1) During the year ended March 31, 2022, 86,916 Deferred Stock Units vested. However, these holders of these awards do not receive shares of common stock in exchange for these DSUs until they leave their position as described above. eRx Awards Upon completion of the eRx acquisition all outstanding eRx equity awards were canceled. Holders of eRx stock options and vested eRx stock appreciation rights were able to elect to receive consideration in the form of a cash payment or vested stock appreciation rights of the Company (“eRx vested SARs”). There were 478,180 of eRx vested SARs granted in conjunction with the eRx acquisition. These awards will remain outstanding until the individual holders exercise their award but are fully vested. As such, these eRx vested SARs are excluded from the unvested awards table below. For individuals with unvested eRx equity awards, we elected to issue replacement awards with vesting and exercisability terms generally identical to the existing eRx awards which were replaced. These replacement awards were granted under the Omnibus Incentive Plan and consisted of unvested restricted share units (“eRx RSUs”) and unvested stock appreciation rights (“eRx unvested SARs”) with terms identical to the original eRx awards. The awards vest subject to the employee’s continued employment through the date when Blackstone has sold at least 25 % of the maximum number of shares held by it (i.e., a liquidity event) and achieved specified rates of return that vary by award. Upon vesting and upon exercise of the outstanding eRx vested SARs, we are required to pay cash in settlement of such eRx awards based on their fair value at the vesting date. As such, these awards are classified as liabilities and are recorded as Accrued liabilities on our consolidated balance sheets. During the year ended March 31, 2022, we made cash payments of $ 4,479 to settle eRx RSUs upon vesting. The following table summarizes the eRx Awards activity for the years ended March 31, 2022: eRx Restricted eRx Unvested Stock Stock Units Appreciation Rights Weighted Weighted Average Average Grant Date Grant Date Shares Fair Value Shares Fair Value Unvested at April 1, 2021 243,833 $ 11.04 11,439 $ 11.04 Granted — — — — Canceled ( 19,253 ) $ 11.04 — — Vested ( 193,458 ) $ 11.04 ( 11,439 ) $ 11.04 Unvested at March 31, 2022 31,122 $ 11.04 — — At March 31, 2022, aggregate unrecognized compensation expense related to awards granted under the Omnibus Incentive Plan was $ 145,919 which is expected to be recognized over a weighted average period of 1.4 years. Legacy CHC Equity Plan In connection with the creation of the Joint Venture, we assumed and amended the Legacy CHC Equity Plan. Pursuant to the amended Legacy CHC Equity Plan, 37.9 million shares of the Company’s common stock have been reserved for the issuance of equity awards to employees, directors and consultants of the Joint Venture and its affiliates. The Company granted equity-based awards of its common stock to certain employees, officers and directors of the Joint Venture under terms of awards that are described below. Grants under the Legacy CHC Equity Plan consist of one or a combination of time-vested and/or performance-based awards. In most circumstances, the shares issued upon exercise of the equity awards are subject to certain call rights by the Company in the event of termination of service of an award holder and put rights by the award holder or his/her beneficiary in the event of death or disability. Replacement Awards In connection with the creation of the Joint Venture, we were obligated to either assume obligations related to existing equity awards or issue substantially equivalent equity awards. We elected to issue replacement awards with terms generally identical to the awards which were replaced. Because the stock of eRx Network and the 2017 Tax Receivable Agreement were distributed to Legacy CHC stockholders immediately prior to the creation of the Joint Venture, certain participants in the Legacy CHC Equity Plan also received equity awards in eRx Network and the right to receive a cash payment related to a proportionate value of the 2017 Tax Receivable Agreement. Replacement awards granted under the Legacy CHC Equity Plan consisted of one, or a combination of, time-vested awards and/or performance-based awards. Vested Awards : • Tier I Time-Vesting Awards became immediately vested in connection with the creation of the Joint Venture, 54.4 % of which were liquidated for cash at the creation. The remaining 45.6 % were exchanged for vested options of the Company with exercise prices and expiration terms that correspond with those of the original grant to Legacy CHC Equity Plan participants (“Replacement Time-Vesting Options”). These Legacy CHC Equity Plan participants also received vested options in eRx Network with exercise prices equal to 25 % of the fair value of the eRx Network stock and a cash payment related to the proportionate value of the 2017 Tax Receivable Agreement at the time of the creation of the Joint Venture. • Tier II Time-Vesting Awards immediately vested when the Joint Venture was formed but because the original exercise price of these awards was greater than the fair value of the stock at the time of the creation of the Joint Venture, none of the awards were liquidated and they were replaced with vested Replacement Time-Vesting Options with an exercise price equal to the original exercise price reduced by the fair value of one share of eRx Network stock. • 2.0x Exit-Vesting Awards immediately vested when the Joint Venture was formed as a result of meeting the specified performance and market conditions outlined in the original award terms. As with the Tier I Time-Vesting Awards, 54.4 % were liquidated for cash upon the closing. The remaining 45.6 % of such options were exchanged for vested Replacement Time-Vesting Options with exercise prices and expiration terms that correspond with those of the original grant to the Legacy CHC Equity Plan participants. The participants also received vested options in eRx Network with exercise prices equal to 25 % of the fair value of the eRx Network stock and a cash payment related to the proportionate value of the 2017 Tax Receivable Agreement at the time of the creation of the Joint Venture. The following table summarizes Replacement Time-Vesting Option activity for the year ended March 31, 2022: Replacement Weighted Average Aggregate Time-Vesting Weighted Average Remaining Intrinsic Options Exercise Price Contractual Term Value Outstanding at April 1, 2021 2,484,082 $ 11.83 2.4 $ 25,517 Exercised ( 95,510 ) $ 11.17 — $ 980 Forfeited ( 6,702 ) $ 7.92 — $ 89 Outstanding at March 31, 2022 2,381,870 $ 11.86 1.4 $ 23,664 Exercisable at March 31, 2022 2,381,870 $ 11.86 1.4 $ 23,664 Unvested Awards : Certain awards granted by Legacy CHC contained conditions that were not satisfied at the time of the creation of the Joint Venture. These awards generally vest subject to the employee’s continued employment through the date when Blackstone has sold at least 25 % of its shares of Legacy CHC (i.e., a liquidity event) and achieved specified rates of return that vary by award. When the Joint Venture was formed, these unvested equity awards were replaced with unvested restricted stock (“Replacement Exit-Vesting Restricted Stock”) with an aggregate intrinsic value and vesting conditions which were identical to the original awards. We estimated the fair value of the Replacement Exit-Vesting Restricted Stock using the Monte Carlo Simulation pricing model. Legacy CHC Equity Plan participants also received unvested restricted stock of eRx Network and a right, contingent upon vesting of the awards, to receive a future cash payment related to the proportionate value of the 2017 Tax Receivable Agreement. As of March 31, 2022, unrecognized expense related to the Replacement Exit-Vesting Restricted Stock was $ 0 . The following table summarizes Replacement Exit-Vesting Restricted Stock activity for the year ended March 31, 2022: Weighted Replacement Average Exit-Vesting Grant Date Restricted Stock Fair Value Unvested at April 1, 2021 922,252 $ 12.89 Released ( 762,837 ) $ 13.08 Canceled ( 80,687 ) $ 13.01 Unvested at March 31, 2022 78,728 $ 9.95 Time-Vesting and Exit-Vesting Options Time-vesting options were granted with an exercise price equal to the fair value of the common stock on the date of grant and generally vest in equal 25 % installments on the first through fourth anniversaries of the designated vesting start date, subject to the awardholders’ continued employment through the vesting date. We estimated the fair value of the time-vesting options using the Black-Scholes option pricing model. As of March 31, 2022, unrecognized expense related to the time-vesting options was $ 68 which is expected to be recognized over a weighted average period of one month. Exit-vesting options were granted with an exercise price equal to the fair value of the common stock on the date of grant and vest, subject to the award holder’s continued employment through the vesting date, on the earlier of (i) the date that affiliates of Blackstone sell 25 % of the equity interests of the Joint Venture held by it on March 1, 2017 (the “Transaction Date”) at a specified weighted average price per share and McKesson distributes more than 50 % of the equity interests of the Joint Venture held by it on the Transaction Date or (2) McKesson and affiliates of Blackstone collectively sell more than 25 % of the aggregate equity interests held by McKesson and Blackstone on the Transaction Date at a specified weighted average price per share. In May 2018, the terms of the exit-vesting options and Replacement Exit-Vesting Restricted Stock were modified to permit, in addition to existing vesting provisions, vesting to occur in three equal installments commencing on the earlier of the date that (i) affiliates of Blackstone sell more than 25 % of the equity interests of the Joint Venture held by it on the Transaction Date and McKesson distributes more than 50 % of the equity interests of the Joint Venture held by it on the Transaction Date or (ii) McKesson and affiliates of Blackstone collectively sell more than 25 % of the aggregate equity interests held by McKesson and Blackstone on the Transaction Date. No effect on compensation expense was recognized in connection with this modification as the vesting of the affected awards remained not probable following the modification. We estimated the fair value of the exit-vesting options using the Monte Carlo Simulation option pricing model. We will not record compensation expense for these awards until the exit-vesting provisions occur. As of March 31, 2022, unrecognized expense related to the exit-vesting options was $ 26,854 . The following table summarizes outstanding time-vesting and exit-vesting option activity for the year ended March 31, 2022: Weighted Average Weighted Average Remaining Aggregate Awards Exercise Price Contractual Term Intrinsic Value Time- Exit- Time- Exit- Time- Exit- Time- Exit- Vesting Vesting Vesting Vesting Vesting Vesting Vesting Vesting Options Options Options Options Options Options Options Options Outstanding at April 1, 2021 5,064,148 4,750,627 $ 18.99 $ 18.99 6.6 6.6 $ 15,764 $ 14,774 Exercised ( 215,197 ) — $ 18.99 — — — $ 588 — Forfeited ( 41,671 ) ( 178,648 ) $ 18.99 $ 18.99 — — $ 102 $ 441 Outstanding at March 31, 2022 4,807,280 4,571,979 $ 18.99 $ 18.99 5.6 5.7 $ 13,508 $ 12,847 Exercisable at March 31, 2022 4,642,802 — $ 18.99 — 5.6 — $ 13,046 $ — The following table summarizes unvested time-vesting and exit-vesting option activity for the year ended March 31, 2022: Time-Vesting Options Exit-Vesting Options Weighted Weighted Average Average Grant Date Grant Date Shares Fair Value Shares Fair Value Unvested at April 1, 2021 637,626 $ 9.78 4,750,627 $ 5.90 Granted — — — — Cancelled ( 11,850 ) $ 9.78 ( 178,648 ) $ 5.90 Vested ( 461,298 ) $ 9.78 — — Unvested at March 31, 2022 164,478 $ 9.78 4,571,979 $ 5.90 Equity Method Investment Prior to the Merger, we provided equity awards to employees of the Joint Venture which were subject to the accounting framework for awards granted to non-employees. Under this framework, we recognized stock compensation expense within Loss from Equity Method Investment in the Joint Venture on the consolidated statements of operations for our proportionate amount of stock compensation expense included in the operating results of the Joint Venture as well as the amount funded for the benefit of the McKesson member. Equity Compensation Expense The following is a summary of equity compensation expense. Prior to the Merger, no net equity compensation expense was recognized in the Change Healthcare Inc. financial statements due to a requirement of the Change Healthcare LLC agreement. As such, equity compensation for the year ended March 31, 2020 was immaterial: Year-Ended Year-Ended Year-Ended March 31, 2022 March 31, 2021 March 31, 2020 Equity compensation expense $ 95,730 $ 59,016 $ 1,701 Deferred tax benefit (expense) recognized $ ( 2,326 ) $ 7,336 $ 166 Actual tax benefit recognized $ 34,008 $ 6,067 $ 152 Upon closing of the UHG Transaction, existing awards will generally convert to equivalent UHG awards with consistent vesting provisions. Certain awards will vest upon closing of the UHG Transaction per the terms of the UHG Agreement.

Retirement Plans and Other Post

Retirement Plans and Other Postretirement Benefits	12 Months Ended
	Mar. 31, 2022
Retirement Plans and Other Postretirement Benefits[Abstract]
Retirement Plans and Other Postretirement Benefits	19. Retirement Plans and Other Postretirement Benefits Defined Contribution Plans Employees may participate in one of our 401(k) plans, which provide for matching contributions. Expenses related to these 401(k) plans were $ 30,780 and $ 30,931 for the years ended March 31, 2022, and 2021, respectively, and were immaterial for the year ended March 31, 2020. Deferred Compensation Plans Certain of our employees are eligible to participate in deferred compensation plans. Pursuant to these deferred compensation plans, certain executives and other highly compensated employees may defer a portion of their salaries and incentive compensation at their discretion. The following table summarizes the liabilities related to this plan: Balance Sheet Location March 31, 2022 March 31, 2021 Accrued expenses $ 1,567 $ 1,746 Other long-term liabilities 24,311 18,860 Total deferred compensation $ 25,878 $ 20,606 Post-employment Benefits We generally offer post-employment benefits to its employees in the case of certain employee termination events consisting of severance and outplacement services. The extent of such benefits varies based on employee title and accumulates based on the respective employee’s years of service. Due to the episodic nature of severance benefit history and the inability to reasonably predict future termination events, no accrual for accumulating severance benefits is accrued until the point that the payment of a severance benefit is probable and can be reasonably estimated. As of March 31, 2022 and 2021, we recognized liabilities related to these benefits of $ 1,845 and $ 1,960 , respectively.

Tax Receivable Agreements

Tax Receivable Agreements	12 Months Ended
	Mar. 31, 2022
Tax Receivable Agreements [Abstract]
Tax Receivable Agreements	20. Tax Receivable Agreements Upon the consummation of the Merger, we assumed obligations related to certain tax receivable agreements (collectively, the “tax receivable agreements”) entered into by the Joint Venture with its current and former owners. Depending on whether the respective tax receivable agreements were assumed as part of the Merger or became effective as result of the Merger, the liabilities related to the tax receivable agreements are subject to differing accounting models as explained below. Under the tax receivable agreements assumed in connection with the Merger, we are obligated to make payments to certain parties to the tax receivable agreements as well as to affiliates of The Blackstone Group, Inc., some of whom are considered related parties. The cash payments made are equal to 85% of the applicable cash savings realized or expected to be realized for the applicable tax receivable agreements. As a portion of the payments are due to current owners, we have separately presented the estimated aggregated payments due to related parties in future fiscal years in the table below. McKesson Tax Receivable Agreement In connection with the closing of the Merger, we, along with the Joint Venture, the subsidiaries of McKesson that served as members of the Joint Venture and McKesson entered into a tax receivable agreement (the “McKesson Tax Receivable Agreement”). The McKesson Tax Receivable Agreement generally requires payment to affiliates of McKesson of 85 % of certain cash tax savings realized (or, in certain circumstances, deemed to be realized) in periods ending on or after the date on which McKesson ceases to own at least 20 % of the Joint Venture as a result of (i) certain amortizable tax basis in assets transferred to the Joint Venture at the Contribution Agreement Closing and (ii) imputed interest deductions and certain other tax attributes arising from payments under the McKesson Tax Receivable Agreement. Future Tax Receivable Agreement Payments Based on facts and circumstances at March 31, 2022, we estimate the aggregate payments due under our tax receivable agreements in future fiscal years to be as follows: Related Party Tax Receivable Agreements McKesson Tax Receivable Agreement Other Tax Receivable Agreements Total 2023 $ 13,057 $ 25,042 $ 11,660 $ 49,759 2024 29,560 15,092 15,120 59,772 2025 29,055 38,184 14,528 81,767 2026 48,559 16,108 19,868 84,535 2027 8,620 32,093 9,359 50,072 Thereafter 41,037 34,950 37,164 113,151 Gross expected payments 169,888 161,469 107,699 439,056 Less: Amounts representing discount ( 51,968 ) — ( 29,704 ) ( 81,672 ) Total tax receivable agreement obligations 117,920 161,469 77,995 357,384 Less: Current portion due ( 13,057 ) ( 25,042 ) ( 11,660 ) ( 49,759 ) Tax receivable agreement long-term obligations $ 104,863 $ 136,427 $ 66,335 $ 307,625 The timing and/or amount of aggregate payments due may vary based on a number of factors, including the amount of net operating losses and income tax rates. The amount of aggregate payments shown above do not reflect any potential impacts from the UHG Transaction.

Income Taxes

Income Taxes	12 Months Ended
	Mar. 31, 2022
Income Taxes [Abstract]
Income Taxes	21. Income Taxes The income (loss) before income tax provision (benefit) includes the following components: Year Ended Year Ended Year Ended March 31, 2022 March 31, 2021 March 31, 2020 Domestic (U.S.) $ ( 129,858 ) $ ( 145,328 ) $ ( 1,091,272 ) Foreign 23,857 ( 2,069 ) 421 Total $ ( 106,001 ) $ ( 147,397 ) $ ( 1,090,851 ) The income tax provision (benefit) was as follows: Year Ended Year Ended Year Ended March 31, 2022 March 31, 2021 March 31, 2020 Current: U.S. Federal $ ( 3,232 ) $ 2,515 $ — U.S. State ( 577 ) 5,805 466 Foreign 4,256 2,789 102 Current income tax provision (benefit) 447 11,109 568 Deferred: U.S. Federal ( 27,514 ) ( 47,052 ) ( 113,523 ) U.S. State ( 21,340 ) ( 1,249 ) ( 30,297 ) Foreign ( 204 ) 2,005 ( 2 ) Deferred income tax provision (benefit) ( 49,058 ) ( 46,296 ) ( 143,822 ) Total income tax provision (benefit) $ ( 48,611 ) $ ( 35,187 ) $ ( 143,254 ) Effective Tax Rate The reconciliation between the federal statutory rate and the effective income tax rate is as follows: Year Ended Year Ended Year Ended March 31, 2022 March 31, 2021 March 31, 2020 Statutory U.S. federal tax rate 21.0 % 21.0 % 21.0 % State income taxes (net of federal benefit) 16.3 ( 2.7 ) 2.1 Research and development credit 9.1 11.0 0.2 Equity compensation 5.2 ( 1.3 ) — — — Transaction Costs ( 6.6 ) — — Foreign income taxes ( 1.0 ) ( 1.5 ) — — — Gain on sale of business — ( 4.4 ) — — — eRx option — 2.9 — — — Change in fair value of equity based awards — — ( 1.2 ) Look through accounting policy election — — 2.1 Goodwill impairment charge — — ( 10.8 ) Other 1.9 ( 1.2 ) ( 0.3 ) Effective income tax rate 45.9 % 23.8 % 13.1 % Deferred Tax Assets and Liabilities Prior to the Merger, we recorded deferred tax assets and liabilities using the outside basis approach and as a result of the Merger, we elected to begin recording deferred tax assets and liabilities using the look through approach. Therefore, the change in deferred tax assets and liabilities for the year ended March 31, 2020 reflects the impact of both our change in accounting as well as the impact of the Merger accounted for under ASC 805 as described in Note 4, Business Combinations . The change in accounting resulted in a reduction to our deferred tax liability of $ 28,576 . Significant components of our deferred tax assets (liabilities) were as follows: March 31, 2022 March 31, 2021 Depreciation and amortization $ ( 964,820 ) $ ( 1,046,755 ) Net operating losses 249,839 299,606 Tax receivable agreements obligations to related parties 69,564 67,633 Fair value of interest rate cap agreements ( 6,574 ) 1,466 Accruals and reserves 43,599 60,661 Tax credits 46,083 38,138 Debt discount and interest ( 3,264 ) ( 6,594 ) Equity compensation 28,218 38,289 Valuation allowance ( 22,076 ) ( 20,238 ) 163(j) Business interest expense limitation 13,862 2,056 Accounting method change (ASC 606 adoption) ( 1,390 ) ( 23,315 ) Right of use asset ( 16,817 ) ( 24,262 ) Right of use liability 18,807 27,377 Residual deferred tax asset 5,449 5,518 Accounts receivable 5,375 6,107 Other ( 1,074 ) ( 2,779 ) Net deferred tax assets (liabilities) $ ( 535,219 ) $ ( 577,092 ) Reported as: Non-current deferred tax assets 28,387 28,199 Non-current deferred tax liabilities ( 563,606 ) ( 605,291 ) Net deferred tax assets (liabilities) $ ( 535,219 ) $ ( 577,092 ) At March 31, 2022, we had net operating loss carryforwards for federal and state income tax purposes of $ 836,227 and $ 1,365,807 , respectively, which expire from 2032 through 2037 and 2023 through 2041 , respectively. At March 31, 2022, we had operating loss carryforwards for foreign tax purposes of $ 6,337 , certain of which expire starting in 2024 . A portion of net operating loss carryforwards may be subject to an annual limitation regarding their utilization against taxable income in future periods due to “change of ownership” provisions; however, we do not believe the limitation will impact our ability to utilize the net operating loss carryforwards. At March 31, 2022, we had research and development (“R&D”) tax credit carryforwards for federal and state income tax purposes of $ 43,862 and $ 1,849 , respectively. The federal credits expire from 2038 through 2042 , while all of the state credits have an indefinite carryforward period. We use the flow-through method to account for investment tax credits on eligible research and development expenditures. Under this method, the investment tax credits are recognized as a reduction to income tax expense or increase in income tax benefit in the year they are earned. We believe that it is more likely than not that the benefit from certain state and foreign net operating loss carryforwards, foreign tax credits, and a residual deferred tax asset recorded under the look through approach will not be realized. In recognition of this risk, we have recorded a valuation allowance of $ 16,627 on the deferred tax assets related to these net operating loss carryforwards and foreign tax credits and a valuation allowance of $ 5,449 on the residual deferred tax asset. If recognized, the tax benefits related to any reversal of the valuation allowance on deferred tax assets will be accounted for as a reduction of income tax expense of $ 22,076 . Unrecognized Tax Benefits The federal, state and foreign net operating loss carryforwards and R&D tax credits within the income tax returns filed included unrecognized tax benefits. The deferred tax assets recognized for those net operating losses and R&D tax credits are presented net of unrecognized tax benefits. A reconciliation of unrecognized tax benefits is as follows: Year Ended Year Ended March 31, 2022 March 31, 2021 Beginning unrecognized benefit $ 64,110 $ 56,177 Decreases from prior period tax positions ( 891 ) — Increases from prior period tax positions — 3,010 Increases from current period tax positions 4,346 4,923 Increases from acquisition — — Ending unrecognized benefit $ 67,565 $ 64,110 If the above unrecognized tax benefits were recognized, $ 57,723 would affect the effective income tax rate. We recognize interest income and expense (if any) related to income taxes as a component of income tax expense. We recognized interest and penalties of $ 42 , $ 121 , and $ 138 for the years ended March 31, 2022, 2021 and 2020, respectively. We file income tax returns in the U.S. federal jurisdiction and various states and foreign jurisdictions. The U.S. federal and state income tax returns for certain subsidiaries remain subject to examination by the Internal Revenue Service for the tax years 2013 and beyond (i.e., periods prior to the Transactions). With respect to state and foreign jurisdictions, we are typically subject to examination for a number of years after the income tax returns have been filed. Although the outcome of tax audits is always uncertain, we believe that adequate amounts of tax, interest and penalties have been provided for in the consolidated financial statements for any adjustments that may be incurred due to state, local or foreign audits. Tax Legislation Updates On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted. Included in the CARES Act are numerous income tax provisions including changes to the net operating loss rules and the business interest expense deduction rules under Code Section 163(j). The Company anticipates benefiting from the changes to the business interest expense deduction rules which temporarily increase the amount of interest expense that businesses are allowed to deduct on their tax returns by increasing the 30% Adjusted Taxable Income limitation to 50% for corporations for tax years 2019 and 2020. Such benefit resulted in an increase in the amount of deductible interest available to the Company in 2020 and 2021. However, this did not result in any immediate change to the Company’s tax position given the amount of net operating losses currently available. In addition, the CARES Act accelerates the remaining alternative minimum tax (“AMT”) credit refund allowances resulting in taxpayers being able to immediately claim a refund in full for any AMT credit carryforwards. The Company accelerated the receipt of the AMT credit refund of $ 869 , which the Company credited as an overpayment to future tax years.

Net Income (Loss) Per Share

Net Income (Loss) Per Share	12 Months Ended
	Mar. 31, 2022
Net Income (Loss) Per Share [Abstract]
Net Income (Loss) Per Share	22. Net Income (Loss) Per Share The following table sets forth the computation of net income (loss) per share of common stock: Years Ended March 31, 2022 2021 2020 Basic net income (loss) per share: Numerator: Net income (loss) $ ( 57,390 ) $ ( 112,210 ) $ ( 947,597 ) Denominator: Weighted average common shares outstanding 310,834,905 304,406,531 123,387,547 Minimum shares issuable under purchase contracts 13,161,695 16,365,258 13,609,077 Total weighted average shares outstanding 323,996,600 320,771,789 136,996,624 Basic net income (loss) per share $ ( 0.18 ) $ ( 0.35 ) $ ( 6.92 ) Diluted net income (loss) per share: Numerator: Net income (loss) $ ( 57,390 ) $ ( 112,210 ) $ ( 947,597 ) Denominator: Number of shares used in basic computation 323,996,600 320,771,789 136,996,624 Weighted average effect of dilutive securities — — — Total weighted average shares outstanding 323,996,600 320,771,789 136,996,624 Diluted net income (loss) per share $ ( 0.18 ) $ ( 0.35 ) $ ( 6.92 ) Due to their antidilutive effect, the following securities have been excluded from diluted net income (loss) per share: Years Ended March 31, 2022 2021 2020 Restricted Share Units 4,507,388 — 1,345,211 Time-Vesting Options 1,614,649 932,968 1,259,594 Deferred Stock Units 160,154 99,964 20,371 Performance Stock Units 100,893 — — Dilutive shares issuable under purchase contracts — 1,184,993 1,829,437

Commitments

Commitments	12 Months Ended
	Mar. 31, 2022
Commitments [Abstract]
Commitments	23. Commitments Wipro Commitment In February 2018, the Joint Venture entered into an agreement with Wipro, LLC and Wipro Limited (jointly, “Wipro”). The original term of the agreement is ten years, with three one -year renewal options. We initially committed to purchase services from Wipro throughout the ten -year term in an aggregate amount of $ 1,000,000 . Subsequently, in March 2020, the commitment was reduced to $ 975,000 . Under the agreement, Wipro will provide professional services for information technology (including infrastructure, application development and maintenance), business process outsourcing, call center services and similar services. The commitment amount may be reduced if certain events occur. If we have not fully satisfied the commitment by the end of the initial ten -year term, we are required to pay Wipro 25 % of the shortfall. During the years ended March 31, 2022 and 2021, we purchased services in the amount of $ 75,869 and $ 80,071 , respectively. Purchased services were immaterial for the year ended March 31, 2020. In connection with the agreement, we have incurred and expect to continue to incur severance costs related to the transition of services currently performed by us to Wipro. We record severance liabilities when we can reliably estimate the timing and amount of such future severance costs. Accrued severance costs associated with Wipro were not material as of March 31, 2022 and 2021. Minimum Commitments Future minimum commitments by fiscal year as of March 31, 2022 consist of the following: Payments by Period Total 2023 2024 2025 2026 2027 Thereafter Operating lease obligations (1) $ 87,231 $ 26,035 $ 18,925 $ 13,837 $ 9,586 $ 7,204 $ 11,644 Finance lease obligations 1,327 468 468 391 — — — Purchase obligations (2) 1,047,479 220,237 219,697 198,737 148,512 130,240 130,056 Total contractual obligations $ 1,136,037 $ 246,740 $ 239,090 $ 212,965 $ 158,098 $ 137,444 $ 141,700 (1) We expect to receive $ 1,086 in the future under noncancelable subleases. See Note 7, Leases . (2) Amounts reflect our best estimate of the timing of future payments in instances when our commitment is for an aggregate amount of purchases over a multi-year period rather than specific annual commitments.

Legal Proceedings

Legal Proceedings	12 Months Ended
	Mar. 31, 2022
Legal Proceedings [Abstract]
Legal Proceedings	24. Legal Proceedings We are subject to various claims with customers and vendors, pending and potential legal actions for damages, investigations relating to governmental laws and regulators and other matters arising out of the normal conduct of its business. UHG Transaction Proceedings Following the announcement of the UHG Transaction, nine lawsuits challenging the UHG Transaction were filed in various jurisdictions. The first lawsuit, a putative class action alleging breaches of fiduciary duty, was filed in Tennessee Chancery Court , and was voluntarily dismissed without prejudice on March 17, 2021. The remaining eight lawsuits were filed in federal court between March 18, 2021 and April 7, 2021. The operative complaints in those actions name d us and our Board of Directors as defendants and allege d , among other things, that the proxy statement filed in conjunction with the UHG Transaction was materially incomplete and misleading in violation of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 and Rule 14a-9 promulgated thereunder (“Section 14(a) Actions”). All of the Section 14(a) Actions were dismissed without prejudice by April 23, 2021. We also received written demands from purported stockholders relating to the UHG Transaction. One of the stockholders who made a written demand subsequently filed a complaint against us in the Delaware Court of Chancery on April 13, 2021 pursuant to 8. Del. C. § 220, seeking certain books and records relating to the UHG Transaction. That action, which is captioned Waterford Township Policy & Fire Retirement System v. Change Healthcare, Inc. , 2021-0317, remains pending and the parties have agreed to stay our deadline to respond to the operative pleading . In addition, on February 24, 2022, the U.S. Department of Justice ( “DOJ”) and certain other parties (including the Attorneys General for the States of New York and Minnesota) filed suit in the U.S. District Court for the District of Columbia to block the UHG Transaction. That action, which is captioned U.S. et al., v. UnitedHealth Group Inc. , et al., No. 22-cv-00481 (DDC), remains pending and is scheduled to begin trial on August 1, 2022. Government Subpoenas and Investigations From time to time, we may receive subpoenas or requests for information from various government agencies. We generally respond to such subpoenas and requests in a cooperative, thorough and timely manner. These responses sometimes require time and effort and can result in considerable costs being incurred by the Company. Such subpoenas and requests also can lead to the assertion of claims or the commencement of civil or criminal proceedings against us and other members of the healthcare industry, as well as to settlements. Other Matters In the ordinary course of business, we are involved in various other claims and legal proceedings. While the ultimate resolution of these matters has yet to be determined, we do not believe that it is reasonably possible that their outcomes will have a material adverse effect on our consolidated financial position, results of operations, or liquidity.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	25. Related Party Transactions Term Loans Held by Related Party Certain investment funds managed by GSO Capital Partners LP (the “GSO-managed funds”) held a portion of the term loans under our Senior Credit Facilities. GSO Advisor Holdings LLC (“GSO Advisor”) is the general partner of GSO Capital Partners LP and Blackstone, indirectly through its subsidiaries, holds all of the issued and outstanding equity interests of GSO Advisor. As of March 31, 2022 and March 31, 2021, the GSO-managed funds held $ 191,049 and $ 162,189 , respectively, in principal amount of the Senior Credit Facilities (none of which is classified within current portion of long-term debt). Transactions with Blackstone Portfolio Companies We provide various services to, and purchase services from, certain Blackstone portfolio companies under contracts that were executed in the normal course of business. The following is a summary of revenue recognized and amounts paid related to service provided to and from Blackstone portfolio companies: Year Ended March 31, 2022 2021 Revenue recognized related to services provided $ 6,930 $ 3,792 Amount paid related to services received $ 17,369 $ 18,057 The revenue recognized and amounts paid were immaterial for the year ended March 31, 2020. Employer Healthcare Program Agreement with Equity Healthcare Effective January 1, 2021, we entered into an employer health program agreement with Equity Healthcare LLC (“Equity Healthcare”), an affiliate of Blackstone, whereby Equity Healthcare provides certain negotiating, monitoring and other services in connection with certain of our health benefit plans. In consideration for Equity Healthcare’s services, we paid a fee of $ 3.00 per participating employee per month. Effective January 1, 2022, we pay a fee of $ 3.25 per participating employee per month. eRx Network Option Agreement Prior to the creation of the Joint Venture, we entered into an option agreement to acquire eRx (the “Option Agreement”). Under the terms of the Option Agreement, the option to acquire eRx would only become exercisable at any such time that McKesson owns (directly or indirectly), in the aggregate, less than 5 % of the outstanding units of the Joint Venture. Subsequent to the Merger, the Option became exercisable and was exercised on May 1, 2020. See Note 4, Business Combinations , for additional information. Transition Services Agreements In connection with the creation of the Joint Venture, we entered into transition services agreements with eRx. Under the agreements, we provided certain transition services to eRx in exchange for specified fees. Prior to the acquisition of eRx, we recognized $ 283 in transition fee income during the year ended March 31, 2021. The amounts received are included in Other, net in the consolidated statement of operations. Transition fee income was immaterial for the year ended March 31, 2020.

Segment Reporting

Segment Reporting	12 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Segment Reporting	26. Segment Reporting Management views the Company’s operating results based on three reportable segments: Software and Analytics, Network Solutions and Technology-Enabled Services. Software and Analytics The Software and Analytics segment provides solutions for revenue cycle management, provider network management, payment accuracy, value-based payments, clinical decision support, consumer engagement, risk adjustment and quality performance, and imaging and clinical workflow. Network Solutions The Network Solutions segment provides solutions for financial, administrative, clinical and pharmacy transactions, electronic payments and aggregation and analytics of clinical and financial data. Technology-Enabled Services The Technology-Enabled Services segment provides solutions for financial and administrative management, value-based care, communication and payment, pharmacy benefits administration and healthcare consulting. Postage and Eliminations Postage and eliminations includes pass-through postage costs, as well as eliminations to remove inter-segment revenue and expenses and consolidating adjustments to classify certain rebates paid to channel partners as a reduction of revenue. These administrative costs are excluded from the adjusted EBITDA measure for each respective reportable segment. Segment Results Revenue and adjusted EBITDA for each of the reportable segments for the years ended March 31, 2022 and 2021 are shown below. Information is reflected in the manner utilized by management to make operating decisions, assess performance and allocate resources. Such amounts include allocations of corporate shared services functions that are essential to the core operations of the reportable segments. Segment assets and related depreciation expenses are not presented to management for purposes of operational decision making, and therefore are not included in the accompanying tables. Year Ended Year Ended March 31, 2022 March 31, 2021 Segment Revenue Software and Analytics $ 1,612,931 $ 1,534,926 Network Solutions 868,425 717,843 Technology-Enabled Services 924,472 869,349 Postage and Eliminations (1) 82,727 96,533 Purchase Accounting Adjustment (2) ( 7,740 ) ( 128,230 ) Net Revenue $ 3,480,815 $ 3,090,421 Segment Adjusted EBITDA Software and Analytics $ 561,994 $ 526,129 Network Solutions 446,378 377,005 Technology-Enabled Services 62,679 31,031 Adjusted EBITDA $ 1,071,051 $ 934,165 Reconciliation of income (loss) before tax provision (benefit) to Adjusted EBITDA Income (loss) before income tax provision (benefit) $ ( 106,001 ) $ ( 147,397 ) Amortization of capitalized software developed for sale 3,509 1,326 Depreciation and amortization 681,808 591,048 Interest expense 234,244 245,241 Equity compensation 95,730 59,016 Acquisition accounting adjustments ( 11,839 ) 109,743 Acquisition and divestiture-related costs 41,120 19,709 Integration and related costs 26,803 40,675 Strategic initiatives, duplicative and transition costs 46,041 21,841 Severance costs 10,178 13,184 Accretion and changes in estimate, net 25,276 11,644 Impairment of long-lived assets and other 4,958 18,190 Loss on extinguishment of debt 3,885 8,924 Gain on sale of businesses — ( 59,143 ) Contingent consideration — ( 3,000 ) Other non-routine, net 15,339 3,164 Adjusted EBITDA $ 1,071,051 $ 934,165 (1) Revenue for the Postage and Eliminations segment includes postage revenue of $ 219,612 and $ 196,532 for the years ended March 31, 2022 and 2021, respectively. (2) Amount reflects the impact to deferred revenue resulting from the Merger which reduced revenue recognized during the period. Prior to the Merger, the Company had minimal operations outside of the investment in the Joint Venture and the Company’s standalone operating results were not utilized by management to make operating decisions, assess performance, or allocate resources. The Company’s chief operating decision maker (“CODM”) and management team, which was the same CODM and management team as of the Joint Venture, did not request or review financial results of the consolidated Company for the period from the date of the Merger through March 31, 2020. As such, the Company reported its results as a single reportable segment for the year ended March 31, 2020.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	12 Months Ended
	Mar. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Abstract]
Accumulated Other Comprehensive Income (Loss)	27. Accumulated Other Comprehensive Income (Loss) The following is a summary of the accumulated other comprehensive income (loss) activity. Prior to the Merger, the activity in Accumulated other comprehensive income (loss) reflects the Company’s proportionate share of the Joint Venture’s accumulated other comprehensive income (loss), net of taxes. Foreign Accumulated Available Currency Other For Sale Translation Cash Flow Comprehensive Debt Security Adjustment Hedge Income (Loss) Balance at March 31, 2019 $ — $ ( 1,565 ) $ ( 1,691 ) $ ( 3,256 ) Cumulative effect of accounting change of the Joint Venture-ASU 2018-02 — — 422 422 Unrealized gain (loss) on available for sale debt securities of the Joint Venture 1,045 — — 1,045 Realized gain (loss) on available for sale debt securities of the Joint Venture ( 1,045 ) — — ( 1,045 ) Change associated with foreign currency translation — ( 5,519 ) — ( 5,519 ) Change associated with current period hedging, net of taxes of $ 607 — — 981 981 Balance at March 31, 2020 $ — $ ( 7,084 ) $ ( 288 ) $ ( 7,372 ) Change associated with foreign currency translation — 21,324 — 21,324 Change associated with current period hedging, net of taxes of ($ 1,033 ) — — ( 3,823 ) ( 3,823 ) Reclassification into earnings — ( 110 ) 1,202 1,092 Balance at March 31, 2021 $ — $ 14,130 $ ( 2,909 ) $ 11,221 Change associated with foreign currency translation — 3,741 — 3,741 Change associated with current period hedging, net of taxes of $ 7,347 — — 18,216 18,216 Reclassification into earnings — — 1,938 1,938 Balance at March 31, 2022 $ — $ 17,871 $ 17,245 $ 35,116 Effective April 1, 2019, the Joint Venture adopted ASU No. 2018-02, which allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act of 2017. The adoption of this update resulted in a reclassification between Accumulated other comprehensive income (loss) and Accumulated deficit.

Subsequent Events

Subsequent Events	12 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	28. Subsequent Events Segment Changes During the first quarter of fiscal year 2023, we made certain changes in the way we manage our business and view operating results. Specifically, we made the following changes:  E stablished the Imaging Solutions business as a standalone reportable segment under its own general manager, reporting directly to our chief executive officer. This business was previously presented within the Software & Analytics reportable segment .  Shifted responsibility for certain products from one reportable segment to another to better align our portfolio of service offerings, which will impact the Technology-Enabled Services, Network Solutions, and Software & Analytics reportable segments. Segment information presented in future periods will reflect the above changes, including retrospective adjustment to any historical segment information presented. Equity Compensation During the first quarter of fiscal year 2023, we granted approximately 5.1 million RSUs to our employees under the Omnibus Incentive Plan. The RSUs are subject to a graded vesting schedule over three years in which the awards vest on a quarterly basis. Upon vesting, the RSUs are exchanged for shares of common stock. Aggregate unrecognized compensation expense related to these awards is approximately $ 122,000 . During the first quarter of fiscal year 2023, the terms of the exit-vesting options were modified to permit, in addition to existing vesting provisions, vesting to occur in three equal annual installments on June 30, 2022, 2023 and 2024. Upon modification, aggregate unrecognized compensation expense related to these awards is approximately $ 51,000 . Expense is expected to be recognized for these awards over the modified vesting period, subject to other existing vesting conditions (i.e., Blackstone selling its interests). Debt Repayment In May 2022, we made a voluntary repayment on the Senior Notes of $ 100,000 and recorded a loss on extinguishment of debt of approximately $ 390.0 .

Significant Accounting Polici_2

Significant Accounting Policies (Policy)	12 Months Ended
	Mar. 31, 2022
Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation Our consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and include the accounts of our wholly owned subsidiaries. The results of operations for companies acquired are included in our consolidated financial statements from the effective date of acquisition. All intercompany accounts and transactions have been eliminated upon consolidation.
Accounting Estimates	Accounting Estimates The preparation of financial statements in conformity with GAAP requires us to make a number of estimates and assumptions that affect the amounts reported in our financial statements and accompanying notes. We base our estimates on historical experience, current business factors and various other assumptions that we believe are necessary in order to form a basis for making judgments about the carrying values of assets and liabilities, the reported amounts of revenues and expenses and disclosure of contingent assets and liabilities. We are subject to uncertainties such as the impact of future events, economic, environmental and political factors and changes in our business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of our financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as our operating environment changes. Changes in estimates are made when circumstances warrant. Estimates and assumptions affect: the allowance for credit losses; the fair value assigned to assets acquired and liabilities assumed in business combinations; the carrying value of long-lived assets (including goodwill and intangible assets); the amortization period of long-lived assets (excluding goodwill); the carrying value, capitalization and amortization of software development costs; operating lease right-of-use assets; the carrying value of our investments; tax receivable agreement obligations; the fair value of interest rate cap agreement obligations; components of our tangible equity units; the values attributed to equity awards; operating lease liabilities; contingent consideration; loss accruals; certain accrued expenses; revenue recognition; and the income tax provision or benefit and related deferred tax accounts.
Business Combinations	Business Combinations We recognize the consideration transferred (i.e., purchase price) in a business combination, as well as the acquired business’ identifiable assets, liabilities and noncontrolling interests at their acquisition date fair value. The excess of the consideration transferred over the fair value of the identifiable assets, liabilities and noncontrolling interest, if any, is recorded as goodwill. The fair values of the consideration transferred, assets, liabilities and noncontrolling interests are estimated based on one or a combination of income, cost or market approaches as determined based on the nature of the asset or liability and the level of inputs available (i.e., quoted prices in an active market, other observable inputs or unobservable inputs). To the extent our initial accounting for a business combination is incomplete at the end of a reporting period, provisional amounts are reported for those items which are incomplete.
Cash and Cash Equivalents	Cash and Cash Equivalents For the purposes of reporting, cash and cash equivalents include unrestricted cash on hand and investments with an original maturity from the date of purchase of three months or less. Our cash and cash equivalents are deposited with several financial institutions. Deposits may exceed the amounts insured by the Federal Deposit Insurance Corporation in the U.S. and similar deposit insurance programs in other jurisdictions. We mitigate the risk of our short-term investment portfolio by depositing funds with reputable financial institutions and monitoring risk profiles. From time to time, our cash balances include funds we manage for customers, the most significant of which relates to funds remitted to retail pharmacies. Such funds are not restricted; however, funds are generally paid out in satisfaction of the processing obligations pursuant to the management contracts. At the time of receipt, we record a corresponding liability within Accrued expenses on the consolidated balance sheets. Such liabilities are summarized as “Pass-through payments” within Note 12, Accrued Expenses .
Allowance for Credit Losses	Allowance for Credit Losses The allowance for credit losses of $ 22,224 and $ 24,126 at March 31, 2022 and 2021, respectively, was primarily based on historical credit loss experience, current conditions, future expected credit losses, and adjustments for certain asset-specific risk characteristics. The following table summarizes activity related to the allowance for credit losses: Year Ended March 31, 2022 2021 Balance at beginning of period $ 24,126 $ 22,360 Cumulative effect of accounting change-ASU 2016-13 — 417 Acquisitions and Dispositions (1) — ( 4,952 ) Provisions 8,733 14,645 Write-offs ( 10,635 ) ( 8,344 ) Balance at end of period $ 22,224 $ 24,126 (1) For the year ended March 31, 2021, this amount relates primarily to the sales of Connected Analytics and Capacity Management.
Capitalized Software Developed for Sale	Capitalized Software Developed for Sale Development costs for software developed for sale to external customers are capitalized once a project has reached the point of technological feasibility. Completed projects are amortized after reaching the point of general availability using the straight-line method based on an estimated useful life of three years . At each balance sheet date, or earlier if an indicator of an impairment exists, we evaluate the recoverability of unamortized capitalized software costs based on estimated future undiscounted revenues net of estimated related costs over the remaining amortization period.
Capitalized Software Developed for Internal Use	Capitalized Software Developed for Internal Use We provide services to many of our customers using software developed for internal use. The costs that are incurred to develop such software are expensed as incurred during the preliminary project stage and classified within Research and development in the consolidated statements of operations. Training and maintenance costs are also expensed as incurred. Once certain criteria have been met, direct costs incurred in developing or obtaining computer software are capitalized. Capitalized software costs are included in Other noncurrent assets, net on the consolidated balance sheets and are generally amortized over the estimated useful life of three years .
Property and Equipment	Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the related assets. Expenditures for maintenance, repair and renewals of minor items are expensed as incurred. Expenditures for repair and renewals that extend the useful life of an asset are capitalized.
Long-Lived Assets	Long-Lived Assets Long-lived assets used in operations , which include capitalized software developed for internal use and property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that carrying amounts may not be recoverable. For long-lived assets to be held and used, we recognize an impairment loss only if the carrying amount is not recoverable when compared to our undiscounted cash flows and the impairment loss is measured based on the difference between the carrying amount and fair value. Long-lived assets held for sale are reported at the lower of cost or fair value less costs to sell.
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill and intangible assets resulting from acquisitions are accounted for using the acquisition method of accounting. In business combinations, we generally recognize goodwill attributable to the assembled workforce and expected synergies among the operations of the acquired entities and our existing operations. Goodwill is generally deductible for federal income tax purposes when a business combination is treated as an asset purchase and is generally not deductible for federal income tax purposes when a business combination is treated as a stock purchase. We assess goodwill for impairment annually (as of January 1 of each year) or whenever significant indicators of impairment are present. Using a qualitative analysis, we first assess whether it is more likely than not that goodwill is impaired. To the extent we cannot reach a conclusion using only a qualitative analysis, we compare the fair value of each reporting unit to its associated carrying value. We will recognize an impairment charge for the amount, if any, by which the carrying amount of the reporting unit exceeds its fair value. Intangible assets with definite lives are amortized over their useful lives either on a straight-line basis or using an accelerated method, depending on the pattern we expect the economic benefits of the assets to be consumed. Useful lives are generally as follows: Customer relationships 12 - 18 years Tradenames 18 years Technology-based intangible assets 6 - 12 years
Derivatives	Derivatives Derivative financial instruments are used to manage our interest rate exposure and we do not enter into financial instruments for speculative purposes. Derivative financial instruments are accounted for and measured at fair value. For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same line item associated with the forecasted transaction in the same period or periods during which the hedged transaction affects earnings (e.g., in “Interest expense, net” when the hedged transactions are interest cash flows associated with floating-rate debt).
Tangible Equity Units	Tangible Equity Units In connection with our initial public offering, we completed an offering of TEUs. Each TEU includes an amortizing note and a purchase contract, both of which are freestanding instruments and separate units of account. The amortizing notes were issued at par and are classified as debt on the consolidated balance sheets. The purchase contracts are accounted for as prepaid forward contracts and are classified as equity. The TEU proceeds and issuance costs were allocated to the amortizing notes and purchase contracts on a relative fair value basis.
Equity Compensation	Equity Compensation We measure stock-based compensation cost based on the estimated fair value of the award on the grant date and recognize the expense over the requisite service period, typically on a straight-line basis. We recognize stock-based compensation cost for awards with performance conditions if and when we conclude that it is probable that the performance conditions will be achieved. The fair value of equity awards is recognized as expense in the same period and in the same manner as if we had paid cash for the goods or services. Forfeitures are recognized as they occur. We issue new shares of common stock upon vesting of equity awards and upon exercise of vested options. We do not intend to repurchase any issued shares of common stock. Prior to the Merger, these equity awards, as well as awards granted under our previous equity incentive plan, were granted to employees of the Joint Venture, and therefore were subject to the accounting framework for awards granted to non-employees. Under this framework, we measured compensation expense for equity awards based on the estimated fair value of such awards at the grant date, in a manner consistent with the recognition of expense for awards to employees. The recognized pre-Merger equity-based compensation is classified within Loss from Equity Method Investment in the Joint Venture on the consolidated statement of operations.
Leases	Leases We determine whether an arrangement contains a lease based on the conveyed rights and obligations at the inception date. If an agreement contains an operating or finance lease, at the commencement date, we record a right-of-use asset and a corresponding lease liability based on the present value of the minimum lease payments. As most of our leases do not provide an implicit borrowing rate, to determine the present value of lease payments, we use the portfolio approach and determine our hypothetical secured borrowing rate based on information available at lease commencement. Further, we make certain estimates and judgements regarding the lease term and lease payments, noted below. Leases with an initial term of 12 months or less are not recorded on the balance sheet and we recognize lease expense for these leases on a straight-line basis over the lease term. Most leases include one or more options to renew, with renewal terms that can extend the lease term from one month to one year or more. Additionally, some of our leases include an option for early termination. We include renewal periods and exclude termination periods from our lease term if, at commencement, we are reasonably certain to exercise the option. For our real estate lease arrangements, we do not consider a lease to be abandoned and do not adjust the corresponding right-of-use asset in instances where we have the intent and ability to sublease the space. Certain of our lease agreements include rental payments that are adjusted periodically for inflation or passage of time. These step payments are included within our present value calculation as they are known adjustments at commencement. Some of our lease agreements include variable payments that are excluded from our present value calculation. For example, some of our equipment leases include a component which varies based on the asset’s use. Additionally, we have lease agreements that include lease and non-lease components, such as equipment leases, which are generally accounted for as a single lease component. For these leases, lease payments include all fixed payments stated within the contract. For other leases, such as office space, lease and non-lease components are accounted for separately. Our lease agreements do not contain any material residual value guarantees that would impact our lease payments.
Tax Receivable Agreements	Tax Receivable Agreements Upon the consummation of the Merger, we assumed obligations related to certain tax receivable agreements entered into by the Joint Venture with its current and former owners. The tax receivable agreements were measured at their fair value as part of the Merger and are recognized at their initial fair value plus recognized accretion to date on the consolidated balance sheets. Accretion expense recorded during the period pertaining to related party payments is recorded within Accretion and changes in estimate with related parties, net, whereas non-related party accretion is recorded within Sales, marketing, general and administrative in the consolidated statement of operations. In connection with the closing of the Merger, we, along with the Joint Venture, the subsidiaries of McKesson that served as members of the Joint Venture and McKesson entered into a tax receivable agreement (the “McKesson Tax Receivable Agreement”). Following the Merger and based on anticipated amortization allocations, we recorded an obligation for the McKesson Tax Receivable Agreement estimated payments, which represents a loss contingency under ASC 450. Future changes in this value will be reflected within Sales, marketing, general and administrative in the consolidated statement of operations. The current and non-current portions of the non-related party obligations for our tax receivable agreements, including the McKesson Tax Receivable agreement, are recorded within Accrued expenses and Tax receivable agreement obligations, respectively, within the consolidated balance sheets. The current and non-current portions of the related party obligations for our tax receivable agreements are recorded within Due to related parties, net and Tax receivable agreement obligations due to related parties, respectively, within the consolidated balance sheets.
Revenue	Revenue We recognize revenue at an amount that reflects the consideration we expect to be entitled to in exchange for transferring goods or services to a customer, in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”), which we adopted on April 1, 2019. We had no revenue-generating operations prior to the Merger, therefore the impact of the adoption of ASC 606 was limited to recognition of an adjustment to Accumulated Deficit as a result of our equity method investment at the time of the Joint Venture’s adoption. See Note 3, Revenue Recognition, for additional information.
Foreign Currency Translation	Foreign Currency Translation Our reporting currency is the U.S. dollar and our foreign subsidiaries generally consider their local currency to be their functional currency. Foreign currency-denominated assets and liabilities of foreign subsidiaries are translated into U.S. dollars at year-end exchange rates, equity accounts are primarily translated at historical exchange rates and revenues and expenses are translated at average exchange rates during the corresponding period. Foreign currency translation adjustments are included in the consolidated statements of comprehensive income (loss) and the cumulative effect is included within Accumulated deficit on the consolidated balance sheets. Realized gains and losses from currency exchange transactions are included in Sales, marketing, general and administrative expenses in the consolidated statements of operations. We release the cumulative translation adjustment from equity into net income as a gain or loss only upon complete or substantially complete liquidation of a controlling interest in a subsidiary or a group of assets within a foreign entity.
Income Taxes	Income Taxes We record deferred income taxes for the tax effect of differences between book and tax bases of our assets and liabilities, as well as differences relating to the timing of recognition of income and expenses. Deferred income taxes reflect the available net operating losses and the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of the future tax benefits related to deferred tax assets is dependent on many factors, including our past earnings history, expected future earnings, the character and jurisdiction of such earnings, reversing taxable temporary differences, unsettled circumstances that, if unfavorably resolved, would adversely affect utilization of its deferred tax assets, carryback and carryforward periods and tax strategies that could potentially enhance the likelihood of realization of a deferred tax asset. We recognize tax benefits for uncertain tax positions when we conclude that the tax position, based solely on its technical merits, is more likely than not to be sustained upon examination. The benefit, if any, is measured as the largest amount of benefit, determined on a cumulative probability basis that is more likely than not to be realized upon ultimate settlement. Tax positions failing to qualify for initial recognition are subsequently recognized when they meet the more likely than not standard, upon resolution through negotiation or litigation with the taxing authority or on expiration of the statute of limitations.
Equity Method Investment in the Joint Venture	Equity Method Investment in the Joint Venture Prior to the Merger, we accounted for our investment in the Joint Venture using the equity method of accounting. During that period, we evaluated our equity method investment for impairment whenever an event or change in circumstances occurred that had a potentially significant adverse impact on the carrying value of our investment. During the period from the inception of the Joint Venture through the date of the Merger, we did not identify any loss in the value of our investment that was deemed other than temporary, and therefore, did no t recognize any impairment loss.
Recently Adopted Accounting Pronouncements and Accounting Pronouncements Not Yet Adopted	Recently Adopted Accounting Pronouncements London Interbank Offered Rate (LIBOR) Reform In March 2020, the FASB issued ASU No. 2020-04, as amended by ASU No. 2021-01, which created Topic 848 – Reference Rate Reform. ASU No. 2020-04 contains optional practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts which may be elected over time as activities occur. Among other things, the ASU intends to ease the transition from LIBOR to an alternative reference rate. During the first quarter of fiscal year 2021, we elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. We continue to evaluate the impacts of ASU No. 2020-04 and may apply other elections as reference rate reform activities progress. Accounting Pronouncements Not Yet Adopted Derivatives and Convertible Instruments In August 2020, the FASB issued ASU No. 2020-06 which simplifies the accounting for convertible instruments and amends the guidance addressing the derivatives scope exception for contracts in an entity’s own equity. The standard is scheduled to be effective for us beginning April 1, 2022. Given the forward purchase contracts of our Tangible Equity Units qualify for the derivatives scope exception and are currently accounted for under that guidance, we do not expect a material impact upon adoption. Contract Assets and Liabilities from Contracts with Customers In October 2021, the FASB issued ASU No. 2021-08 which improves the accounting for revenue contracts with customers acquired in a business combination by addressing diversity in practice and requiring the acquirer to measure contract assets and liabilities acquired in accordance with ASC 606. The standard is scheduled to be effective for us beginning April 1, 2023, with early adoption permitted. Once adopted, the updated guidance could potentially have a material impact on the amount of assets, liabilities, and revenue recognized from acquired businesses, depending on the size and nature of those transactions.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	12 Months Ended
	Mar. 31, 2022
Significant Accounting Policies [Abstract]
Summary of Activity Related to Allowance for Credit Losses	Year Ended March 31, 2022 2021 Balance at beginning of period $ 24,126 $ 22,360 Cumulative effect of accounting change-ASU 2016-13 — 417 Acquisitions and Dispositions (1) — ( 4,952 ) Provisions 8,733 14,645 Write-offs ( 10,635 ) ( 8,344 ) Balance at end of period $ 22,224 $ 24,126 (1) For the year ended March 31, 2021, this amount relates primarily to the sales of Connected Analytics and Capacity Management.
Schedule of Finite-Lived Intangible Assets Useful Lives	Customer relationships 12 - 18 years Tradenames 18 years Technology-based intangible assets 6 - 12 years

Business Combinations (Tables)

Business Combinations (Tables)	12 Months Ended
	Mar. 31, 2022
Business Acquisition [Line Items]
Supplemental Pro Forma Results	(Unaudited) Year Ended March 31, 2021 (1) 2020 2019 Total revenue n/a $ 3,290,734 $ 3,133,907 Net income (loss) n/a $ ( 228,234 ) $ ( 128,889 ) Net income (loss) per share, basic and diluted n/a $ ( 0.75 ) $ ( 0.43 ) (1) Pro forma information is not applicable as the Joint Venture’s results are fully consolidated for the year ended March 31, 2021 .
eRx Network Holdings, Inc. [Member]
Business Acquisition [Line Items]
Summary of Information Related to Acquisition	eRx Cash paid at closing $ 249,359 Fair value of eRx purchase option 140,500 Fair value of vested stock appreciation rights 5,097 Cash paid for canceled eRx equity awards 5,891 Total Consideration Fair Value at Acquisition Date $ 400,847 Allocation of the Consideration Transferred: Cash $ 54,108 Accounts receivable 12,747 Prepaid expenses and other current assets 609 Goodwill 225,156 Identifiable intangible assets: Customer relationships (life 17 years) 131,200 Technology-based intangible assets (life 9 - 12 years) 29,700 Other noncurrent assets 20 Accounts payable ( 2,543 ) Accrued expenses and other current liabilities ( 10,933 ) Deferred income tax liabilities ( 39,217 ) Total consideration transferred $ 400,847
PDX, Inc. [Member]
Business Acquisition [Line Items]
Summary of Information Related to Acquisition	PDX Cash $ 755 Accounts receivable 5,739 Prepaid expenses and other current assets 2,251 Property and equipment 840 Goodwill 98,830 Identifiable intangible assets: Customer relationships (life 18 years) 74,300 Technology-based intangible assets (life 10 - 11 years) 25,300 Other noncurrent assets 690 Accounts payable ( 3,882 ) Deferred revenue, current ( 2,946 ) Accrued expenses and other current liabilities ( 3,364 ) Other long-term liabilities ( 222 ) Total consideration transferred $ 198,291
The Merger [Member]
Business Acquisition [Line Items]
Summary of Information Related to Acquisition	Net assets acquired: Amount Cash $ 330,665 Accounts receivable, net of allowance of $ 22,059 718,895 Contract assets 132,704 Prepaid expenses and other current assets 115,436 Investment in business purchase option 146,500 Property and equipment, net 206,751 Goodwill 4,363,282 Other noncurrent assets 169,539 Identified intangible assets: Customer relationships (life 12 - 16 years) 3,056,000 Tradenames (life 18 years) 146,000 Technology-based intangible assets (life 6 - 12 years) 1,188,000 Accounts payable ( 60,637 ) Accrued expenses ( 563,791 ) Deferred revenue, current ( 292,528 ) Current portion of long-term debt ( 28,969 ) Other current liabilities ( 22,732 ) Long-term debt, excluding current portion ( 4,713,565 ) Deferred income tax liabilities ( 576,546 ) Tax receivable agreement obligations due to related parties ( 176,586 ) Other long-term liabilities ( 102,675 ) Net assets acquired $ 4,035,743 Summary of purchase consideration: Fair value of shares issued to SpinCo shareholders ( 175,995,192 shares at $ 12.47 per share): Common Stock, $ 0.001 par value $ 176 Additional paid-in capital 2,194,484 Fair value of Joint Venture equity interest previously held 1,589,040 Fair value of Joint Venture equity interest previously held through TEUs 216,764 Settlement of dividend receivable 42,778 Repayment of advances to member ( 7,499 ) Purchase consideration $ 4,035,743

Leases (Tables)

Leases (Tables)	12 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Components of Lease Cost	Year Ended Year Ended Statement of Operations Location March 31, 2022 March 31, 2021 Operating lease cost (1) $ 35,025 $ 43,950 Finance lease cost Amortization expense Depreciation and amortization 356 429 Interest expense Interest expense, net 93 120 Short-term lease cost (1) 2,113 1,473 Variable lease cost (1) 5,179 6,804 Sublease income Other, net ( 1,089 ) ( 1,293 ) Total lease cost $ 41,677 $ 51,483 (1) Cost classification varies depending on the leased asset. Costs are primarily included within Sales, marketing, general and administrative and Cost of operations.
Right-of-use Assets and Lease Liabilities	Balance Sheet Location March 31, 2022 March 31, 2021 Right-of-use assets Operating leases Operating lease right-of-use assets, net $ 65,680 $ 93,412 Finance leases Property and equipment, net 1,370 1,858 Total right-of-use assets $ 67,050 $ 95,270 Lease liabilities Current liabilities Operating leases Current portion of operating lease liabilities $ 21,726 $ 30,608 Finance leases Current portion of long-term debt 405 568 Noncurrent liabilities Operating leases Long-term operating lease liabilities 52,286 75,396 Finance leases Long-term debt, excluding current portion 772 1,225 Total lease liabilities $ 75,189 $ 107,797
Lease Liability Maturities	Maturities of lease liabilities by fiscal year as of March 31, 2022 are as follows: Operating Leases Finance Leases Total 2023 $ 26,035 $ 468 $ 26,503 2024 18,925 468 19,393 2025 13,837 391 14,228 2026 9,586 — 9,586 2027 7,204 — 7,204 2028 and thereafter 11,644 — 11,644 Total lease liabilities, undiscounted 87,231 1,327 88,558 Less: Imputed interest 13,219 150 13,369 Total lease liabilities $ 74,012 $ 1,177 $ 75,189
Other Information Related to Leases	Other information related to our leases as of March 31, 2022 is as follows: Operating Leases Finance Leases Weighted-average remaining lease term 4.68 years 2.84 years Weighted-average discount rate 7.14 % 6.36 % Other information related to our leases as of March 31, 2021 is as follows: Operating Leases Finance Leases Weighted-average remaining lease term 4.76 years 3.52 years Weighted-average discount rate 7.29 % 6.51 %

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Mar. 31, 2022
Prepaid Expenses and Other Current Assets [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	March 31, 2022 March 31, 2021 Prepaid expenses $ 103,023 $ 86,307 Other current assets 74,636 53,951 Prepaid expenses and other current assets $ 177,659 $ 140,258

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Mar. 31, 2022
Property and Equipment [Abstract]
Schedule of Property and Equipment	March 31, 2022 March 31, 2021 Land $ 406 $ 406 Buildings and leasehold improvements 59,067 60,716 Computer equipment 125,847 105,450 Production equipment 17,215 17,046 Office equipment, furniture and fixtures 33,702 34,696 Construction in process 21,010 15,497 Property and equipment, gross 257,247 233,811 Accumulated depreciation ( 115,907 ) ( 59,441 ) Property and equipment, net $ 141,340 $ 174,370

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets [Abstract]
Schedule of Goodwill	Software and Analytics Network Solutions Technology-Enabled Services Total Balance at March 31, 2020 $ 1,770,118 $ 1,645,831 $ 379,376 $ 3,795,325 Acquisitions 22,341 323,986 — 346,327 Dispositions ( 51,136 ) — — ( 51,136 ) Effects of foreign currency 15,583 — — 15,583 Adjustments 1,396 922 376 2,693 Balance at March 31, 2021 $ 1,758,302 $ 1,970,739 $ 379,752 $ 4,108,792 Effects of foreign currency 4,254 — — 4,254 Adjustments ( 142 ) — — ( 142 ) Balance at March 31, 2022 $ 1,762,414 $ 1,970,739 $ 379,752 $ 4,112,904
Schedule of Intangible Assets	March 31, 2022 March 31, 2021 Gross Carrying Accumulated Gross Carrying Accumulated Amount Amortization Net Amount Amortization Net Customer relationships $ 3,263,631 $ ( 556,029 ) $ 2,707,602 $ 3,263,653 $ ( 276,682 ) $ 2,986,971 Technology-based intangible assets 1,262,020 ( 407,940 ) 854,080 1,261,285 ( 200,773 ) 1,060,512 Tradenames and other 158,010 ( 20,089 ) 137,921 150,538 ( 10,948 ) 139,590 Total $ 4,683,661 $ ( 984,058 ) $ 3,699,603 $ 4,675,476 $ ( 488,403 ) $ 4,187,073
Schedule of Aggregate Amortization Expense	2023 $ 450,660 2024 403,831 2025 369,362 2026 335,823 2027 302,891 Thereafter 1,837,036 Total $ 3,699,603

Other Noncurrent Assets (Tables

Other Noncurrent Assets (Tables)	12 Months Ended
	Mar. 31, 2022
Other Noncurrent Assets [Abstract]
Schedule of Other Noncurrent Assets	March 31, 2022 March 31, 2021 Capitalized software developed for internal use, net $ 364,617 $ 260,858 Other noncurrent assets, net 235,444 169,283 Other noncurrent assets, net $ 600,061 $ 430,141
Changes in Carrying Amount of Capitalized Computer Software Developed for Sale	March 31, 2022 March 31, 2021 Balance at beginning of period $ 10,779 $ 574 Amounts capitalized 11,343 13,919 Amortization expense ( 3,509 ) ( 1,326 ) Disposal from sale of businesses — ( 837 ) Other ( 846 ) ( 1,551 ) Balance at end of period $ 17,767 $ 10,779

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Mar. 31, 2022
Accrued Expenses [Abstract]
Schedule of Accrued Expenses	March 31, 2022 March 31, 2021 Customer deposits $ 46,129 $ 48,337 Accrued compensation 143,092 177,509 Accrued outside services 53,844 45,349 Accrued insurance 12,784 10,897 Accrued income, sales and other taxes 39,496 57,742 Accrued interest 6,715 6,783 Pass-through payments 29,762 16,799 Tax receivable agreement obligations 36,702 10,646 Interest rate cap agreements — 22,360 Other accrued liabilities 92,982 87,871 Accrued expenses $ 461,506 $ 484,293

Long-Term Debt (Tables)

Long-Term Debt (Tables)	12 Months Ended
	Mar. 31, 2022
Long-Term Debt [Abstract]
Schedule of Long-Term Debt	March 31, 2022 March 31, 2021 Senior Credit Facilities $ 5,100,000 Term Loan Facility, due March 1, 2024 , net of unamortized discount of $ 55,763 and $ 87,698 at March 31, 2022 and March 31, 2021, respectively (effective interest rate of 4.42 % and 4.42 %, respectively) $ 3,257,487 $ 3,405,552 $ 785,000 Revolving Facility, expiring July 3, 2024 , and bearing interest at a variable interest rate — — Senior Notes $ 1,325,000 5.75 % Senior Notes due March 1, 2025 , net of unamortized discount of $ 5,303 and $ 6,921 at March 31, 2022 and March 31, 2021, respectively (effective interest rate of 5.90 % and 5.90 %, respectively) 1,319,697 1,318,079 Tangible Equity Unit Senior Amortizing Note $ 47,367 Senior Amortizing Notes due June 30, 2022 , net of unamortized discount of $ 20 and $ 293 at March 31, 2022 and March 31, 2021, respectively (effective interest rate of 7.44 % and 7.44 %, respectively) 4,234 20,345 Other 8,675 18,138 Less current portion ( 10,006 ) ( 27,339 ) Long-term debt, excluding current portion $ 4,580,087 $ 4,734,775
Schedule of Future Maturities	2023 $ 10,006 2024 3,315,832 2025 1,325,340 2026 — 2027 — Thereafter — Total $ 4,651,178

Interest Rate Cap Agreements (T

Interest Rate Cap Agreements (Tables)	12 Months Ended
	Mar. 31, 2022
Interest Rate Cap Agreements [Abstract]
Schedule of Fair Value of Derivative Instruments	Fair Values of Derivative Financial Instruments Asset (Liability) Derivative financial instruments designated as hedging instruments: Balance Sheet Location March 31, 2022 March 31, 2021 Interest rate cap agreements Prepaid and other current assets $ 7,214 $ — Interest rate cap agreements Other noncurrent assets, net 18,257 — Interest rate cap agreements Accrued expenses — ( 22,360 ) Interest rate cap agreements Other long-term liabilities — ( 365 ) Total $ 25,471 $ ( 22,725 )
Schedule of Effect of Derivative Instruments on Statement of Operations	Year Ended Year Ended Year Ended Derivative financial instruments in cash flow hedging relationships: March 31, 2022 March 31, 2021 March 31, 2020 Gain (loss) related to derivative financial instruments recognized in other comprehensive income (loss) $ 25,563 $ ( 4,855 ) $ ( 1,361 ) (Gain) loss related to portion of derivative financial instruments reclassified from accumulated other comprehensive (income) loss to interest expense $ 1,938 $ 1,202 $ ( 22 )

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Mar. 31, 2022
Fair Value Measurements [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis	Quoted in Significant Other Significant Identical Markets Observable Inputs Unobservable Inputs Total (Level 1) (Level 2) (Level 3) Balance at March 31, 2022: Interest rate cap agreements $ 25,471 $ — $ 25,471 $ — Total $ 25,471 $ — $ 25,471 $ — Balance at March 31, 2021: Interest rate cap agreements $ (22,725) $ — $ (22,725) $ — Total $ ( 22,725 ) $ — $ ( 22,725 ) $ —
Reconciliation of Fair Value Derivative Using Unobservable Inputs	Year Ended Year Ended March 31, 2022 March 31, 2021 Balance at beginning of period $ — $ ( 3,000 ) Gain (loss) included in Other, net — 3,000 Balance at end of period $ — $ —
Carrying Amount and Estimated Fair Value of Financial Instruments	March 31, 2022 March 31, 2021 Carrying Amount Fair Value Carrying Amount Fair Value Cash and cash equivalents $ 252,298 $ 252,298 $ 113,101 $ 113,101 Senior Credit Facilities (Level 2) $ 3,257,487 $ 3,288,401 $ 3,405,552 $ 3,488,883 Senior Notes (Level 2) $ 1,319,697 $ 1,316,785 $ 1,318,079 $ 1,351,500 Debt component of tangible equity units (Level 2) $ 4,234 $ 4,284 $ 20,345 $ 21,435

Tangible Equity Units (Tables)

Tangible Equity Units (Tables)	12 Months Ended
	Mar. 31, 2022
Tangible Equity Units [Abstract]
Schedule of Aggregate Values Assigned upon Issuance of Tangible Equity Units	Equity Component Debt Component Total Price per TEU $ 41.7622 $ 8.2378 $ 50.00 Gross proceeds 240,133 47,367 287,500 Issuance costs ( 7,204 ) ( 1,421 ) ( 8,625 ) Net proceeds $ 232,929 $ 45,946 $ 278,875
Schedule of Tangible Equity Units Activity	Tangible Equity Units Outstanding at March 31, 2020 5,137,345 Conversions ( 303,700 ) Outstanding at March 31, 2021 4,833,645 Conversions ( 779,325 ) Outstanding at March 31, 2022 4,054,320

Equity Method Investment in C_2

Equity Method Investment in Change Healthcare LLC (Tables)	12 Months Ended
	Mar. 31, 2022
Equity Method Investment in Change Healthcare LLC [Abstract]
Summarized Financial Information of the Joint Venture	Period of April 1, 2019 to Statement of Operations Data: March 10, 2020 Total revenue $ 3,092,875 Cost of operations (exclusive of depreciation and amortization) $ 1,263,244 Customer postage $ 215,448 Net income (loss) $ 123,771
Reconciliation of Other Investments	Year Ended March 31, 2020 Balance at beginning of period $ — Acquisition of forward purchase contracts 232,928 Acquisition of available-for-sale debt securities 45,946 Receipt of payments on debt securities ( 7,332 ) Change in fair value of forward purchase contracts 14,836 Change in fair value of debt securities 1,489 TEU conversions of forward purchase contracts ( 31,000 ) Settlement of investment in forward purchase contracts (1) ( 216,764 ) Elimination of investment in debt securities (2) ( 40,103 ) Balance at end of period $ — (1) Amount is included as part of the Merger purchase price. See Note 4, Business Combinations for additional information. (2) Amount is eliminated as part of consolidation.

Incentive Compensation Plans (T

Incentive Compensation Plans (Tables)	12 Months Ended
	Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of Equity Compensation Expense	Year-Ended Year-Ended Year-Ended March 31, 2022 March 31, 2021 March 31, 2020 Equity compensation expense $ 95,730 $ 59,016 $ 1,701 Deferred tax benefit (expense) recognized $ ( 2,326 ) $ 7,336 $ 166 Actual tax benefit recognized $ 34,008 $ 6,067 $ 152
Replacement Time-Vesting Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Option Activity	Replacement Weighted Average Aggregate Time-Vesting Weighted Average Remaining Intrinsic Options Exercise Price Contractual Term Value Outstanding at April 1, 2021 2,484,082 $ 11.83 2.4 $ 25,517 Exercised ( 95,510 ) $ 11.17 — $ 980 Forfeited ( 6,702 ) $ 7.92 — $ 89 Outstanding at March 31, 2022 2,381,870 $ 11.86 1.4 $ 23,664 Exercisable at March 31, 2022 2,381,870 $ 11.86 1.4 $ 23,664
Replacement Exit-Vesting Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Replacement Exit-Vesting Restricted Stock Activity	Weighted Replacement Average Exit-Vesting Grant Date Restricted Stock Fair Value Unvested at April 1, 2021 922,252 $ 12.89 Released ( 762,837 ) $ 13.08 Canceled ( 80,687 ) $ 13.01 Unvested at March 31, 2022 78,728 $ 9.95
Time-Vesting and Exit-Vesting Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Option Activity	Weighted Average Weighted Average Remaining Aggregate Awards Exercise Price Contractual Term Intrinsic Value Time- Exit- Time- Exit- Time- Exit- Time- Exit- Vesting Vesting Vesting Vesting Vesting Vesting Vesting Vesting Options Options Options Options Options Options Options Options Outstanding at April 1, 2021 5,064,148 4,750,627 $ 18.99 $ 18.99 6.6 6.6 $ 15,764 $ 14,774 Exercised ( 215,197 ) — $ 18.99 — — — $ 588 — Forfeited ( 41,671 ) ( 178,648 ) $ 18.99 $ 18.99 — — $ 102 $ 441 Outstanding at March 31, 2022 4,807,280 4,571,979 $ 18.99 $ 18.99 5.6 5.7 $ 13,508 $ 12,847 Exercisable at March 31, 2022 4,642,802 — $ 18.99 — 5.6 — $ 13,046 $ —
Schedule of Time-Vesting and Exist-Vesting Nonvested Option Activity	Time-Vesting Options Exit-Vesting Options Weighted Weighted Average Average Grant Date Grant Date Shares Fair Value Shares Fair Value Unvested at April 1, 2021 637,626 $ 9.78 4,750,627 $ 5.90 Granted — — — — Cancelled ( 11,850 ) $ 9.78 ( 178,648 ) $ 5.90 Vested ( 461,298 ) $ 9.78 — — Unvested at March 31, 2022 164,478 $ 9.78 4,571,979 $ 5.90
Long-term Incentive Plan Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Stock Unit Activity	Restricted Deferred Cash Settled Performance Stock Units Stock Units Restricted Stock Units Stock Units Weighted Weighted Weighted Weighted Average Average Average Average Grant Date Grant Date Grant Date Grant Date Shares Fair Value Shares Fair Value Shares Fair Value Shares Fair Value Unvested at April 1, 2021 14,120,518 $ 16.98 86,916 $ 11.93 434,512 $ 13.49 2,058,530 $ 14.32 Granted 1,188,176 $ 22.20 49,952 $ 23.15 — — — — Canceled ( 1,600,533 ) $ 17.50 — — ( 6,126 ) $ 13.54 ( 107,134 ) $ 14.00 Vested (1) ( 4,465,437 ) $ 17.58 ( 86,916 ) $ 11.93 ( 373,153 ) $ 13.45 ( 8,817 ) $ 13.76 Unvested at March 31, 2022 9,242,724 $ 17.26 49,952 $ 23.15 55,233 $ 13.78 1,942,579 $ 14.34 (1) During the year ended March 31, 2022, 86,916 Deferred Stock Units vested. However, these holders of these awards do not receive shares of common stock in exchange for these DSUs until they leave their position as described above.
eRx Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Stock Unit Activity	eRx Restricted eRx Unvested Stock Stock Units Appreciation Rights Weighted Weighted Average Average Grant Date Grant Date Shares Fair Value Shares Fair Value Unvested at April 1, 2021 243,833 $ 11.04 11,439 $ 11.04 Granted — — — — Canceled ( 19,253 ) $ 11.04 — — Vested ( 193,458 ) $ 11.04 ( 11,439 ) $ 11.04 Unvested at March 31, 2022 31,122 $ 11.04 — —

Retirement Plans and Other Po_2

Retirement Plans and Other Postretirement Benefits (Tables)	12 Months Ended
	Mar. 31, 2022
Retirement Plans and Other Postretirement Benefits[Abstract]
Summary of Liabilities Related to Deferred Compensation Plan	Balance Sheet Location March 31, 2022 March 31, 2021 Accrued expenses $ 1,567 $ 1,746 Other long-term liabilities 24,311 18,860 Total deferred compensation $ 25,878 $ 20,606

Tax Receivable Agreements (Tabl

Tax Receivable Agreements (Tables)	12 Months Ended
	Mar. 31, 2022
Tax Receivable Agreements [Abstract]
Aggregate Payments Due Under Tax Receivable Agreements	Related Party Tax Receivable Agreements McKesson Tax Receivable Agreement Other Tax Receivable Agreements Total 2023 $ 13,057 $ 25,042 $ 11,660 $ 49,759 2024 29,560 15,092 15,120 59,772 2025 29,055 38,184 14,528 81,767 2026 48,559 16,108 19,868 84,535 2027 8,620 32,093 9,359 50,072 Thereafter 41,037 34,950 37,164 113,151 Gross expected payments 169,888 161,469 107,699 439,056 Less: Amounts representing discount ( 51,968 ) — ( 29,704 ) ( 81,672 ) Total tax receivable agreement obligations 117,920 161,469 77,995 357,384 Less: Current portion due ( 13,057 ) ( 25,042 ) ( 11,660 ) ( 49,759 ) Tax receivable agreement long-term obligations $ 104,863 $ 136,427 $ 66,335 $ 307,625

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2022
Income Taxes [Abstract]
Schedule of Income (Loss) before Income Tax	Year Ended Year Ended Year Ended March 31, 2022 March 31, 2021 March 31, 2020 Domestic (U.S.) $ ( 129,858 ) $ ( 145,328 ) $ ( 1,091,272 ) Foreign 23,857 ( 2,069 ) 421 Total $ ( 106,001 ) $ ( 147,397 ) $ ( 1,090,851 )
Schedule of Components of Income Tax Expense (Benefit)	Year Ended Year Ended Year Ended March 31, 2022 March 31, 2021 March 31, 2020 Current: U.S. Federal $ ( 3,232 ) $ 2,515 $ — U.S. State ( 577 ) 5,805 466 Foreign 4,256 2,789 102 Current income tax provision (benefit) 447 11,109 568 Deferred: U.S. Federal ( 27,514 ) ( 47,052 ) ( 113,523 ) U.S. State ( 21,340 ) ( 1,249 ) ( 30,297 ) Foreign ( 204 ) 2,005 ( 2 ) Deferred income tax provision (benefit) ( 49,058 ) ( 46,296 ) ( 143,822 ) Total income tax provision (benefit) $ ( 48,611 ) $ ( 35,187 ) $ ( 143,254 )
Schedule of Effective Income Tax Rate Reconciliation	Year Ended Year Ended Year Ended March 31, 2022 March 31, 2021 March 31, 2020 Statutory U.S. federal tax rate 21.0 % 21.0 % 21.0 % State income taxes (net of federal benefit) 16.3 ( 2.7 ) 2.1 Research and development credit 9.1 11.0 0.2 Equity compensation 5.2 ( 1.3 ) — — — Transaction Costs ( 6.6 ) — — Foreign income taxes ( 1.0 ) ( 1.5 ) — — — Gain on sale of business — ( 4.4 ) — — — eRx option — 2.9 — — — Change in fair value of equity based awards — — ( 1.2 ) Look through accounting policy election — — 2.1 Goodwill impairment charge — — ( 10.8 ) Other 1.9 ( 1.2 ) ( 0.3 ) Effective income tax rate 45.9 % 23.8 % 13.1 %
Schedule of Deferred Tax Assets (Liabilities)	March 31, 2022 March 31, 2021 Depreciation and amortization $ ( 964,820 ) $ ( 1,046,755 ) Net operating losses 249,839 299,606 Tax receivable agreements obligations to related parties 69,564 67,633 Fair value of interest rate cap agreements ( 6,574 ) 1,466 Accruals and reserves 43,599 60,661 Tax credits 46,083 38,138 Debt discount and interest ( 3,264 ) ( 6,594 ) Equity compensation 28,218 38,289 Valuation allowance ( 22,076 ) ( 20,238 ) 163(j) Business interest expense limitation 13,862 2,056 Accounting method change (ASC 606 adoption) ( 1,390 ) ( 23,315 ) Right of use asset ( 16,817 ) ( 24,262 ) Right of use liability 18,807 27,377 Residual deferred tax asset 5,449 5,518 Accounts receivable 5,375 6,107 Other ( 1,074 ) ( 2,779 ) Net deferred tax assets (liabilities) $ ( 535,219 ) $ ( 577,092 ) Reported as: Non-current deferred tax assets 28,387 28,199 Non-current deferred tax liabilities ( 563,606 ) ( 605,291 ) Net deferred tax assets (liabilities) $ ( 535,219 ) $ ( 577,092 )
Reconciliation of Unrecognized Tax Benefits	Year Ended Year Ended March 31, 2022 March 31, 2021 Beginning unrecognized benefit $ 64,110 $ 56,177 Decreases from prior period tax positions ( 891 ) — Increases from prior period tax positions — 3,010 Increases from current period tax positions 4,346 4,923 Increases from acquisition — — Ending unrecognized benefit $ 67,565 $ 64,110

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	12 Months Ended
	Mar. 31, 2022
Net Income (Loss) Per Share [Abstract]
Computation of Basic Net Income (Loss) Per Share of Common Stock	Years Ended March 31, 2022 2021 2020 Basic net income (loss) per share: Numerator: Net income (loss) $ ( 57,390 ) $ ( 112,210 ) $ ( 947,597 ) Denominator: Weighted average common shares outstanding 310,834,905 304,406,531 123,387,547 Minimum shares issuable under purchase contracts 13,161,695 16,365,258 13,609,077 Total weighted average shares outstanding 323,996,600 320,771,789 136,996,624 Basic net income (loss) per share $ ( 0.18 ) $ ( 0.35 ) $ ( 6.92 ) Diluted net income (loss) per share: Numerator: Net income (loss) $ ( 57,390 ) $ ( 112,210 ) $ ( 947,597 ) Denominator: Number of shares used in basic computation 323,996,600 320,771,789 136,996,624 Weighted average effect of dilutive securities — — — Total weighted average shares outstanding 323,996,600 320,771,789 136,996,624 Diluted net income (loss) per share $ ( 0.18 ) $ ( 0.35 ) $ ( 6.92 )
Antidilutive Securities Excluded from Diluted Net Income (Loss) Per Share	Years Ended March 31, 2022 2021 2020 Restricted Share Units 4,507,388 — 1,345,211 Time-Vesting Options 1,614,649 932,968 1,259,594 Deferred Stock Units 160,154 99,964 20,371 Performance Stock Units 100,893 — — Dilutive shares issuable under purchase contracts — 1,184,993 1,829,437

Commitments (Tables)

Commitments (Tables)	12 Months Ended
	Mar. 31, 2022
Commitments [Abstract]
Schedule of Future Minimum Commitments	Payments by Period Total 2023 2024 2025 2026 2027 Thereafter Operating lease obligations (1) $ 87,231 $ 26,035 $ 18,925 $ 13,837 $ 9,586 $ 7,204 $ 11,644 Finance lease obligations 1,327 468 468 391 — — — Purchase obligations (2) 1,047,479 220,237 219,697 198,737 148,512 130,240 130,056 Total contractual obligations $ 1,136,037 $ 246,740 $ 239,090 $ 212,965 $ 158,098 $ 137,444 $ 141,700 (1) We expect to receive $ 1,086 in the future under noncancelable subleases. See Note 7, Leases . (2) Amounts reflect our best estimate of the timing of future payments in instances when our commitment is for an aggregate amount of purchases over a multi-year period rather than specific annual commitments.

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
Summary of Revenue Recognized and Amounts Paid Related to Service Provided to and from Portfolio Companies	Year Ended March 31, 2022 2021 Revenue recognized related to services provided $ 6,930 $ 3,792 Amount paid related to services received $ 17,369 $ 18,057

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Revenue and Adjusted EBITDA for each Reportable Segment	Year Ended Year Ended March 31, 2022 March 31, 2021 Segment Revenue Software and Analytics $ 1,612,931 $ 1,534,926 Network Solutions 868,425 717,843 Technology-Enabled Services 924,472 869,349 Postage and Eliminations (1) 82,727 96,533 Purchase Accounting Adjustment (2) ( 7,740 ) ( 128,230 ) Net Revenue $ 3,480,815 $ 3,090,421 Segment Adjusted EBITDA Software and Analytics $ 561,994 $ 526,129 Network Solutions 446,378 377,005 Technology-Enabled Services 62,679 31,031 Adjusted EBITDA $ 1,071,051 $ 934,165 Reconciliation of income (loss) before tax provision (benefit) to Adjusted EBITDA Income (loss) before income tax provision (benefit) $ ( 106,001 ) $ ( 147,397 ) Amortization of capitalized software developed for sale 3,509 1,326 Depreciation and amortization 681,808 591,048 Interest expense 234,244 245,241 Equity compensation 95,730 59,016 Acquisition accounting adjustments ( 11,839 ) 109,743 Acquisition and divestiture-related costs 41,120 19,709 Integration and related costs 26,803 40,675 Strategic initiatives, duplicative and transition costs 46,041 21,841 Severance costs 10,178 13,184 Accretion and changes in estimate, net 25,276 11,644 Impairment of long-lived assets and other 4,958 18,190 Loss on extinguishment of debt 3,885 8,924 Gain on sale of businesses — ( 59,143 ) Contingent consideration — ( 3,000 ) Other non-routine, net 15,339 3,164 Adjusted EBITDA $ 1,071,051 $ 934,165 (1) Revenue for the Postage and Eliminations segment includes postage revenue of $ 219,612 and $ 196,532 for the years ended March 31, 2022 and 2021, respectively. (2) Amount reflects the impact to deferred revenue resulting from the Merger which reduced revenue recognized during the period.

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	12 Months Ended
	Mar. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Abstract]
Summary of Accumulated Other Comprehensive Income (Loss)	Foreign Accumulated Available Currency Other For Sale Translation Cash Flow Comprehensive Debt Security Adjustment Hedge Income (Loss) Balance at March 31, 2019 $ — $ ( 1,565 ) $ ( 1,691 ) $ ( 3,256 ) Cumulative effect of accounting change of the Joint Venture-ASU 2018-02 — — 422 422 Unrealized gain (loss) on available for sale debt securities of the Joint Venture 1,045 — — 1,045 Realized gain (loss) on available for sale debt securities of the Joint Venture ( 1,045 ) — — ( 1,045 ) Change associated with foreign currency translation — ( 5,519 ) — ( 5,519 ) Change associated with current period hedging, net of taxes of $ 607 — — 981 981 Balance at March 31, 2020 $ — $ ( 7,084 ) $ ( 288 ) $ ( 7,372 ) Change associated with foreign currency translation — 21,324 — 21,324 Change associated with current period hedging, net of taxes of ($ 1,033 ) — — ( 3,823 ) ( 3,823 ) Reclassification into earnings — ( 110 ) 1,202 1,092 Balance at March 31, 2021 $ — $ 14,130 $ ( 2,909 ) $ 11,221 Change associated with foreign currency translation — 3,741 — 3,741 Change associated with current period hedging, net of taxes of $ 7,347 — — 18,216 18,216 Reclassification into earnings — — 1,938 1,938 Balance at March 31, 2022 $ — $ 17,871 $ 17,245 $ 35,116

Nature of Business and Organi_2

Nature of Business and Organization (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	Apr. 22, 2022	Jul. 01, 2019	Mar. 31, 2022	Mar. 31, 2020	Mar. 31, 2021	Jan. 05, 2021
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Termination fee if alternative transaction subsequently consummated			$ 300,000
Proceeds from initial public offering				$ 608,679
Lease, Liability			75,189		$ 107,797
UnitedHealth Group [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Litigation settlement			$ 650,000
UnitedHealth Group [Member] | Subsequent Event [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Payment for purchase of euqity	$ 2,200,000
Common Stock [Member] | UnitedHealth Group [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Dividend Payable			$ 2
Joint Venture [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Ownership percentage		41.00%
Shares received from Joint Venture			49,285,713
Change Healthcare Inc. [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Ownership percentage			100.00%
Business acquisition, share price						$ 25.75

Significant Accounting Polici_4

Significant Accounting Policies (Narrative) (Details) $ in Thousands	12 Months Ended
	Mar. 31, 2022USD ($)item	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)
Significant Accounting Policies [Line Items]
Allowance for credit losses	$ 22,224	$ 24,126	$ 22,360
Equity method investment, impairment loss	$ 0
Minimum [Member]
Significant Accounting Policies [Line Items]
Number of lease renewal options | item	1
Lease renewal option, extension period	1 month
Maximum [Member]
Significant Accounting Policies [Line Items]
Lease renewal option, extension period	1 year
Capitalized Software Developed for Internal Use [Member]
Significant Accounting Policies [Line Items]
Useful life	3 years
Capitalized Software Developed for Sale [Member]
Significant Accounting Policies [Line Items]
Useful life	3 years

Significant Accounting Polici_5

Significant Accounting Policies (Summary of Activity Related to Allowance for Credit Losses) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Accounts Receivable, Allowance for Credit Loss [Line Items]
Balance at beginning of period	$ 24,126	$ 22,360
Acquisitions and Dispositions		(4,952)
Provisions	8,733	14,645
Write-offs	(10,635)	(8,344)
Balance at end of period	$ 22,224	24,126
Accumulated Deficit [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member] | ASU 2016-13 [Member]
Accounts Receivable, Allowance for Credit Loss [Line Items]
Balance at beginning of period		$ 417

Significant Accounting Polici_6

Significant Accounting Policies (Schedule of Finite-Lived Intangible Assets Useful Lives) (Details)	12 Months Ended
	Mar. 31, 2022
Customer Relationships [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life	12 years
Customer Relationships [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life	18 years
Tradenames [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life	18 years
Technology-Based Intangible Assets [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life	6 years
Technology-Based Intangible Assets [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life	12 years

Revenue Recognition (Narrative)

Revenue Recognition (Narrative) (Details) - USD ($)	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue from Contract with Customer [Line Items]
Customer contracts, impairment loss	$ 0
Percentage of deferred revenue balance expected to be recognized in one year or less	94.00%
Deferred revenue recognized	$ 409,808,000
Remaining performance obligation	$ 1,444,943,000
Over Time [Member]
Revenue from Contract with Customer [Line Items]
Percentage of revenue recognized	96.00%
Point in Time [Member]
Revenue from Contract with Customer [Line Items]
Percentage of revenue recognized		4.00%
Obtain Contract [Member]
Revenue from Contract with Customer [Line Items]
Amortization of capitalized cost	$ 10,878,000	$ 2,182,000
Prepaid and Other Current Assets [Member] | Obtain Contract [Member]
Revenue from Contract with Customer [Line Items]
Capitalized contract costs, noncurrent	12,478,000	6,042,000
Prepaid and Other Current Assets [Member] | Fulfill Contract [Member]
Revenue from Contract with Customer [Line Items]
Capitalized contract costs, noncurrent	7,096,000	3,526,000
Other Noncurrent Assets [Member] | Obtain Contract [Member]
Revenue from Contract with Customer [Line Items]
Capitalized contract costs, noncurrent	79,351,000	38,833,000
Other Noncurrent Assets [Member] | Fulfill Contract [Member]
Revenue from Contract with Customer [Line Items]
Capitalized contract costs, noncurrent	$ 40,460,000	$ 24,240,000

Revenue Recognition (Remaining

Revenue Recognition (Remaining Performance Obligation - Narrative) (Details)	Mar. 31, 2022
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, expected satisfaction, period	12 months
Remaining performance obligation, percentage	53.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, expected satisfaction, period	1 year
Remaining performance obligation, percentage	47.00%

Business Combinations (eRx Netw

Business Combinations (eRx Network Holdings, Inc. - Narrative) (Details) - USD ($) $ in Thousands	May 01, 2020	Mar. 31, 2021	Mar. 31, 2020
Business Acquisition [Line Items]
Revenue		$ 3,290,734	$ 3,133,907
eRx Network Holdings, Inc. [Member]
Business Acquisition [Line Items]
Ownership interest acquired	100.00%
Remeasurement loss	$ 6,000
Revenue		$ 63,393

Business Combinations (PDX, Inc

Business Combinations (PDX, Inc. - Narrative) (Details) - USD ($) $ in Thousands	Jun. 01, 2020	Mar. 31, 2021	Mar. 31, 2020
Business Acquisition [Line Items]
Revenue		$ 3,290,734	$ 3,133,907
PDX, Inc. [Member]
Business Acquisition [Line Items]
Ownership interest acquired	100.00%
Total consideration	$ 198,291
Revenue		$ 57,599

Business Combinations (Nucleus.

Business Combinations (Nucleus.io - Narrative) (Details) - USD ($) $ in Thousands	1 Months Ended
	Aug. 31, 2020	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Business Acquisition [Line Items]
Goodwill		$ 4,112,904	$ 4,108,792	$ 3,795,325
Nucleus.io [Member]
Business Acquisition [Line Items]
Total consideration	$ 35,120
Goodwill	22,341
Technology-Based Intangible Assets [Member] | Nucleus.io [Member]
Business Acquisition [Line Items]
Identified intangible assets	$ 11,700
Useful life	15 years

Business Combinations (The Merg

Business Combinations (The Merger - Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	Mar. 10, 2020	Jul. 01, 2019	Mar. 31, 2020	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Business Acquisition [Line Items]
Common Stock, par value				$ 0.001	$ 0.001
Total revenue				$ 3,480,815	$ 3,090,421	$ 196,792
Loss from Equity Method Investment in the Joint Venture						$ 380,713
Joint Venture [Member]
Business Acquisition [Line Items]
Ownership percentage		41.00%
Total revenue			$ 196,792
Loss from Equity Method Investment in the Joint Venture			$ 4,288
Joint Venture [Member] | Prior to Merger [Member]
Business Acquisition [Line Items]
Percentage of remaining equity interest being acquired	58.00%
Loss from Equity Method Investment in the Joint Venture	$ 230,229
Change Common Stock [Member] | SpinCo [Member]
Business Acquisition [Line Items]
Ownership percentage	42.00%
The Merger [Member]
Business Acquisition [Line Items]
Common Stock, par value	$ 0.001
Number of shares of equity interests issued	175,995,192
The Merger [Member] | McKesson Common Stock [Member]
Business Acquisition [Line Items]
Common Stock, par value	$ 0.01
Number of shares of equity interests issued	15,426,537
The Merger [Member] | McKesson Common Stock [Member] | Held by Pre-Merger Holders [Member]
Business Acquisition [Line Items]
Ownership percentage	58.00%
The Merger [Member] | SpinCo Common Stock [Member]
Business Acquisition [Line Items]
Common Stock, par value	$ 0.001
Number of shares of equity interests issued	175,995,192
The Merger [Member] | Change Common Stock [Member]
Business Acquisition [Line Items]
Common Stock, par value	$ 0.001
The Merger [Member] | Change Common Stock [Member] | Held by Pre-Merger Holders [Member]
Business Acquisition [Line Items]
Ownership percentage	42.00%

Business Combinations (eRx Ne_2

Business Combinations (eRx Network Holdings, Inc. - Summary of Information Related to Acquisition) (Details) - USD ($) $ in Thousands	May 01, 2020	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Business Acquisition [Line Items]
Goodwill		$ 4,112,904	$ 4,108,792	$ 3,795,325
Deferred income tax liabilities		$ (28,576)
eRx Network Holdings, Inc. [Member]
Business Acquisition [Line Items]
Cash paid at closing	$ 249,359
Fair value of eRx purchase option	140,500
Fair value of vested stock appreciation rights	5,097
Cash paid for canceled eRx equity awards	5,891
Total Consideration Fair Value at Acquisition Date	400,847
Cash	54,108
Accounts receivable	12,747
Prepaid expenses and other current assets	609
Goodwill	225,156
Other noncurrent assets	20
Accounts payable	(2,543)
Accrued expenses and other current liabilities	(10,933)
Deferred income tax liabilities	(39,217)
Total consideration transferred	400,847
Customer Relationships [Member] | Minimum [Member]
Business Acquisition [Line Items]
Useful life		12 years
Customer Relationships [Member] | Maximum [Member]
Business Acquisition [Line Items]
Useful life		18 years
Customer Relationships [Member] | eRx Network Holdings, Inc. [Member]
Business Acquisition [Line Items]
Identified intangible assets	$ 131,200
Useful life	17 years
Technology-Based Intangible Assets [Member] | Minimum [Member]
Business Acquisition [Line Items]
Useful life		6 years
Technology-Based Intangible Assets [Member] | Maximum [Member]
Business Acquisition [Line Items]
Useful life		12 years
Technology-Based Intangible Assets [Member] | eRx Network Holdings, Inc. [Member]
Business Acquisition [Line Items]
Identified intangible assets	$ 29,700
Technology-Based Intangible Assets [Member] | eRx Network Holdings, Inc. [Member] | Minimum [Member]
Business Acquisition [Line Items]
Useful life	9 years
Technology-Based Intangible Assets [Member] | eRx Network Holdings, Inc. [Member] | Maximum [Member]
Business Acquisition [Line Items]
Useful life	12 years

Business Combinations (PDX, I_2

Business Combinations (PDX, Inc. - Summary of Information Related to Acquisition) (Details) - USD ($) $ in Thousands	Jun. 01, 2020	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Business Acquisition [Line Items]
Goodwill		$ 4,112,904	$ 4,108,792	$ 3,795,325
PDX, Inc. [Member]
Business Acquisition [Line Items]
Cash	$ 755
Accounts receivable	5,739
Prepaid expenses and other current assets	2,251
Property and equipment	840
Goodwill	98,830
Other noncurrent assets	690
Accounts payable	(3,882)
Deferred revenue, current	(2,946)
Accrued expenses and other current liabilities	(3,364)
Other long-term liabilities	(222)
Total consideration transferred	198,291
Customer Relationships [Member] | Minimum [Member]
Business Acquisition [Line Items]
Useful life		12 years
Customer Relationships [Member] | Maximum [Member]
Business Acquisition [Line Items]
Useful life		18 years
Customer Relationships [Member] | PDX, Inc. [Member]
Business Acquisition [Line Items]
Identified intangible assets	$ 74,300
Useful life	18 years
Technology-Based Intangible Assets [Member] | Minimum [Member]
Business Acquisition [Line Items]
Useful life		6 years
Technology-Based Intangible Assets [Member] | Maximum [Member]
Business Acquisition [Line Items]
Useful life		12 years
Technology-Based Intangible Assets [Member] | PDX, Inc. [Member]
Business Acquisition [Line Items]
Identified intangible assets	$ 25,300
Technology-Based Intangible Assets [Member] | PDX, Inc. [Member] | Minimum [Member]
Business Acquisition [Line Items]
Useful life	10 years
Technology-Based Intangible Assets [Member] | PDX, Inc. [Member] | Maximum [Member]
Business Acquisition [Line Items]
Useful life	11 years

Business Combinations (The Me_2

Business Combinations (The Merger - Summary of Information Related to Acquisition) (Details) - USD ($) $ / shares in Units, $ in Thousands	Jun. 01, 2020	Mar. 10, 2020	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Business Acquisition [Line Items]
Goodwill			$ 4,112,904	$ 4,108,792	$ 3,795,325
Deferred income tax liabilities			$ (28,576)
Common Stock, par value			$ 0.001	$ 0.001
PDX, Inc. [Member]
Business Acquisition [Line Items]
Cash	$ 755
Accounts receivable	5,739
Prepaid expenses and other current assets	2,251
Property and equipment	840
Goodwill	98,830
Other noncurrent assets	690
Accounts payable	(3,882)
Deferred revenue, current	(2,946)
Accrued expenses and other current liabilities	(3,364)
Other long-term liabilities	(222)
Total consideration transferred	198,291
Purchace price	198,291
The Merger [Member]
Business Acquisition [Line Items]
Cash		$ 330,665
Accounts receivable		718,895
Contract assets		132,704
Prepaid expenses and other current assets		115,436
Investment in business purchase option		146,500
Property and equipment		206,751
Goodwill		4,363,282
Other noncurrent assets		169,539
Accounts payable		(60,637)
Accrued expenses		(563,791)
Deferred revenue, current		(292,528)
Current portion of long-term debt		(28,969)
Other current liabilities		(22,732)
Long-term debt, excluding current portion		(4,713,565)
Deferred income tax liabilities		(576,546)
Tax receivable agreement obligations due to related parties		(176,586)
Other long-term liabilities		(102,675)
Total consideration transferred		4,035,743
Accounts receivable, allownace for doubtful accounts		22,059
Fair value of shares issued to SpinCo shareholders (175,995,192 shares at $12.47 per share): Common Stock, $0.001 par value		176
Additional paid-in capital		2,194,484
Fair value of Joint Venture equity interest previously held		1,589,040
Fair value of Joint Venture equity interest previously held through TEUs		216,764
Settlement of dividend receivable		42,778
Repayment of advances to member		7,499
Purchace price		$ 4,035,743
Fair value of shares issued to SpinCo shareholders , shares		175,995,192
Fair value of shares issued to SpinCo shareholders, share price		$ 12.47
Common Stock, par value		$ 0.001
Customer Relationships [Member] | Minimum [Member]
Business Acquisition [Line Items]
Useful life			12 years
Customer Relationships [Member] | Maximum [Member]
Business Acquisition [Line Items]
Useful life			18 years
Customer Relationships [Member] | PDX, Inc. [Member]
Business Acquisition [Line Items]
Identified intangible assets	$ 74,300
Useful life	18 years
Customer Relationships [Member] | The Merger [Member]
Business Acquisition [Line Items]
Identified intangible assets		$ 3,056,000
Customer Relationships [Member] | The Merger [Member] | Minimum [Member]
Business Acquisition [Line Items]
Useful life		12 years
Customer Relationships [Member] | The Merger [Member] | Maximum [Member]
Business Acquisition [Line Items]
Useful life		16 years
Tradenames [Member]
Business Acquisition [Line Items]
Useful life			18 years
Tradenames [Member] | The Merger [Member]
Business Acquisition [Line Items]
Identified intangible assets		$ 146,000
Useful life		18 years
Technology-Based Intangible Assets [Member] | Minimum [Member]
Business Acquisition [Line Items]
Useful life			6 years
Technology-Based Intangible Assets [Member] | Maximum [Member]
Business Acquisition [Line Items]
Useful life			12 years
Technology-Based Intangible Assets [Member] | PDX, Inc. [Member]
Business Acquisition [Line Items]
Identified intangible assets	$ 25,300
Technology-Based Intangible Assets [Member] | PDX, Inc. [Member] | Minimum [Member]
Business Acquisition [Line Items]
Useful life	10 years
Technology-Based Intangible Assets [Member] | PDX, Inc. [Member] | Maximum [Member]
Business Acquisition [Line Items]
Useful life	11 years
Technology-Based Intangible Assets [Member] | The Merger [Member]
Business Acquisition [Line Items]
Identified intangible assets		$ 1,188,000
Technology-Based Intangible Assets [Member] | The Merger [Member] | Minimum [Member]
Business Acquisition [Line Items]
Useful life		6 years
Technology-Based Intangible Assets [Member] | The Merger [Member] | Maximum [Member]
Business Acquisition [Line Items]
Useful life		12 years

Business Combinations (Suppleme

Business Combinations (Supplemental Pro Forma Results) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Business Combinations [Abstract]
Total revenue	$ 3,290,734	$ 3,133,907
Net income (loss)	$ (228,234)	$ (128,889)
Net income (loss) per share, basic and diluted	$ (0.75)	$ (0.43)

Dispositions (Narrative) (Detai

Dispositions (Narrative) (Details) - USD ($) $ in Thousands	Dec. 02, 2020	May 01, 2020	Jul. 31, 2020	Mar. 31, 2021	Mar. 31, 2022	Dec. 01, 2020	Apr. 30, 2020	Mar. 31, 2020	Mar. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net book value				$ 3,252,228	$ 3,276,107			$ 3,285,447	$ 1,132,487
Gain on sale of business				$ 59,143
Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | Connected Analytics [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration		$ 55,000
Net book value							$ 23,428
Net accounts receivable							16,636
Goodwill							21,705
Deferred revenue							$ 17,083
Gain on sale of business		24,337
Payment received on notes receivable			$ 25,000
Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | Connected Analytics [Member] | Notes Receivable [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Other noncurrent assets		$ 25,000
Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] | Capacity Management [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration	$ 67,500
Net book value						$ 31,690
Net accounts receivable						14,991
Goodwill						26,944
Deferred revenue						$ 15,230
Gain on sale of business	$ 31,690

Leases (Narrative) (Details)

Leases (Narrative) (Details)	12 Months Ended
	Mar. 31, 2022
Minimum [Member]
Operating and finance lease terms	1 year
Maximum [Member]
Operating and finance lease terms	15 years

Leases (Components of Lease Cos

Leases (Components of Lease Cost) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Leases [Abstract]
Operating lease cost	$ 35,025	$ 43,950
Finance lease cost: Amortization expense	356	429
Finance lease cost: Interest expense	93	120
Short-term lease cost	2,113	1,473
Variable lease cost	5,179	6,804
Sublease income	(1,089)	(1,293)
Total lease cost	$ 41,677	$ 51,483

Leases (Right-of-use Assets and

Leases (Right-of-use Assets and Lease Liabilities) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Leases [Abstract]
Right-of-use assets, Operating leases	$ 65,680	$ 93,412
Right-of-use assets, Finance leases	1,370	1,858
Total right-of-use assets	67,050	95,270
Current liabilities: Operating leases	21,726	30,608
Current liabilities: Finance leases	405	568
Noncurrent liabilities: Operating leases	52,286	75,396
Noncurrent liabilities: Finance leases	772	1,225
Total lease liabilities	$ 75,189	$ 107,797

Leases (Lease Liability Maturit

Leases (Lease Liability Maturities) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Operating Leases
2023	$ 26,035
2024	18,925
2025	13,837
2026	9,586
2027	7,204
Thereafter	11,644
Total operating lease obligations	87,231
Less: Imputed interest	13,219
Total lease liabilities	74,012
Finance Leases
2023	468
2024	468
2025	391
Total finance lease obligations	1,327
Less: Imputed interest	150
Total lease liabilities	1,177
2023	26,503
2024	19,393
2025	14,228
2026	9,586
2027	7,204
2028 and thereafter	11,644
Total lease liabilities, undiscounted	88,558
Less: Imputed interest	13,369
Total lease liabilities	$ 75,189	$ 107,797

Leases (Other Information Relat

Leases (Other Information Related to Leases) (Details)	Mar. 31, 2022	Mar. 31, 2021
Operating Leases
Weighted-average remaining lease term	4 years 8 months 5 days	4 years 9 months 4 days
Weighted-average discount rate	7.14%	7.29%
Finance Leases
Weighted-average remaining lease term	2 years 10 months 2 days	3 years 6 months 7 days
Weighted-average discount rate	6.36%	6.51%

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Schedule of Prepaid Expenses and Other Current Assets) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Prepaid Expenses and Other Current Assets [Abstract]
Prepaid expenses	$ 103,023	$ 86,307
Other current assets	74,636	53,951
Total prepaid expenses and other current assets	$ 177,659	$ 140,258

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 257,247	$ 233,811
Accumulated depreciation	(115,907)	(59,441)
Property and equipment, net	141,340	174,370
Depreciation expense	56,708	56,240	$ 2,960
Land [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	406	406
Buildings and Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	59,067	60,716
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	125,847	105,450
Production Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	17,215	17,046
Office Equipment, Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	33,702	34,696
Construction in Process [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 21,010	$ 15,497

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Goodwill and Intangible Assets [Abstract]
Goodwill impairment charge			$ 561,164
Amortization expense	$ 498,843	$ 463,334	$ 24,194

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets (Schedule of Goodwill) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Goodwill [Line Items]
Balance at March 31,	$ 4,108,792	$ 3,795,325
Acquisitions		346,327
Dispositions		(51,136)
Goodwill impairment			$ (561,164)
Effects of foreign currency	4,254	15,583
Adjustments	(142)	2,693
Balance at March 31,	4,112,904	4,108,792	3,795,325
Software and Analytics [Member]
Goodwill [Line Items]
Balance at March 31,	1,758,302	1,770,118
Acquisitions		22,341
Dispositions		(51,136)
Effects of foreign currency	4,254	15,583
Adjustments	(142)	1,396
Balance at March 31,	1,762,414	1,758,302	1,770,118
Network Solutions [Member]
Goodwill [Line Items]
Balance at March 31,	1,970,739	1,645,831
Acquisitions		323,986
Dispositions
Effects of foreign currency
Adjustments		922
Balance at March 31,	1,970,739	1,970,739	1,645,831
Technology-Enabled Services [Member]
Goodwill [Line Items]
Balance at March 31,	379,752	379,376
Acquisitions
Dispositions
Effects of foreign currency
Adjustments		376
Balance at March 31,	$ 379,752	$ 379,752	$ 379,376

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets (Schedule of Intangible Assets) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Gross Amount	$ 4,683,661	$ 4,675,476
Accumulated Amortization	(984,058)	(488,403)
Net	3,699,603	4,187,073
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount	3,263,631	3,263,653
Accumulated Amortization	(556,029)	(276,682)
Net	2,707,602	2,986,971
Technology-Based Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount	1,262,020	1,261,285
Accumulated Amortization	(407,940)	(200,773)
Net	854,080	1,060,512
Tradenames and Other [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount	158,010	150,538
Accumulated Amortization	(20,089)	(10,948)
Net	$ 137,921	$ 139,590

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets (Schedule of Aggregate Amortization Expense) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Goodwill and Intangible Assets [Abstract]
2023	$ 450,660
2024	403,831
2025	369,362
2026	335,823
2027	302,891
Thereafter	1,837,036
Net	$ 3,699,603	$ 4,187,073

Other Noncurrent Assets (Narrat

Other Noncurrent Assets (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Other Noncurrent Assets [Abstract]
Capitalized software developed for internal use, accumulated amortization	$ 168,532	$ 71,356
Capitalized software developed for internal use, amortization expense	$ 126,257	$ 71,473

Other Noncurrent Assets (Schedu

Other Noncurrent Assets (Schedule of Other Noncurrent Assets) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Other Noncurrent Assets [Abstract]
Capitalized software developed for internal use, net	$ 364,617	$ 260,858
Other noncurrent assets, net	235,444	169,283
Other noncurrent assets, net	$ 600,061	$ 430,141

Other Noncurrent Assets (Change

Other Noncurrent Assets (Changes in Carrying Amount of Capitalized Software Developed for Sale ) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Other Noncurrent Assets [Abstract]
Balance at beginning of period	$ 10,779	$ 574
Amounts capitalized	11,343	13,919
Amortization expense	(3,509)	(1,326)
Disposal from sale of businesses		(837)
Other	(846)	(1,551)
Balance at end of period	$ 17,767	$ 10,779

Accrued Expenses (Schedule of A

Accrued Expenses (Schedule of Accued Expenses) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Accrued Expenses [Abstract]
Customer deposits	$ 46,129	$ 48,337
Accrued compensation	143,092	177,509
Accrued outside services	53,844	45,349
Accrued insurance	12,784	10,897
Accrued income, sales and other taxes	39,496	57,742
Accrued interest	6,715	6,783
Pass-through payments	29,762	16,799
Tax receivable agreement obligations	36,702	10,646
Interest rate cap agreements		22,360
Other accrued liabilities	92,982	87,871
Total accrued expenses	$ 461,506	$ 484,293

Long-Term Debt (Senior Credit F

Long-Term Debt (Senior Credit Facilities - Narrative) (Details) - USD ($)	1 Months Ended	12 Months Ended
	Jun. 30, 2020	Mar. 31, 2022	Mar. 31, 2021
Debt Instrument [Line Items]
Payments on Revolving Facility			$ 250,000,000
Letters of credit		$ 5,485,000	6,194,000
Loss on extinguishment of debt		3,885,000	8,924,000
Senior Credit Facilities [Member]
Debt Instrument [Line Items]
Right to request additional sums, maximum amount		$ 1,080,000,000
Right to request additional sums, maximum percentage amount equal to EBITDA		100.00%
Additional indebtedness incurred if leverage ratio exceeded		1
Consolidated interest coverage ratio		2
Percentage of Parent borrower’s annual excess cash flows required to be exempt from requirement to prepay outstanding term loans		50.00%
Percentage of net cash proceeds of non-ordinary course asset sales or other dispositions of property required to be exempt from requirement to prepay outstanding term loans		100.00%
Percentage of net cash proceeds of any incurrence of debt by borrowers other than proceeds from debt permitted under the terms required to be exempt from requirement to prepay outstanding term loans		100.00%
Maximum percentage of capital stock of wholly owned foreign restricted subsidiary pledged		65.00%
Senior Credit Facilities [Member] | Specified Consolidated First Lien Net Leverage Ratios Achieved and Maintained Second Fiscal Year [Member]
Debt Instrument [Line Items]
Leverage ratio		4.90
Percentage of Parent borrower’s annual excess cash flows required to be exempt from requirement to prepay outstanding term loans		25.00%
Percentage of net cash proceeds of non-ordinary course asset sales or other dispositions of property required to be exempt from requirement to prepay outstanding term loans		50.00%
Senior Credit Facilities [Member] | Specified Consolidated First Lien Net Leverage Ratios Achieved and Maintained Third Fiscal Year [Member]
Debt Instrument [Line Items]
Leverage ratio		5.75
Percentage of Parent borrower’s annual excess cash flows required to be exempt from requirement to prepay outstanding term loans		0.00%
Percentage of net cash proceeds of non-ordinary course asset sales or other dispositions of property required to be exempt from requirement to prepay outstanding term loans		25.00%
Senior Credit Facilities [Member] | Specified Consolidated First Lien Net Leverage Ratios Achieved and Maintained Forth Fiscal Year [Member]
Debt Instrument [Line Items]
Leverage ratio		6
Percentage of net cash proceeds of non-ordinary course asset sales or other dispositions of property required to be exempt from requirement to prepay outstanding term loans		0.00%
Senior Credit Facilities [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Basis spread		1.00%
Senior Credit Facilities [Member] | Fed Funds Effective Rate Overnight Index Swap Rate [Member]
Debt Instrument [Line Items]
Basis spread		0.50%
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Payments on Revolving Facility	$ 250,000,000
Floor rate		0.00%
Current borrowing capacity		$ 785,000,000
Remaining borrowing capacity		$ 779,515,000	778,806,000
Commitment fee percentage		0.375%
Term Loan Facility [Member]
Debt Instrument [Line Items]
Floor rate		1.00%
Percentage of principal amount amortized in equal quarterly installments		1.00%
Remaining quarterly amortization payments		$ 0
Repayment of debt		$ 180,000,000	$ 315,000,000
Term Loan Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Floor rate		2.00%

Long-Term Debt (Senior Notes -

Long-Term Debt (Senior Notes - Narrative) (Details) - USD ($)	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Apr. 30, 2020	Feb. 28, 2017
Senior Notes due March 1, 2025 [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 1,325,000,000	$ 1,325,000,000
Stated interest rate	5.75%	5.75%
Maturity date	Mar. 1, 2025
Redemption price percentage	101.00%
Senior Notes - Issuance 2 [Member]
Debt Instrument [Line Items]
Debt instrument, face amount			$ 325,000,000
Issuance costs			$ 6,161,000
Senior Notes - Issuance 1 [Member]
Debt Instrument [Line Items]
Debt instrument, face amount				$ 1,000,000,000

Long-Term Debt (Other - Narrati

Long-Term Debt (Other - Narrative) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Debt Instrument [Line Items]
Long-term debt	$ 4,651,178
Deferred Financing Arrangements [Member]
Debt Instrument [Line Items]
Long-term debt	$ 7,498	$ 16,346

Long-Term Debt (Schedule of Lon

Long-Term Debt (Schedule of Long-Term Debt) (Details) - USD ($)	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Debt Instrument [Line Items]
Long-term debt	$ 4,651,178,000
Less current portion	(10,006,000)	$ (27,339,000)
Long-term debt, excluding current portion	4,580,087,000	4,734,775,000
Senior Notes due March 1, 2025 [Member]
Debt Instrument [Line Items]
Long-term debt	1,319,697,000	1,318,079,000
Debt instrument, face amount	$ 1,325,000,000	$ 1,325,000,000
Stated interest rate	5.75%	5.75%
Maturity date	Mar. 1, 2025
Unamortized discount	$ 5,303,000	$ 6,921,000
Effective interest rate	5.90%	5.90%
Senior Amortizing Notes due June 30, 2022 [Member]
Debt Instrument [Line Items]
Long-term debt	$ 4,234,000	$ 20,345,000
Debt instrument, face amount	$ 47,367,000	47,367,000
Maturity date	Jun. 30, 2022
Unamortized discount	$ 20,000	$ 293,000
Effective interest rate	7.44%	7.44%
Other [Member]
Debt Instrument [Line Items]
Long-term debt	$ 8,675,000	$ 18,138,000
Term Loan Facility [Member]
Debt Instrument [Line Items]
Long-term debt	3,257,487,000	3,405,552,000
Debt instrument, face amount	$ 5,100,000,000	5,100,000,000
Maturity date	Mar. 1, 2024
Unamortized discount	$ 55,763,000	$ 87,698,000
Effective interest rate	4.42%	4.42%
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 785,000,000	$ 785,000,000
Maturity date	Jul. 3, 2024

Long-Term Debt (Schedule of Fut

Long-Term Debt (Schedule of Future Maturities) (Details) $ in Thousands	Mar. 31, 2022USD ($)
Long-Term Debt [Abstract]
2023	$ 10,006
2024	3,315,832
2025	1,325,340
2026
2027
Thereafter
Total	$ 4,651,178

Interest Rate Cap Agreements (N

Interest Rate Cap Agreements (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020	Aug. 31, 2018
Derivative [Line Items]
Reclassified as interest expense	$ 6,025
Fair value derivative net liability		$ 23,063
Interest Rate Cap Agreements [Member]
Derivative [Line Items]
Notional amount			$ 1,000,000
Effective date	Mar. 31, 2020
Derivative, maturity date	Mar. 31, 2024
Interest Rate Cap Agreements [Member] | Maximum [Member]
Derivative [Line Items]
Variable rate			1.00%
Joint Venture [Member] | Interest Rate Cap Agreements [Member]
Derivative [Line Items]
Notional amount				$ 1,500,000
Effective date	Aug. 31, 2018
Derivative, maturity date	Dec. 31, 2021
Joint Venture [Member] | Interest Rate Cap Agreements [Member] | Minimum [Member]
Derivative [Line Items]
Notional amount				500,000
Joint Venture [Member] | Interest Rate Cap Agreements [Member] | Maximum [Member]
Derivative [Line Items]
Notional amount				$ 1,500,000
Variable rate				1.00%

Interest Rate Cap Agreements (S

Interest Rate Cap Agreements (Schedule of Fair Value of Derivative Instruments) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Derivatives Fair Value [Line Items]
Prepaid expenses and other current assets	$ 177,659	$ 140,258
Other noncurrent assets, net	600,061	430,141
Accrued expenses	(461,506)	(484,293)
Other long-term liabilities	(73,118)	(65,572)
Fair Values of Derivative Instruments Asset (Liability) Derivatives		(23,063)
Designated as Hedging Instrument [Member] | Interest Rate Cap Agreements [Member]
Derivatives Fair Value [Line Items]
Prepaid expenses and other current assets	7,214
Other noncurrent assets, net	18,257
Accrued expenses		(22,360)
Other long-term liabilities		(365)
Fair Values of Derivative Instruments Asset (Liability) Derivatives	$ 25,471	$ (22,725)

Interest Rate Cap Agreements _2

Interest Rate Cap Agreements (Schedule of Effect of Derivative Instruments on Statement of Operations) (Details) - Cash Flow Hedging [Member] - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) related to derivative financial instruments recognized in other comprehensive income (loss)	$ 25,563	$ (4,855)	$ (1,361)
(Gain) loss related to portion of derivative financial instruments reclassified from accumulated other comprehensive (income) loss to interest expense	$ 1,938	$ 1,202	$ (22)

Fair Value Measurements (Schedu

Fair Value Measurements (Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Derivatives Fair Value [Line Items]
Interest rate cap agreements	$ 25,471
Interest rate cap agreements		$ (22,725)
Significant Other Observable Inputs (Level 2)
Derivatives Fair Value [Line Items]
Interest rate cap agreements	$ 25,471
Interest rate cap agreements		$ (22,725)

Fair Value Measurements (Reconc

Fair Value Measurements (Reconciliation of Fair Value Derivative Using Unobservable Inputs) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Fair Value Measurements [Abstract]
Balance at beginning of period		$ (3,000)
Gain (loss) included in Other, net		3,000
Balance at end of period

Fair Value Measurements (Carryi

Fair Value Measurements (Carrying Amount and Estimated Fair Value of Financial Instruments) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Carrying [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash equivalents	$ 252,298	$ 113,101
Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash equivalents	252,298	113,101
Senior Notes due March 1, 2025 [Member] | Significant Other Observable Inputs (Level 2) | Carrying [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt	1,319,697	1,318,079
Senior Notes due March 1, 2025 [Member] | Significant Other Observable Inputs (Level 2) | Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt	1,316,785	1,351,500
Senior Amortizing Notes due June 30, 2022 [Member] | Significant Other Observable Inputs (Level 2) | Carrying [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt component of tangible equity units	4,234	20,345
Senior Amortizing Notes due June 30, 2022 [Member] | Significant Other Observable Inputs (Level 2) | Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt component of tangible equity units	4,284	21,435
Senior Credit Facilities [Member] | Significant Other Observable Inputs (Level 2) | Carrying [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt	3,257,487	3,405,552
Senior Credit Facilities [Member] | Significant Other Observable Inputs (Level 2) | Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt	$ 3,288,401	$ 3,488,883

Tangible Equity Units (Narrativ

Tangible Equity Units (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Jul. 31, 2019	Mar. 31, 2022	Sep. 30, 2019
Tangible Equity Units [Line Items]
Conversion to shares		$ 3.2051
Senior Amortizing Note [Member]
Tangible Equity Units [Line Items]
Maturity date		Jun. 30, 2022
Initial principal amount		$ 8.2378
Stated interest rate		5.50%
Cash installment		$ 0.7500	$ 0.7417
Settlement date		Jun. 30, 2022
Minimum [Member]
Tangible Equity Units [Line Items]
Share offering		12,994,501
Maximum [Member]
Tangible Equity Units [Line Items]
Share offering		15,593,320
Applicable Market Value is greater than $15.60 per share [Member]
Tangible Equity Units [Line Items]
Share price		$ 15.60
Conversion to shares		3.2051
Applicable Market Value is less than or equal to $15.60 per share but greater than or equal to $13.00 per share [Member]
Tangible Equity Units [Line Items]
Conversion to shares		50
Applicable Market Value is less than or equal to $15.60 per share but greater than or equal to $13.00 per share [Member] | Minimum [Member]
Tangible Equity Units [Line Items]
Share price		13
Applicable Market Value is less than or equal to $15.60 per share but greater than or equal to $13.00 per share [Member] | Maximum [Member]
Tangible Equity Units [Line Items]
Share price		15.60
Applicable Market Value is less than $13.00 per share [Member]
Tangible Equity Units [Line Items]
Share price		13
Conversion to shares		3.8461
Tangible Equity Units [Member]
Tangible Equity Units [Line Items]
Tangible equity unit offering	5,750,000
Total proceeds, net of issuance costs	$ 278,875
TEU price per share	$ 50
Initial principal amount	$ 8.2378
Tangible Equity Units [Member] | Applicable Market Value is less than or equal to $15.60 per share but greater than or equal to $13.00 per share [Member] | Minimum [Member]
Tangible Equity Units [Line Items]
Share price		13
Tangible Equity Units [Member] | Applicable Market Value is less than or equal to $15.60 per share but greater than or equal to $13.00 per share [Member] | Maximum [Member]
Tangible Equity Units [Line Items]
Share price		$ 15.60

Tangible Equity Units (Schedule

Tangible Equity Units (Schedule of Aggregate Values Assigned upon Issuance of Tangible Equity Units) (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Jul. 31, 2019	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Tangible Equity Units [Line Items]
Equity Component, Net proceeds				$ 232,929
Debt Component, Gross proceeds				$ 47,367
Debt Component, Issuance costs		$ (10,991)	$ (19,519)
Tangible Equity Units [Member]
Tangible Equity Units [Line Items]
Equity Component, Price per TEU	$ 41.7622
Equity Component, Gross proceeds	$ 240,133
Equity Component, Issuance costs	(7,204)
Equity Component, Net proceeds	$ 232,929
Debt Component, Price per TEU	$ 8.2378
Debt Component, Gross proceeds	$ 47,367
Debt Component, Issuance costs	(1,421)
Debt Component, Net proceeds	$ 45,946
Total, Price per share	$ 50
Total, Gross proceeds	$ 287,500
Total, Issuance costs	(8,625)
Total, Net proceeds	$ 278,875

Tangible Equity Units (Schedu_2

Tangible Equity Units (Schedule of Tangible Equity Units Activity) (Details) - Tangible Equity Units [Member] - shares	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Tangible Equity Units [Line Items]
Outstanding at March 31,	4,833,645	5,137,345
Conversions	(779,325)	(303,700)
Outstanding at December 31,	4,054,320	4,833,645

Equity Method Investment in C_3

Equity Method Investment in Change Healthcare LLC (Narrative) (Details) - USD ($) $ in Thousands	Jul. 01, 2019	Mar. 31, 2022
Legacy CHC [Member]
Schedule of Equity Method Investments [Line Items]
Percentage investment exchanged for membership interest in Joint Venture		45.615%
Joint Venture [Member]
Schedule of Equity Method Investments [Line Items]
Ownership percentage	41.00%
Ownership percentage acquired in exchange		30.00%
Shares received from Joint Venture		49,285,713
Additional ownership percentage acquired		11.00%
Write-off of basis differences within Loss from Equity Method Investment in the Joint Venture		$ 380,713
Joint Venture [Member] | Legacy CHC [Member]
Schedule of Equity Method Investments [Line Items]
Ownership percentage		54.385%

Equity Method Investment in C_4

Equity Method Investment in Change Healthcare LLC (Summarized Financial Information of the Joint Venture) (Details) - Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member] $ in Thousands	11 Months Ended
	Mar. 10, 2020USD ($)
Schedule of Equity Method Investments [Line Items]
Total revenue	$ 3,092,875
Cost of operations (exclusive of depreciation and amortization)	1,263,244
Customer postage	215,448
Net income (loss)	$ 123,771

Equity Method Investment in C_5

Equity Method Investment in Change Healthcare LLC (Reconciliation of Other Investments) (Details) $ in Thousands	12 Months Ended
	Mar. 31, 2022USD ($)
Marketable Securities [Line Items]
Balance
Forward Contracts [Member]
Marketable Securities [Line Items]
Acquisition	232,928
Change in fair value	14,836
TEU conversions of forward purchase contracts	(31,000)
Settlement of investment in forward purchase contracts	(216,764)	[1]
Debt Securities [Member]
Marketable Securities [Line Items]
Acquisition	45,946
Receipt of payments on debt securities	(7,332)
Change in fair value	1,489
Elimination of investment in debt securities	(40,103)	[2]
Balance
[1]	Amount is included as part of the Merger purchase price. See Note 4, Business Combinations for additional information.
[2]	Amount is eliminated as part of consolidation.

Incentive Compensation Plans (N

Incentive Compensation Plans (Narrative) (Details)	11 Months Ended	12 Months Ended
	Mar. 09, 2020USD ($)	Mar. 31, 2022USD ($)itemshares	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense | $	$ 0	$ 95,730,000	$ 59,016,000	$ 1,701,000
Legacy CHC Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance		37,900,000
Liquidity event, percentage threshold of shares sold		25.00%
Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance		25,000,000
Granted in period		1
Unrecognized compensation expense | $		$ 145,919,000
Unrecognized compensation expense period for recognition		1 year 4 months 24 days
Replacement Exit-Vesting Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense | $		$ 0
Time-Vesting Options [Member] | Legacy CHC Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of tranches | item		4
Unrecognized compensation expense | $		$ 68,000
Time-Vesting Options [Member] | Legacy CHC Equity Plan [Member] | Share-based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of awards liquidated for cash		54.40%
Percentage of awards exchanged for vested options		45.60%
Awards received as, exercise price equal to percentage of fair value, percentage		25.00%
Vesting percentage		25.00%
Time-Vesting Options [Member] | Legacy CHC Equity Plan [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		25.00%
Time-Vesting Options [Member] | Legacy CHC Equity Plan [Member] | Share-based Payment Arrangement, Tranche Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		25.00%
Time-Vesting Options [Member] | Legacy CHC Equity Plan [Member] | Share-based Payment Arrangement, Tranche Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		25.00%
Exit-Vesting Options [Member] | Legacy CHC Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of awards liquidated for cash		54.40%
Percentage of awards exchanged for vested options		45.60%
Awards received as, exercise price equal to percentage of fair value, percentage		25.00%
Number of tranches | item		3
Unrecognized compensation expense | $		$ 26,854,000
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted in period		1,188,176
Vested		4,465,437
Restricted Stock Units [Member] | Omnibus Incentive Plan [Member] | Graded Vesting Schedule [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		4 years
Restricted Stock Units [Member] | Omnibus Incentive Plan [Member] | Share-based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Vesting percentage		50.00%
Restricted Stock Units [Member] | Omnibus Incentive Plan [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		25.00%
Restricted Stock Units [Member] | Omnibus Incentive Plan [Member] | Share-based Payment Arrangement, Tranche Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		25.00%
Cash Settled Restricted Stock Units CSRSU [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested		373,153
Cash Settled Restricted Stock Units CSRSU [Member] | Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Cash paid to settle awards upon vesting | $		$ 8,300,000	$ 2,273,000
Performance Stock Units PSU [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested		8,817
Performance Stock Units PSU [Member] | Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of tranches | item		2
Performance Stock Units PSU [Member] | Omnibus Incentive Plan [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Deferred Stock Units DSU [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted in period		49,952
Vested		86,916
Deferred Stock Units DSU [Member] | Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		1 year
Vesting percentage		100.00%
eRx Vested Stock Appreciation Rights (SARs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Cash paid to settle awards upon vesting | $		$ 4,479,000
Vested		478,180
Minimum [Member] | Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		1 year
Minimum [Member] | Restricted Stock Units [Member] | Omnibus Incentive Plan [Member] | Cliff Vesting Schedule [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		1 year
Minimum [Member] | Cash Settled Restricted Stock Units CSRSU [Member] | Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		1 year
Maximum [Member] | Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		4 years
Maximum [Member] | Restricted Stock Units [Member] | Omnibus Incentive Plan [Member] | Cliff Vesting Schedule [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		4 years
Maximum [Member] | Cash Settled Restricted Stock Units CSRSU [Member] | Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Blackstone [Member] | eRx Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Liquidity event, percentage threshold of shares sold		25.00%
Blackstone [Member] | Joint Venture [Member] | Exit-Vesting Options [Member] | Legacy CHC Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Liquidity event, percentage threshold of shares sold		25.00%
McKesson Corporation [Member] | Joint Venture [Member] | Exit-Vesting Options [Member] | Legacy CHC Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Liquidity event, percentage threshold of shares sold		50.00%
Blackstone And McKesson [Member] | Joint Venture [Member] | Exit-Vesting Options [Member] | Legacy CHC Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Liquidity event, percentage threshold of shares sold		25.00%

Incentive Compensation Plans (S

Incentive Compensation Plans (Schedule of Replacement Time-Vesting Option Activity) (Details) - Replacement Time-Vesting Options [Member] - USD ($)	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at April 1, 2021	2,484,082
Exercised	(95,510)
Forfeited	(6,702)
Outstanding at March 31, 2022	2,381,870	2,484,082
Exercisable at March 31, 2022	2,381,870
Weighted Average Exercise Price, Outstanding at April 1, 2021	$ 11.83
Weighted Average Exercise Price, Exercised	11.17
Weighted Average Exercise Price, Forfeited	7.92
Weighted Average Exercise Price, Outstanding at March 31, 2022	11.86	$ 11.83
Weighted Average Exercise Price, Exercisable at March 31, 2022	$ 11.86
Weighted Average Remaining Contractual Term, Outstanding	1 year 4 months 24 days	2 years 4 months 24 days
Weighted Average Remaining Contractual Term, Exercisable at March 31, 2022	1 year 4 months 24 days
Aggregate Intrinsic Value, Outstanding at April 1, 2021	$ 25,517,000
Aggregate Intrinsic Value, Exercised	980,000
Aggregate Intrinsic Value, Forfeited	89,000
Aggregate Intrinsic Value, Outstanding at March 31, 2022	23,664,000	$ 25,517,000
Aggregate Intrinsic Value, Exercisable at March 31, 2021	$ 23,664,000

Incentive Compensation Plans _2

Incentive Compensation Plans (Schedule of Replacement Exit-Vesting Restricted Stock Activity) (Details) - Replacement Exit-Vesting Restricted Stock [Member]	12 Months Ended
	Mar. 31, 2022$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested at April 1, 2021 | shares	922,252
Released | shares	(762,837)
Canceled | shares	(80,687)
Unvested at March 31, 2022 | shares	78,728
Weighted Average Grant Date Fair Value, Unvested at April 1, 2021 | $ / shares	$ 12.89
Weighted Average Grant Date Fair Value, Released | $ / shares	(13.08)
Weighted Average Grant Date Fair Value, Canceled | $ / shares	13.01
Weighted Average Grant Date Fair Value, Unvested at March 31, 2022 | $ / shares	$ 9.95

Incentive Compensation Plans _3

Incentive Compensation Plans (Schedule of Time-Vesting and Exit-Vesting Option Activity) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Time-Vesting Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at April 1, 2021	5,064,148
Exercised	(215,197)
Forfeited	(41,671)
Outstanding at March 31, 2022	4,807,280	5,064,148
Exercisable at March 31, 2022	4,642,802
Weighted Average Exercise Price, Outstanding at April 1, 2021	$ 18.99
Weighted Average Exercise Price, Exercised	18.99
Weighted Average Exercise Price, Forfeited	18.99
Weighted Average Exercise Price, Outstanding at March 31, 2022	18.99	$ 18.99
Weighted Average Exercise Price, Exercisable at March 31, 2022	$ 18.99
Weighted Average Remaining Contractual Term, Outstanding	5 years 7 months 6 days	6 years 7 months 6 days
Weighted Average Remaining Contractual Term, Exercisable at March 31, 2022	5 years 7 months 6 days
Aggregate Intrinsic Value, Outstanding at April 1, 2021	$ 15,764
Aggregate Intrinsic Value, Exercised	588
Aggregate Intrinsic Value, Forfeited	102
Aggregate Intrinsic Value, Outstanding at March 31, 2022	13,508	$ 15,764
Aggregate Intrinsic Value, Exercisable at March 31, 2021	$ 13,046
Exit-Vesting Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at April 1, 2021	4,750,627
Forfeited	(178,648)
Outstanding at March 31, 2022	4,571,979	4,750,627
Weighted Average Exercise Price, Outstanding at April 1, 2021	$ 18.99
Weighted Average Exercise Price, Forfeited	18.99
Weighted Average Exercise Price, Outstanding at March 31, 2022	$ 18.99	$ 18.99
Weighted Average Remaining Contractual Term, Outstanding	5 years 8 months 12 days	6 years 7 months 6 days
Aggregate Intrinsic Value, Outstanding at April 1, 2021	$ 14,774
Aggregate Intrinsic Value, Forfeited	441
Aggregate Intrinsic Value, Outstanding at March 31, 2022	$ 12,847	$ 14,774

Incentive Compensation Plans _4

Incentive Compensation Plans (Schedule of Time-Vesting and Exist-Vesting Nonvested Option Activity) (Details)	12 Months Ended
	Mar. 31, 2022$ / sharesshares
Time-Vesting Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested at April 1, 2021 | shares	637,626
Cancelled | shares	(11,850)
Vested | shares	461,298
Unvested at March 31, 2022 | shares	164,478
Weighted Average Grant Date Fair Value, Unvested at April 1, 2021 | $ / shares	$ 9.78
Weighted Average Grant Date Fair Value, Cancelled | $ / shares	9.78
Weighted Average Grant Date Fair Value, Vested | $ / shares	9.78
Weighted Average Grant Date Fair Value, Unvested at March 31, 2022 | $ / shares	$ 9.78
Exit-Vesting Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested at April 1, 2021 | shares	4,750,627
Cancelled | shares	(178,648)
Unvested at March 31, 2022 | shares	4,571,979
Weighted Average Grant Date Fair Value, Unvested at April 1, 2021 | $ / shares	$ 5.90
Weighted Average Grant Date Fair Value, Cancelled | $ / shares	5.90
Weighted Average Grant Date Fair Value, Unvested at March 31, 2022 | $ / shares	$ 5.90

Incentive Compensation Plans _5

Incentive Compensation Plans (Schedule of Long Term Incentive Plans Stock Unit Activity) (Details)	12 Months Ended
	Mar. 31, 2022$ / sharesshares
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested at April 1, 2021	14,120,518
Granted	1,188,176
Canceled	(1,600,533)
Vested	(4,465,437)
Unvested at March 31, 2022	9,242,724
Weighted Average Grant Date Fair Value, Unvested at April 1, 2021 | $ / shares	$ 16.98
Weighted Average Grant Date Fair Value, Granted | $ / shares	22.20
Weighted Average Grant Date Fair Value, Canceled | $ / shares	17.50
Weighted Average Grant Date Fair Value, Vested | $ / shares	17.58
Weighted Average Grant Date Fair Value, Unvested at March 31, 2022 | $ / shares	$ 17.26
Deferred Stock Units DSU [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested at April 1, 2021	86,916
Granted	49,952
Vested	(86,916)
Unvested at March 31, 2022	49,952
Weighted Average Grant Date Fair Value, Unvested at April 1, 2021 | $ / shares	$ 11.93
Weighted Average Grant Date Fair Value, Granted | $ / shares	23.15
Weighted Average Grant Date Fair Value, Vested | $ / shares	11.93
Weighted Average Grant Date Fair Value, Unvested at March 31, 2022 | $ / shares	$ 23.15
Deferred Stock Units DSU [Member] | Shares to be Received After Leaving Position [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested	(86,916)
Cash Settled Restricted Stock Units CSRSU [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested at April 1, 2021	434,512
Canceled	(6,126)
Vested	(373,153)
Unvested at March 31, 2022	55,233
Weighted Average Grant Date Fair Value, Unvested at April 1, 2021 | $ / shares	$ 13.49
Weighted Average Grant Date Fair Value, Canceled | $ / shares	13.54
Weighted Average Grant Date Fair Value, Vested | $ / shares	13.45
Weighted Average Grant Date Fair Value, Unvested at March 31, 2022 | $ / shares	$ 13.78
Performance Stock Units PSU [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested at April 1, 2021	2,058,530
Canceled	(107,134)
Vested	(8,817)
Unvested at March 31, 2022	1,942,579
Weighted Average Grant Date Fair Value, Unvested at April 1, 2021 | $ / shares	$ 14.32
Weighted Average Grant Date Fair Value, Canceled | $ / shares	14
Weighted Average Grant Date Fair Value, Vested | $ / shares	13.76
Weighted Average Grant Date Fair Value, Unvested at March 31, 2022 | $ / shares	$ 14.34

Incentive Compensation Plans _6

Incentive Compensation Plans (Summary of eRX Award Stock Unit Activity) (Details)	12 Months Ended
	Mar. 31, 2022$ / sharesshares
eRx Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested at April 1, 2021 | shares	243,833
Granted | shares
Canceled | shares	(19,253)
Vested | shares	(193,458)
Unvested at March 31, 2022 | shares	31,122
Weighted Average Grant Date Fair Value, Unvested at April 1, 2021 | $ / shares	$ 11.04
Weighted Average Grant Date Fair Value, Granted | $ / shares
Weighted Average Grant Date Fair Value, Canceled | $ / shares	11.04
Weighted Average Grant Date Fair Value, Vested | $ / shares	11.04
Weighted Average Grant Date Fair Value, Unvested at March 31, 2022 | $ / shares	$ 11.04
eRx Unvested Stock Appreciation Rights (SARs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested at April 1, 2021 | shares	11,439
Granted | shares
Canceled | shares
Vested | shares	(11,439)
Unvested at March 31, 2022 | shares
Weighted Average Grant Date Fair Value, Unvested at April 1, 2021 | $ / shares	$ 11.04
Weighted Average Grant Date Fair Value, Granted | $ / shares
Weighted Average Grant Date Fair Value, Canceled | $ / shares
Weighted Average Grant Date Fair Value, Vested | $ / shares	11.04
Weighted Average Grant Date Fair Value, Unvested at March 31, 2022 | $ / shares

Incentive Compensation Plans _7

Incentive Compensation Plans (Summary of Equity Compensation Expensed) (Details) - USD ($)	11 Months Ended	12 Months Ended
	Mar. 09, 2020	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Incentive Compensation Plans [Abstract]
Equity compensation expense	$ 0	$ 95,730,000	$ 59,016,000	$ 1,701,000
Deferred tax benefit recognized		(2,326,000)	7,336,000	166,000
Actual tax benefit recognized		$ 34,008,000	$ 6,067,000	$ 152,000

Retirement Plans and Other Po_3

Retirement Plans and Other Postretirement Benefits (Narrative) (Details) $ in Thousands	12 Months Ended
	Mar. 31, 2022USD ($)item	Mar. 31, 2021USD ($)
Defined Contribution Plan Disclosure [Line Items]
Number of defined contribution plans employee may participate in | item	1
Defined contribution plan, expense	$ 30,780	$ 30,931
Post-Employment Benefits [Member]
Defined Contribution Plan Disclosure [Line Items]
Benefit obligation	$ 1,845	$ 1,960

Retirement Plans and Other Po_4

Retirement Plans and Other Postretirement Benefits (Summary of Liabilities Related to Deferred Compensation Plan) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Retirement Plans and Other Postretirement Benefits[Abstract]
Accrued expenses	$ 1,567	$ 1,746
Other long-term liabilities	24,311	18,860
Total deferred compensation	$ 25,878	$ 20,606

Tax Receivable Agreements (Narr

Tax Receivable Agreements (Narrative) (Details) - McKesson Tax Receivable Agreement [Member]	12 Months Ended
	Mar. 31, 2022
Related Party Transaction [Line Items]
Net cash tax savings, percentage payment provided by agreement	85.00%
Joint Venture [Member]
Related Party Transaction [Line Items]
Maximum percentage ownership allowed to receive net cash tax savings payment	20.00%

Tax Receivable Agreements (Aggr

Tax Receivable Agreements (Aggregate Payments Due Under Tax Receivable Agreements (Details) $ in Thousands	Mar. 31, 2022USD ($)
Related Party Transaction [Line Items]
2023	$ 49,759
2024	59,772
2025	81,767
2026	84,535
2027	50,072
Thereafter	113,151
Gross expected payments	439,056
Less: Amounts representing discount	(81,672)
Total tax receivable agreement obligations	357,384
Less: Current portion due	(49,759)
Tax receivable agreement long-term obligations	307,625
Related Party Tax Receivable Agreements [Member]
Related Party Transaction [Line Items]
2023	13,057
2024	29,560
2025	29,055
2026	48,559
2027	8,620
Thereafter	41,037
Gross expected payments	169,888
Less: Amounts representing discount	(51,968)
Total tax receivable agreement obligations	117,920
Less: Current portion due	(13,057)
Tax receivable agreement long-term obligations	104,863
McKesson Tax Receivable Agreement [Member]
Related Party Transaction [Line Items]
2023	25,042
2024	15,092
2025	38,184
2026	16,108
2027	32,093
Thereafter	34,950
Gross expected payments	161,469
Total tax receivable agreement obligations	161,469
Less: Current portion due	(25,042)
Tax receivable agreement long-term obligations	136,427
Other Tax Receivable Agreements [Member]
Related Party Transaction [Line Items]
2023	11,660
2024	15,120
2025	14,528
2026	19,868
2027	9,359
Thereafter	37,164
Gross expected payments	107,699
Less: Amounts representing discount	(29,704)
Total tax receivable agreement obligations	77,995
Less: Current portion due	(11,660)
Tax receivable agreement long-term obligations	$ 66,335

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Income Taxes [Line Items]
Deferred tax liability	$ 563,606	$ 605,291
Valuation allowance	22,076	20,238
Reduction to income tax expense if benefits from net operating loss carryforwards are realized	22,076
Unrecognized tax benefits that would affect the effective tax rate	57,723
Interest and penalties	42	$ 121	$ 138
Accelerated receipt of AMT credit refund amount	869
Deferred tax liability	28,576
Residual Deferred Tax Asset [Member]
Income Taxes [Line Items]
Valuation allowance	5,449
Federal [Member]
Income Taxes [Line Items]
Operating loss carryforwards	836,227
Federal [Member] | Research and Development Tax Credit Carryforward [Member]
Income Taxes [Line Items]
Tax credit carryforwards	43,862
State [Member]
Income Taxes [Line Items]
Operating loss carryforwards	1,365,807
State [Member] | Research and Development Tax Credit Carryforward [Member]
Income Taxes [Line Items]
Tax credit carryforwards	1,849
Foreign [Member]
Income Taxes [Line Items]
Operating loss carryforwards	$ 6,337
Operating loss carryforwards, expiration date	Dec. 31, 2024
State and Foreign [Member]
Income Taxes [Line Items]
Valuation allowance	$ 16,627
Minimum [Member] | Federal [Member]
Income Taxes [Line Items]
Operating loss carryforwards, expiration date	Dec. 31, 2032
Minimum [Member] | Federal [Member] | Research and Development Tax Credit Carryforward [Member]
Income Taxes [Line Items]
Tax credit carryforwards, expiration date	Dec. 31, 2038
Minimum [Member] | State [Member]
Income Taxes [Line Items]
Operating loss carryforwards, expiration date	Dec. 31, 2023
Maximum [Member] | Federal [Member]
Income Taxes [Line Items]
Operating loss carryforwards, expiration date	Dec. 31, 2037
Maximum [Member] | Federal [Member] | Research and Development Tax Credit Carryforward [Member]
Income Taxes [Line Items]
Tax credit carryforwards, expiration date	Dec. 31, 2042
Maximum [Member] | State [Member]
Income Taxes [Line Items]
Operating loss carryforwards, expiration date	Dec. 31, 2041

Income Taxes (Schedule of Incom

Income Taxes (Schedule of Income (Loss) before Income Tax) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Income Taxes [Line Items]
Income (loss) before income taxes	$ (106,001)	$ (147,397)	$ (1,090,851)
Federal [Member]
Income Taxes [Line Items]
Income (loss) before income taxes	(129,858)	(145,328)	(1,091,272)
Foreign [Member]
Income Taxes [Line Items]
Income (loss) before income taxes	$ 23,857	$ (2,069)	$ 421

Income Taxes (Schedule of Compo

Income Taxes (Schedule of Components of Income Tax Expense (Benefit)) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Current:
U.S. Federal	$ (3,232)	$ 2,515
U.S. State	(577)	5,805	466
Foreign	4,256	2,789	102
Current income tax provision (benefit)	447	11,109	568
Deferred:
U.S. Federal	(27,514)	(47,052)	(113,523)
U.S. State	(21,340)	(1,249)	(30,297)
Foreign	(204)	2,005	(2)
Deferred income tax provision (benefit)	(49,058)	(46,296)	(143,822)
Total income tax provision (benefit)	$ (48,611)	$ (35,187)	$ (143,254)

Income Taxes (Schedule of Effec

Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Income Taxes [Abstract]
Statutory U.S. federal tax rate	21.00%	21.00%	21.00%
State income taxes (net of federal benefit)	16.30%	(2.70%)	2.10%
Research and development credit	9.10%	11.00%	0.20%
Equity compensation	5.20%	(1.30%)
Transaction costs	(6.60%)
Foreign income taxes	(1.00%)	(1.50%)
Gain on sale of business		(4.40%)
eRx option		2.90%
Change in fair value of equity based awards			(1.20%)
Look through accounting policy election			2.10%
Goodwill impairment charge			(10.80%)
Other	1.90%	(1.20%)	(0.30%)
Effective income tax rate	45.90%	23.80%	13.10%

Income Taxes (Schedule of Defer

Income Taxes (Schedule of Deferred Tax Assets (Liabilities)) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Income Taxes [Abstract]
Depreciation and amortization	$ (964,820)	$ (1,046,755)
Net operating losses	249,839	299,606
Tax receivable agreements obligation to related parties	69,564	67,633
Fair value of interest rate cap agreements	(6,574)	1,466
Accruals and reserves	43,599	60,661
Tax credits	46,083	38,138
Debt discount and interest	(3,264)	(6,594)
Equity compensation	28,218	38,289
Valuation allowance	(22,076)	(20,238)
163(j) Business interest expense limitation	13,862	2,056
Accounting method change (ASC 606 adoption)	(1,390)	(23,315)
Right of use asset	(16,817)	(24,262)
Right of use liability	18,807	27,377
Residual deferred tax assets	5,449	5,518
Accounts receivable	5,375	6,107
Other	(1,074)	(2,779)
Net deferred tax assets (liabilities)	(535,219)	(577,092)
Reported as:
Non-current deferred tax assets	28,387	28,199
Non-current deferred tax liabilities	(563,606)	(605,291)
Net deferred tax assets (liabilities)	$ (535,219)	$ (577,092)

Income Taxes (Reconciliation of

Income Taxes (Reconciliation of Unrecognized Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Taxes [Abstract]
Beginning unrecognized benefit	$ 64,110	$ 56,177
Decreases from prior period tax positions	(891)
Increases from prior period tax positions		3,010
Increases from current period tax positions	4,346	4,923
Increases from acquisition
Ending unrecognized benefit	$ 67,565	$ 64,110

Net Income (Loss) Per Share (Co

Net Income (Loss) Per Share (Computation of Basic Net Income (Loss) Per Share of Common Stock) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Net Income (Loss) Per Share [Abstract]
Net income (loss)	$ (57,390)	$ (112,210)	$ (947,597)
Weighted average common shares outstanding	310,834,905	304,406,531	123,387,547
Minimum shares issuable under purchase contracts	13,161,695	16,365,258	13,609,077
Total weighted average shares outstanding	323,996,600	320,771,789	136,996,624
Basic net income (loss) per share	$ (0.18)	$ (0.35)	$ (6.92)
Diluted net income (loss) per share:
Net income (loss)	$ (57,390)	$ (112,210)	$ (947,597)
Number of shares used in basic computation	323,996,600	320,771,789	136,996,624
Weighted average effect of dilutive securities
Total weighted average shares outstanding	323,996,600	320,771,789	136,996,624
Diluted net income (loss) per share	$ (0.18)	$ (0.35)	$ (6.92)

Net Income (Loss) Per Share (An

Net Income (Loss) Per Share (Antidilutive Securities Excluded from Diluted Net Income (Loss) Per Share) (Details) - shares	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from diluted net income (loss) per share	4,507,388		1,345,211
Time-Vesting Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from diluted net income (loss) per share	1,614,649	932,968	1,259,594
Deferred Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from diluted net income (loss) per share	160,154	99,964	20,371
Performance Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from diluted net income (loss) per share	100,893
Dilutive Shares Issuable Under Purchase Contracts [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from diluted net income (loss) per share		1,184,993	1,829,437

Commitments (Narrative) (Detail

Commitments (Narrative) (Details) - Master Services Agreement [Member] $ in Thousands	1 Months Ended		12 Months Ended
	Mar. 31, 2020USD ($)	Feb. 28, 2018USD ($)item	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)
Commitments [Line Items]
Commitment term		10 years
Number of agreement renewal options | item		3
Renewal option term		1 year
Percentage shortfall required if minimum commitment not met		25.00%
Purchase commitment amount		$ 1,000,000	$ 75,869	$ 80,071
Minimum [Member]
Commitments [Line Items]
Purchase commitment amount	$ 975,000
Joint Venture [Member]
Commitments [Line Items]
Commitment term		10 years

Commitments (Schedule of Future

Commitments (Schedule of Future Minimum Commitments) (Details) $ in Thousands	Mar. 31, 2022USD ($)
Operating Lease Obligations
Total operating lease obligations	$ 87,231
2023	26,035
2024	18,925
2025	13,837
2026	9,586
2027	7,204
Thereafter	11,644
Finance Lease Obligations
Total finance lease obligations	1,327
2023	468
2024	468
2025	391
Purchase Obligations
Total purchase obligations	1,047,479
2023	220,237
2024	219,697
2025	198,737
2026	148,512
2027	130,240
Thereafter	130,056
Contractual
Total contractual	1,136,037
2023	246,740
2024	239,090
2025	212,965
2026	158,098
2027	137,444
Thereafter	141,700
Future minimum sublease receivable	$ 1,086

Legal Proceedings (Narrative) (

Legal Proceedings (Narrative) (Details) - item	Apr. 13, 2021	Apr. 30, 2021	Mar. 31, 2021
Number of lawsuits filed			9
Filed in Federal Court [Member]
Number of lawsuits filed		8
Delaware Court of Chancery [Member]
Number of stockholders who made written demand and subsequently filed complaint	1

Related Party Transactions (Nar

Related Party Transactions (Narrative) (Details) $ in Thousands	Jan. 01, 2022$ / employee	Jan. 01, 2021$ / employee	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)
Related Party Transaction [Line Items]
Long-term debt, excluding current portion			$ 4,580,087	$ 4,734,775
Employer Healthcare Program Agreement [Member]
Related Party Transaction [Line Items]
Service fee per participating employee per month | $ / employee	3.25	3
Option Agreement [Member[ | McKesson Corporation [Member]
Related Party Transaction [Line Items]
Maximum percentage of ownership in the outstanding units of the Joint Venture allowed for option to acquire can be exercised			5.00%
Transition Services Agreements [Member]
Related Party Transaction [Line Items]
Transition fee income			$ 283
Senior Credit Facilities [Member] | GSO-Managed Funds [Member]
Related Party Transaction [Line Items]
Long-term debt, excluding current portion			$ 191,049	$ 162,189

Related Party Transactions (Sum

Related Party Transactions (Summary of Revenue Recognized and Amounts Paid Related to Service Provided to and from Portfolio Companies) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Related Party Transactions [Abstract]
Revenue recognized related to services provided	$ 6,930	$ 3,792
Amount paid related to services received	$ 17,369	$ 18,057

Segment Reporting (Narrative) (

Segment Reporting (Narrative) (Details)	12 Months Ended
	Mar. 31, 2022segment
Segment Reporting [Abstract]
Number of Reportable Segments	3

Segment Reporting (Revenue and

Segment Reporting (Revenue and Adjusted EBITDA for each Reportable Segment) (Details) - USD ($) $ in Thousands		12 Months Ended
		Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Segment Reporting Information [Line Items]
Net revenue		$ 3,480,815	$ 3,090,421	$ 196,792
Adjusted EBITDA		1,071,051	934,165
Reconciliation of income (loss) before tax provision (benefit) to Adjusted EBITDA
Income (loss) before income tax provision (benefit)		(106,001)	(147,397)	(1,090,851)
Amortization of capitalized software developed for sale		3,509	1,326
Depreciation and amortization		681,808	591,048	30,838
Interest expense		234,244	245,241	16,652
Equity compensation		95,730	59,016
Acquisition accounting adjustments		(11,839)	109,743
Acquisition and divestiture-related costs		41,120	19,709
Integration and related costs		26,803	40,675
Strategic initiatives, duplicative and transition costs		46,041	21,841
Severance costs		10,178	13,184
Accretion and changes in estimate, net		25,276	11,644	15,823
Impairment of long-lived assets and other		4,958	18,190
Loss on extinguishment of debt		3,885	8,924
Gain on sale of businesses			(59,143)
Contingent consideration			(3,000)
Other non-routine, net		15,339	3,164
Adjusted EBITDA		1,071,051	934,165
Postage and Eliminations [Member]
Segment Reporting Information [Line Items]
Net revenue	[1]	82,727	96,533
Purchase Accounting Adjustment [Member]
Segment Reporting Information [Line Items]
Net revenue	[2]	(7,740)	(128,230)
Software and Analytics [Member]
Segment Reporting Information [Line Items]
Net revenue		1,612,931	1,534,926
Adjusted EBITDA		561,994	526,129
Reconciliation of income (loss) before tax provision (benefit) to Adjusted EBITDA
Adjusted EBITDA		561,994	526,129
Network Solutions [Member]
Segment Reporting Information [Line Items]
Net revenue		868,425	717,843
Adjusted EBITDA		446,378	377,005
Reconciliation of income (loss) before tax provision (benefit) to Adjusted EBITDA
Adjusted EBITDA		446,378	377,005
Technology-Enabled Services [Member]
Segment Reporting Information [Line Items]
Net revenue		924,472	869,349
Adjusted EBITDA		62,679	31,031
Reconciliation of income (loss) before tax provision (benefit) to Adjusted EBITDA
Adjusted EBITDA		62,679	31,031
Postage [Member]
Segment Reporting Information [Line Items]
Net revenue		$ 219,612	$ 196,532	$ 12,631
[1]	Revenue for the Postage and Eliminations segment includes postage revenue of $ 219,612 and $ 196,532 for the years ended March 31, 2022 and 2021, respectively.
[2]	Amount reflects the impact to deferred revenue resulting from the Merger which reduced revenue recognized during the period.

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) (Summary Of Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Accumulated Other Comprehensive Income Loss [Line Items]
Balance	$ 3,252,228	$ 3,285,447	$ 1,132,487
Unrealized gain (loss) on available for sale debt securities of the Joint Venture			1,045
Realized gain (loss) on available for sale debt securities of the Joint Venture			(1,045)
Balance	3,276,107	3,252,228	3,285,447
Change associated with current period hedging, tax	7,347	1,033	607
Available For Sale Debt Security [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance
Unrealized gain (loss) on available for sale debt securities of the Joint Venture			1,045
Realized gain (loss) on available for sale debt securities of the Joint Venture			(1,045)
Balance
Foreign Currency Translation Adjustment [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance	14,130	(7,084)	(1,565)
Change associated with foreign currency translation	3,741	21,324	(5,519)
Reclassification into earnings		(110)
Balance	17,871	14,130	(7,084)
Cash Flow Hedge [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance	(2,909)	(288)	(1,691)
Change associated with current period hedging	18,216	(3,823)	981
Reclassification into earnings	1,938	1,202
Balance	17,245	(2,909)	(288)
Accumulated Other Comprehensive Income (Loss) [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance	11,221	(7,372)	(3,256)
Unrealized gain (loss) on available for sale debt securities of the Joint Venture			1,045
Realized gain (loss) on available for sale debt securities of the Joint Venture			(1,045)
Change associated with foreign currency translation	3,741	21,324	(5,519)
Change associated with current period hedging	18,216	(3,823)	981
Reclassification into earnings	1,938	1,092
Balance	$ 35,116	$ 11,221	(7,372)
Cumulative Effect, Period of Adoption, Adjustment [Member] | ASU 2018-02 [Member] | Cash Flow Hedge [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance			422
Cumulative Effect, Period of Adoption, Adjustment [Member] | ASU 2018-02 [Member] | Accumulated Other Comprehensive Income (Loss) [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance			$ 422

Subsequent Events (Narrative) (

Subsequent Events (Narrative) (Details) - USD ($)	1 Months Ended	3 Months Ended	11 Months Ended	12 Months Ended
	May 31, 2022	Jun. 30, 2022	Mar. 09, 2020	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Subsequent Event [Line Items]
Compensation expense			$ 0	$ 95,730,000	$ 59,016,000	$ 1,701,000
Loss on extinguishment of debt				$ (3,885,000)	$ (8,924,000)
Forecast [Member]
Subsequent Event [Line Items]
Granted in period		5,100,000
Repayments of Long-term Debt	$ 100,000,000
Loss on extinguishment of debt	$ 390,000,000
Restricted Stock Units [Member]
Subsequent Event [Line Items]
Granted in period				1,188,176
Restricted Stock Units [Member] | Forecast [Member]
Subsequent Event [Line Items]
Graded Vesting Schedule in Years		3 years
Unrecognized compensation expense		$ 122,000,000
Compensation expense		$ 51,000,000